Biopharmaceuticals in the U.S. and European Markets: Products/Active Index Terms

BIOPHARMA: Biopharmaceuticals in the U.S. and European Markets

Products/Active Agents Index

Biopharmaceuticals in the U.S. and European Markets

Chemical Index

Biological Index

Products database

10A1C6, Chinese ovary hamster (CHO) cells -- 148;
1454 Saccharomyces cerevisiae (yeast) cells -- 182;
2.131 Chinese hamster ovary (CHO) cell line -- 187;
20,752, Haemophilus influenzae type b strain -- 456.5;
2150-2-3, Saccharomyces cerevisiae (yeast) strain -- 174; 175; 178;
225 murine hybridoma cells -- 128;
225.28S murine hybridoma -- 309;
2B8 murine hybridoma cells -- 117;
(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) [MTT] -- 652;
3T3 feeder cells, murine -- 653;
4-4FC102A5-3 Chinese hamster ovary cells -- 267;
4-hydroxydehydrogenase -- 241;
4D5 murine hybridoma cells -- 179;
4D5-8 5 murine hybridoma cells -- 179;
5'HS4 element -- 102;
5G1.1 murine monoclonal antibody -- 120;
7E11-C5.3 murine hybridoma cells -- 312;
89-12C2, rotavirus -- 530;
A2 murine hybridoma cells -- 264;
A375 cells -- 267;
A4.6.1 hybridoma cells -- 275;
AB103 -- 193;
ABX-CHO2-P media -- 129;
AcNPV p10 promotor -- 271;
ACUSYST perfusion bioreactors -- 119; 312;
Ad5 vector -- 232; 233;
Adekanol LG-109 -- 415;
adenine -- 651; 659;
adenosine -- 148;
adenosine diphosphate (ADP) ribosylation -- 217;
adenovirus 2 late promoter -- 243;
adenovirus serotype 5 (Ad5) vector -- 232; 233; 261.7;
adenovirus vector -- 261.7;
adw, hepatitis B virus subtype -- 174;
African green monkey kidney (AFMK) cells -- 483.8;
African green monkey kidney cells -- 437.5; 440; 445; 446.5; 490; 517; 520; 521; 530; 531; 532; 540;
agar -- 406; 563;
agarose -- 651; 659;
Agkistrodon contortrix contortrix -- 153;
Agkistrodon piscivorus venom -- 908;
AIM media -- 242;
air-lift fermenters -- 313;
Albumin (Human) -- 491; 504;
albumin-digoxin conjugate -- 913;
albumin, bovine serum -- 115; 147; 152; 162; 245; 312; 651;
aldehyde dehydrogenase -- 241;
alkaline phosphatase secretory signal sequence -- 271;
allantoic fluid -- 471; 472; 478; 479; 480; 504; 567; 932;
alpha-2 plasmin inhibitor signal sequence -- 261;
alpha-S1 casein milk-specific promoter, bovine -- 113;
Alpine goats -- 102;
amphotericin B -- 402; 403; 529; 532;
ampicillin -- 220;
ampicillin resistance marker gene -- 105;
animal source materials (unspecified) -- 143;
Anthrax Vaccine Adsorbed -- 744; 745; 746;
antibody photoactivation -- 301;
antifoam agent -- 230;
Antigen Presenting Cells (APC) -- 242;
apheresis (hemapheresis) -- 802;
apoptosis -- 232; 233; 261.7; 713.5;
AR58, Escherichia coli (E. coli) -- 230;
ARG3 gene termination sequence -- 175;
arylsulfatase -- 182;
ascitic fluid -- 303; 304; 307;
asparagine -- 105; 410;
Aspergillus flavus -- 272;
ATCC 10762 -- 123;
ATCC 20670 -- 193;
ATCC 20705 -- 175;
ATCC 27325 -- 120;
ATCC 39262 -- 230;
ATCC 39626 -- 218;
ATCC 39685 -- 166;
ATCC 53281 -- 457;
ATCC 68088 -- 267;
ATCC CCL 10 -- 149;
ATCC CCL 81 -- 517;
ATCC CRL 10859 and 10860 -- 185;
ATCC CRL 1573 -- 243;
ATCC CRL 8001 -- 303;
ATCC CRL 8287 -- 264;
ATCC CRL1573 -- 261.7;
ATCC HB 10494 -- 312;
ATCC HB 11552 -- 147; 148; 719; 721; 722;
ATCC HB-11625 -- 120;
ATCC HB-8483 -- 701;
ATCC HB10710 -- 275;
ATCC HB11388 -- 117;
ATCC HB8832 -- 240;
ATCC no. CCL 61 -- 269;
ATCC PTA 2104 -- 123.5;
ATCC PTA-1883 -- 301;
ATCC VR 2089, VR 2090, VR 2091, VR 2092, VR 2093 -- 463;
ATCC VR-2272 -- 530;
Autographa californica nuclear polyhedrosis virus (AcNPV) baculovirus polyhedron expression promoter -- 191.5;
autologous blood
autologous cells, human -- 649.5; 650; 650.3; 650.5; 654; 702; 742;
B-lymphocytes -- 271; 417;
B2.6.2, hybridoma cells -- 275;
B43.13
B72.3 hybridoma cells -- 313;
baby hamster kidney (BHK) cells -- 145; 149; 151;
Bacille Calmette Guerin (BCG) -- 407; 408; 409; 410; 411; 412;
Bacillis anthracis Vollum strain (V770) -- 404;
bacillus Calmette-Guerin (BCG) -- 649.5; 649.5;
bacterial culture -- 103; 104; 110; 118; 158; 159; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 165; 170; 171; 192; 192.3; 192.5; 194; 197; 198; 199; 201; 202; 204; 205; 206; 208; 209; 212; 213; 214; 216; 217; 218; 219; 220; 226; 229; 230; 231; 234; 235; 236; 250; 251; 252; 253; 254; 256; 258; 259; 261.5; 266; 268; 274; 404; 405; 406; 407; 408; 409; 410; 411; 412; 413; 414; 415; 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 453; 454; 455; 456; 456.5; 457; 458; 459; 460; 497; 498; 499; 500; 502; 502.5; 503; 505; 506; 507; 508; 509; 510; 511; 512; 513;
bacterial culture -- 513.3; 513.5; 514; 515; 542; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 560; 561; 562; 563; 602; 604; 608; 609; 611; 624; 625; 700; 926; 927; 929; 938;
bacteriophage T4 -- 260;
baculovirus 61K signal peptide -- 191.5;
baculovirus expression -- 185; 242; 271;
baculovirus pPSC12 plasmid -- 191.5;
BALB/c mice -- 264; 304; 312;
Bcl-2 gene -- 945;
Bean strain, Clostridium botulinum -- 604;
beef extract -- 196;
beef heart infusion -- 612;
Benzonase -- 245;
Benzonase -- 483.8; 539; 540;
beta casein gene (CSN2), goat -- 102;
beta-casein promoter -- 102;
BG9015/BG9216, Chinese Hamster Ovary cells -- 210;
BgII fragment of pNM1 -- 112;
BHK-21 (C-13) -- 149;
bioreactors, 10,000 Liter -- 245;
bioreactors, 12,000 L -- 270;
bioreactors, air-lift fermentors -- 313;
bioreactors, CellCube parallel-plate -- 232;
bioreactors, hollow-fiber -- 416;
bioreactors, parallel-plate -- 539;
bioreactors, perfusion -- 105; 119; 149; 150; 150.5; 163; 232; 264; 312; 409; 539; 540;
bioreactors, spinner culture -- 105; 144; 245; 275;
BK virus enhancer -- 243;
black widow spiders -- 909;
blood infusion media, ovine -- 406;
blood chromatography, human -- 700;
blood donations -- 702;
Bluescript (Stratagene) plasmid -- 267;
bone marrow -- 649;
Bordet Gengou medium -- 447; 509;
Bordetella pertussis -- 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 443; 444; 445; 446; 447; 448; 449; 450; 451; 452; 505; 506; 507; 508; 509; 510;
Bordetella pertussis S1 subunit gene -- 236;
Borellia burgdorferi -- 229;
Borellia burgdorferi, sensu stricto ZS7 strain -- 230;
Bothrops atrox -- 907;
botulinum toxins -- 911; 912;
bouillon (beef) -- 624;
bovine (veal) infusion agar -- 563;
bovine Achilles tendon -- 612;
bovine brain infusion media -- 406;
bovine collagen -- 656;
bovine heart -- 406;
bovine heart infusion media -- 406;
bovine insulin -- 651; 659;
bovine lipoproteins -- 245;
bovine lymph -- 536; 537;
bovine materials -- 264; 445; 531; 565; 602; 605; 614; 921; 941; 942;
bovine pancreas -- 614; 631;
bovine proteins -- 514;
bovine rotavirus G6 strain WC-3 (WC-3) -- 531;
bovine serum -- 145; 163; 304; 312; 491; 504; 517; 520; 521; 531; 532; 533; 540; 564; 653; 659; 794;
bovine serum albumin -- 490;
bovine serum albumin (BSA) -- 147; 152; 245; 312; 651; 659; 900;
bovine testes -- 616; 617; 618;
bovine tissue digest -- 562;
bovine transferrin -- 162; 245; 312;
bovine-human reassortant viruses -- 531;
brains, bovine media -- 406;
Branhamella catarrhalis -- 406;
BrB, human rotavirus stain -- 531;
butyric acid (butyrate) -- 168; 168.5;
C-127 (C127) murine tumor cells -- 257;
c-ErbB-1 -- 128;
c168A, mammalian cell line -- 264;
C7 (beta197), Corynebacterium diphtheriae -- 457;
CA 125, ovarian tumor antigen -- 302;
CA125
cabbage looper Trichoplasia ni High Five cell line -- 185; 271;
CAF3, mice, CAF3 pathogen-free males -- 303;
calcitonin-glycine fusion protein -- 110;
calcium chloride -- 651; 659;
calves, postmortem lung lavage -- 942;
canine kidney cells Madin-Darby (MDCK) -- 483;
carbon dioxide -- 651;
carcinoembryonic antigen (CEA) gene -- 111;
Carica papaya -- 622;
carrot cells -- 167.3;
cartilage, femoral articular (human) -- 650; 650.3;
casamino acids -- 220; 430; 457;
casein -- 436; 562;
casein gene (CSN2), beta, goat -- 102;
casein hydrolysate -- 423; 547; 601;
caterpillar 242; 271;
cathepsin L inhibition -- 105;
CC49 murine hybridoma cells -- 315;
CD15 antigen -- 305;
CD3 -- 131; 131.5;
CDF1 mice -- 304;
cell proliferation bioassay -- 258;
CellCube parallel-plate bioreactors -- 232;
CelliGen bioreactors -- 232;
cells, human -- 261.7; 702; 797; 802; 803; 806;
cells, human -- 118; 121; 141; 162; 232; 233; 242; 243; 261.7; 265; 267; 402; 403; 463; 464; 466; 489; 492; 493; 493.5; 494; 494.5; 495; 496; 518; 526; 527; 533; 534; 539; 540; 564; 565; 626; 627; 649; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 794; 795;
Challenge Virus Standard (CVS; rabies virus) -- 528;
CHAT 10A-11 cell line -- 516;
chicken (rooster) combs -- 926; 928; 930;
chicken beta-globin insulator sequence -- 102;
chicken embryo (egg) culture -- 191.1;
chicken embryo (egg) culture -- 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481.5; 482;
chicken embryo (egg) culture -- 483.11;
chicken embryo (egg) culture -- 483.2;
chicken embryo (egg) culture -- 483.3;
chicken embryo (egg) culture -- 483.4;
chicken embryo (egg) culture -- 483.7; 487; 488; 491; 492; 493; 493.5; 494; 494.5; 495; 496; 504; 529; 534; 566; 567; 932;
chicken embryo dermal cells -- 111;
chicken embryo fibroblast (CEF) cells -- 541;
chicken embryo fibroblast cell culture -- 541;
chicken embryos (eggs) -- 190; 191; 485;
chicken embryos (eggs) (mammalian.poultry.chicken) -- 191;
chimpanzee kidney cells -- 516;
Chinese hamster ovary (CHO) cells -- 105; 108; 109; 110; 114; 115; 116; 116.5; 117; 119; 122; 123; 123.5; 126; 129; 130; 131.5; 133; 134; 135; 136; 137; 139; 140; 143; 144; 146; 147; 150; 150.5; 152; 155; 156; 160; 163; 167; 172; 179; 186; 188; 189; 202; 210; 211; 222.4; 222.6; 227; 228; 244; 261; 262; 267; 270;
Chinese hamster ovary (CHO) cells, 2.131 -- 187;
Chinese hamster ovary (CHO) cells, CHO-K1 -- 269;
Chinese hamster ovary (CHO) cells, CHO-K1 DUX B11 -- 275;
Chinese hamster ovary (CHO) cells, CTLA4Ig-24 -- 123;
Chinese hamster ovary (CHO) cells, K1 -- 155; 168; 168.5;
Chinese hamster ovary (CHO) CHO-DND-3.alpha.3 cells -- 138; 142;
Chinese ovary hamster (CHO) cells -- 148;
Chinese ovary hamster (CHO) cells, 10A1C6 -- 148;
Chinese ovary hamster (CHO) cells, DUKX-B11 -- 148;
Chinese ovary hamster (CHO) cells, GD8/6 -- 148;
Chinese ovary hamster (CHO) cells, MCB 9710 -- 148;
chlortetracycline -- 529;
CHO-DND-3.alpha.3 cells, Chinese hamster ovary (CHO) cells -- 138; 142;
CHO-K1 cells -- 105;
CHO-K1 DUX B11, Chinese hamster ovary (CHO) cells -- 275;
cholera enterotoxin -- 653;
chondrocytes, human -- 650; 650.3;
Cibracon blue dye resin -- 105;
citric acid -- 410;
cleavable fusion expression -- 253;
Clostridiumbotulinum type A, Hall Strain -- 602;
Clostridium botulinum -- 413; 600; 601; 602.5; 603; 604; 911; 912;
Clostridium botulinum toxins A, B, C, D, E and F -- 747;
Clostridium hisolyticum -- 612;
Clostridium tetani -- 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 455; 456.5; 459; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 786; 787;
CMM1 (Cytogen), serum-free medium -- 312;
CMV promoter -- 167.5;
COBE Spectra Apheresis System -- 242;
coenzyme A transferase -- 241;
Cohn Fraction II -- 752; 775; 777;
collagen matrix, bovine -- 651;
collagen, bovine -- 656;
collagen, porcine dermal -- 657;
complement monoclonal antibody -- 120;
Conn-Master 17633, vaccinia virus -- 537; 539; 540;
copper -- 110;
copperhead snake -- 153;
coral snakes -- 910;
Corynebacterium diphtheriae -- 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 454; 457; 502.5; 503; 513;
Corynebacterium diphtheriae -- 513.3; 513.5; 555; 556; 557; 558; 559; 916;
Costar cubes -- 464;
costimulatory molecules (B7.1, ICAM-1 and LFA-3) -- 111;
Cottonmouth venom -- 908;
Crotalus adeamanteus venom -- 907;
Crotalus atrox venom -- 907; 908;
Crotalus durissus venom -- 907;
Crotalus scutulatus venom -- 908;
Cryoprecipitated AHF (antihemophilic factor) -- 722;
CSL4S-342 Chinese hamster ovary (CHO) cells -- 105;
CTAA16.88 cytokeratin tumor antigen -- 121;
CTLA4Ig-24 Chinese hamster ovary (CHO) cells -- 123;
culture, fungal -- 610;
CVA vaccinia virus strain -- 541;
CY medium -- 513;
CY medium -- 513.3;
cyclodextrin, methyl- beta- -- 430;
CYT-063 monoclonal antibody -- 312;
CYT-351 monoclonal antibody -- 312;
Cytodex (microcarrier beads) -- 483.8;
Cytodex 2 beads, microcarriers -- 187;
cytomegalovirus (CMV) -- 748; 749;
cytomegalovirus (CMV) major immediate early region 2 (IE2) mRNA -- 946;
cytomegalovirus (CMV) promoter -- 141; 168; 168.5;
cytomegalovirus (hCMV) promoter -- 261.7;
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) -- 123; 123.5; 124; 125;
Davis strain, cytomegalovirus (CMV) -- 748;
DC5 (RT4376), Saccharomyces cerevisiae (yeast) strain -- 175; 177; 438; 441; 442; 463;
deep cell culture (DCC) -- 794;
dendritic cell vaccination -- 271;
dendritic cells -- 416;
dendritic cells, human -- 242;
deoxycoformycin (dCF) -- 148;
dextrose -- 562; 601;
DG5.3, Chinese hamster ovary (CHO) cells -- 163;
DI mouse strain -- 129;
digoxin-albumin conjugate -- 913;
dihydrofolate reductase (DHFR) -- 168; 168.5; 269;
diol oxidoreductase -- 241;
dipeptidyl aminopeptidase I -- 253;
Diplococcus pneumoniae -- 406;
Directed Molecular Evolution (DME) -- 246;
DNA intercalation -- 803;
Dryvax -- 788; 789; 790;
DSM 3184 -- 166;
Dubos medium -- 408;
DUKX-B11 Chinese ovary hamster (CHO) cells -- 148;
Dulbecco's Modified Eagle Medium (DMEM) -- 530;
Dulbecco's Modified Eagles Medium (DMEM) -- 304; 312; 540; 650; 651; 656; 659;
DXB-11 Chinese hamster ovary cells -- 267;
E. coli maltose binding (MBP) protein-hyaluronidase fusion protein -- 186;
E7.6.3 murine hybridoma cells -- 129;
Eagle's Minimum Essential Medium -- 402; 403; 517; 521;
Earle's balanced salt solution -- 521;
ECACC 05030201 -- 796;
ECACC V00083008 -- 541;
ECACC V00120707 -- 541;
Edmonston strain, measles virus -- 491; 492; 496;
eggs, frog -- 628;
elongation factor 1 alpha gene promoter -- 168; 168.5;
Elstree-BN vaccinia virus strain -- 538;
embryonic stem (ES) cells, murine -- 129;
EMEM/NCTC medium -- 312;
Ender strain, measles virus -- 491; 492; 493; 494; 496;
eneticin sulfate -- 243;
EpCAM -- 131; 131.5;
epidermal growth factor -- 653;
epidermal growth factor (EGF) receptor -- 130;
epidermal growth factor receptor (EGFr) -- 128; 129; 244;
epithelial cell adhesion molecule (EpCAM 131.5;
epithelial cell growth factors -- 226;
Epstein-Barr virus (EBV) transformed cells -- 121;
equine plasma/serum -- 794; 907; 909; 910; 911; 912; 916; 918;
Erwinia chrysanthemi -- 610;
erythrocyte cell line, human -- 141; 162;
Escherichia coli (E. coli -- 160.3;
Escherichia coli (E. coli) -- 100; 103; 104; 106; 110; 158; 159; 160.1; 160.7; 160.8; 165; 170; 173; 192; 192.3; 192.5; 193.5; 194; 197; 198; 199; 201; 202; 204; 205; 206; 207; 208; 209; 212; 212.5; 213; 216; 219; 220; 226; 229; 230; 231; 234; 235; 236; 248; 249; 250; 251; 252; 253; 254; 255; 256; 258; 261.5; 263; 266; 268; 274; 415; 542; 608; 609; 611;
Escherichia coli (E. coli) BL21 (.lambda.DE3) -- 217;
Escherichia coli (E. coli) JM101 -- 220;
Escherichia coli (E. coli) JM107 -- 214;
Escherichia coli (E. coli) K-12 strain W3110 -- 202;
Escherichia coli (E. coli) K12 -- 241;
Escherichia coli (E. coli) K12/MM294-1 -- 218;
Escherichia coli (E. coli) K802 -- 160.2; 160.9;
Escherichia coli (E. coli) SGE90 -- 214;
Escherichia coli (E. coli) strain RV308 -- 112;
Escherichia coli (E. coli) strain SR1268 -- 260;
ethanolamine -- 659;
Eu human monoclonal antibody -- 222;
Excell 302 medium -- 105;
expresSF+
expression, bacterial -- 103; 104; 112; 226; 266;
expression, cleavable fusion -- 253;
expression, human cells (gene activated) -- 141; 162; 188;
expression, murine (mouse) cells -- 176;
F8.1, murine monoclonal antibody -- 148;
Factor VIII inhibitor bypassing activity -- 704;
Factor Xa-complex cleavages -- 261;
fascia -- 658;
fed-batch system -- 245; 266;
Fenton medium -- 436;
Fer-de-lance -- 907;
fermenters, 1,000 liter -- 268;
fermenters, 500 L -- 415;
fermenters, 550 L -- 415;
ferrous sulfate -- 115;
fetal bovine serum (FBS) -- 304; 532;
fetal rhesus monkey diploid cells -- 224; 528; 532; 532;
Fibra-Cel disks -- 232;
fibroblast growth factor -- 226;
fibroblasts, autologous -- 650.5;
fibroblasts, guinea pig embryonic -- 494; 564;
fibroblasts, human -- 162; 267; 651; 652; 657; 924;
fibroblasts, MRC-5 human diploid -- 462; 463; 464; 465; 466; 518; 526; 539; 565;
fibroblasts, WI-38 human diploid -- 402; 403; 494; 527; 533; 564;
fibrosarcoma cells -- 167.5;
filamentous hemagglutinin (FHA), Bordetella pertussis -- 440;
Flavobacterium heparinum -- 924.5;
Flury LEP (Low Egg Passage) C25, rabies virus -- 529;
fms-like tyrosine kinase (FLT)-1 -- 949;
folic acid -- 105; 656;
fowlpox virus vector -- 111;
Fraction II+III paste -- 620;
FRhL diploid fetal rhesus lung cells -- 224;
FRhL-2 diploid fetal rhesus lung cells -- 224; 528; 532;
frog eggs -- 628;
fusion proteins, recombinant -- 186; 202; 253; 259; 261.5;
Ga-23-902-530 -- 209;
GAGPL promoter -- 182;
galactose -- 562;
GBM strain, hepatitis A virus -- 465; 467;
GD8/6 Chinese ovary hamster (CHO) cells -- 148;
Gene Activation -- 141; 162;
genetic diseases -- 188;
geneticin -- 105;
gentamicin (gentamycin) -- 114; 115; 179; 270; 402; 403; 653;
GI-F8/1.5.6 murine hybridoma cells -- 147; 148; 719; 721; 722;
glass beads -- 742;
glucose -- 550; 601;
glutamate -- 491; 504; 651;
glutamine synthetase (GS) expression system -- 100; 115; 116; 118; 119; 179; 221; 222; 240; 245; 257; 264;
glutamine, L- -- 105; 656; 659;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter -- 175;
glycerin -- 410;
glycerinated-water-potato medium -- 408; 409;
glycine-extended precursor -- 110;
glycine/hypoxanthine/thmidine (GHT)-free medium -- 275;
glycogen degradation -- 168; 168.5;
glycosaminoglycans (GAGs) degradation -- 105; 161; 167; 168; 168.5; 187; 188; 615;
goat milk protein promoter gene -- 102;
goats, transgenic -- 102; 123;
guinea pig embryonic fibroblast cells -- 494; 564;
Haemophilus influenzae type b -- 439; 440; 453; 454; 457; 458; 459;
Haemophilus influenzae type b strain 20,752 -- 456.5;
hair follicles, autologous -- 654;
Hall strain, Clostridium botulinum -- 601;
HAM's F-12 medium -- 651; 659;
hamster, Chinese ovary (CHO) cells -- 142;
Hank's medium (use Medium 199) -- 467;
Harvard strain, Clostridium tetani -- 455;
heat shock protein 90 -- 173;
HEK 293 human embryonic kidney cells -- 232; 233; 243;
HEK-293 cells -- 261.7; 261.7;
Helix pomatia arylsulfatase -- 182;
heparin resistance -- 102;
hepatitis A virus (HAV) -- 461; 462; 464; 465;
hepatitis A virus (HAV) HM-175 strain -- 463; 466;
hepatitis A virus GBM strain -- 465; 467;
hepatitis A virus RG-SB strain -- 462;
hepatitis B virus (HBV) -- 174; 175; 176; 177; 178; 428; 438; 439; 440; 441; 442; 452; 468; 567;
hepatitis B virus subtype adw2 -- 175; 177; 438; 441; 442;
hepatitis B virus surface antigen (HBsAg) -- 174; 175; 176; 177; 178; 460; 466; 468; 469;
hepatitis B virus surface antigen terminator -- 269;
HEPES buffer -- 656;
HER1 -- 128;
Herpes simplex virus thymidine kinase
hexametaphosphate -- 415;
Hi-5 Rix4446 cells -- 185;
High Five cell line -- 185; 271;
high molecular weight-melanoma-associated antigen (HMW-MAA) -- 309;
high-calcium medium -- 651;
hirudin variant I (HVI) -- 182;
Hirudo medicinalis (medicinal leech) -- 180; 181; 182;
HIV -- 516; 521;
HIV-1 gp41 glycoprotein -- 933;
HM-175, hepatitis A virus strain -- 463; 466;
Holt's media, modified -- 514;
honey bee melittin secretory signal sequence -- 271;
hP67.6, monoclonal antibody -- 118;
HSP90 -- 173;
HSV 1-TK cDNA--simian virus 40 (SV40) polyadenylation signal
HT-1080 human cells -- 167.5;
HuMAb-Mouse -- 116.5; 222.4; 265.5;
HuMAb-Mouse transgenic mice -- 214.5;
human cells HT-1080 -- 167.5;
human cells R223 -- 141;
human cells, chondrocytes -- 650; 650.3;
human cells, lymphoblastoid -- 121;
human cells, mesenchymal stem cells (MSCs) -- 649;
human cells, unspecified -- 265;
human cells/tissues sources -- 263;
human cytomegalovirus (hCMV) promoter -- 261.7;
human diploid cells -- 494.5; 495; 774;
human diploid fibroblast cells, MRC-5 -- 565;
human embryonic cells -- 489;
human embryonic kidney (HEK 293) cells -- 232; 233; 243;
human embryonic kidney (HEK-293) cells -- 261.7;
human embryonic lung cells -- 494; 564;
human epidermal and dermal cells -- 656;
human fibroblast cells -- 267; 462; 464; 465; 651; 652;
human keratinocytes -- 651; 653; 654; 656;
human kidney cells, neonatal -- 626; 627;
human leukocytes -- 795; 796;
human lymphoblastoid cells -- 794;
human neonatal foreskins -- 651; 652; 656; 657;
human P3x63Ag8.653 myeloma cells -- 312;
human papillomavirus (HPV) type 11 L1 virus-like particles (VLPs) -- 183; 184; 185;
human placental tissue -- 615;
human Rho(D) cells -- 776; 777; 778; 779; 780;
human rotavirus P1A -- 531;
human rotavirus stain W179 -- 531;
human thymus lymphocytes (T-cells) -- 917; 918;
human tissues -- 652;
human transferrin -- 651;
human-bovine reassortant viruses -- 531;
human-rhesus rotavirus reassortant virus serotypes 1, 2, and 4 -- 532;
hyaluronidase-E. coli maltose binding (MBP) protein fusion protein -- 186;
hybridoma 3-A3-2 -- 796;
hydridoma, murine Sp2/0-Ag14 -- 214.5;
hydrocortisone -- 651; 653; 659;
hypoxanthine, glycine, and thymidine (HGT) medium -- 269;
IMMU-4 hybridoma, murine -- 304; 307;
immune globulin (IgE) -- 189;
inase insert domain-containing region (KDR) -- 949;
influenza A/California/07/2009 (H1N1) virus -- 483.8;
influenza A/California/7/2009 (H1N1)v -- 191.1;
influenza A/California/7/2009 (H1N1)v -- 483.11;
influenza A/California/7/2009 (H1N1)v -- 483.7;
influenza A/California/7/2009 (H1N1)v NYMC X-179A virus -- 483.7;
influenza A/California/7/2009 (H1N1)v-like virus -- 483.1;
influenza A/California/7/2009 (H1N1)v-like virus -- 483.2;
influenza A/California/7/2009 (H1N1)v-like virus -- 483.3;
influenza A/California/7/2009 (H1N1)v-like virus -- 483.4;
influenza A/California/7/2009 (H1N1)v-like virus -- 483.8;
influenza A/Viet Nam/1194/2004 (H5N1) NIBRG-14 virus -- 483.7;
influenza NIBRG-14 virus -- 483.7;
influenza polymerase Basic Protein 2 (PB2) gene -- 190;
influenza strain A/Viet Nam/1194/2004 (H5N1) -- 487;
influenza virus -- 190; 191.5; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 483;
influenza virus -- 483.2;
influenza virus -- 483.3;
influenza virus A/Indonesia) (H5N1, clade 2)
influenza virus A/Vietnam/1203/2004 (H5N1, clade 1)
influenza virus H5N1 Reverse Genetics Strain NIBRG 14 -- 487;
influenza virus, cold-adapted -- 191; 486;
influenza virus, H5N1 -- 484; 485; 486; 487; 488;
insulin, bovine -- 651; 659;
insulin, recombinant -- 481; 653;
insulin, recombinant human -- 150; 150.5; 245;
integrin alpha(4) receptors -- 203;
intercellular adhesion molecule-1 (ICAM-1) -- 114;
interleukin-12 (IL-12)
interleukin-13 (IL-13) -- 217;
interleukin-23 (IL-23)
interleukin-6 receptors (IL-6r) -- 223;
irculating immune complexes (CICs) -- 700;
iron ammonium citrate -- 410;
Iscove�s medium -- 168; 168.5;
isopropyl-beta-D- thiogalactopyranoside (IPTG) -- 120; 260; 266;
IVI-10028 -- 110;
Japanese encephalitis virus -- 224; 489;
Japanese encephalitis virus (JE) prM -- 224;
Jeryl Lynn strain, mumps virus -- 492; 493; 494; 504; 534;
JM101, Escherichia coli (E. coli) -- 220;
JM107, Escherichia coli (E. coli) -- 214;
JRH Excell 302 medium -- 105; 105;
K-12 strain W3110, Escherichia coli (E. coli) -- 202;
K-12, Escherichia coli (E. coli) -- 192; 197; 213; 268;
K1 Chinese hamster ovary (CHO) cells -- 155; 168; 168.5;
K12/MM294-1, E. coli -- 218;
kanamycin sulfate -- 230;
keratinocytes, human -- 651; 653; 654; 656;
kidney (HEK 293) cells, human embryonic -- 232; 243;
kidney cells, baby hamster -- 122; 145; 149; 151;
kidney cells, canine Madin-Darby (MDCK) -- 483;
kidney cells, human embryonic -- 232; 233; 243;
kidney cells, human neonatal -- 626; 627;
kidney cells, monkey -- 224; 490; 516; 517; 520; 521; 530; 531; 532; 540;
kifunensine -- 167.5;
Klebsiella pneumoniae -- 406;
KMAC-43 vector -- 206;
KSSKC epitope -- 120;
lacI9 gene (Amersham) -- 220;
lacIq gene -- 266;
lactalbumin hydrolysate -- 520; 521;
lactose -- 500;
Latrodectus mactans -- 909;
leeches, medicinal -- 180; 181; 182;
leopard frog -- 628;
leukocyte function antigen-1 (LFA-1) -- 114;
leukocyte removal -- 806;
leukocytes, human -- 242; 795; 796;
lung cell cultures, human embryonic -- 564;
lymphoblastoid cell line SB -- 117;
lymphoblastoid cells, human -- 121; 794;
lymphocytes, B-cells -- 271; 417;
lymphocytes, human -- 115; 203; 222; 303; 917; 918;
M9 minimal medium -- 220;
MA-104 cells -- 530;
Mab 1129, murine monoclonal antibody -- 245;
Madin-Darby canine kidney cells (MDCK) -- 483;
magnesium sulfate -- 410;
maltose binding (MBP) protein, E. coli -- 186;
mammalian cell culture -- 100; 109; 114; 115; 116; 116.5; 118; 119; 121; 124; 125; 126; 128; 131; 131.5; 133; 136; 141; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 155; 156; 163; 167; 167.5; 172; 176; 179; 187; 189; 202; 203; 210; 211; 222; 222.4; 222.6; 223; 224; 227; 240; 242; 244; 245; 246; 257; 261; 262; 264; 267; 269; 270; 302; 303; 304; 305; 307; 309; 310; 311; 312; 313; 314; 315; 402; 403; 462; 463; 464; 466; 481; 483; 491; 492; 493; 493.5; 494; 496; 504; 517; 518; 519; 520; 521; 522; 523; 524; 526; 527; 528; 529; 530; 531; 532; 533; 534; 538; 539; 540; 541; 564; 565; 567; 626; 627; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 659; 794;
mannose-6-phosphate (M6P) ligands -- 168; 168.5;
mannose-6-phosphate receptors -- 105;
MCB 9710 Chinese ovary hamster (CHO) cells -- 148;
ME1719, Saccharomyces cerevisiae (yeast) strain -- 166.5;
measles virus Schertz strain -- 493.5;
measles virus Schwarz strain -- 495;
measles virus, Edmonston strain -- 491; 492; 493; 494;
measles virus, Ender strain -- 491; 492; 493; 494; 496;
media, AIM -- 242;
media, defined nutrient -- 206; 457;
media, semi-synthetic -- 455; 550; 561;
media, serum-based -- 150;
media, serum-free -- 105; 108; 115; 129; 179; 242; 275; 314; 540; 653; 732;
Medium 199 -- 446.5;
Medium 199 (M-199; Hank's medium) -- 440; 441; 442; 465; 467; 491; 504; 516; 517;
megakaryocytes -- 216; 802;
melittin secretory signal sequence -- 271;
membrane translocation -- 217;
mesenchymal stem cells (MSCs) -- 649;
mice -- 264; 303; 304; 489;
mice, Viral Antigen Free -- 304;
Microbial Surface Components Recognizing Adhesive Matrix Molecules -- 783;
microcarrier beads -- 483.8;
microcarrier culture -- 145; 187; 211; 517; 518; 519; 520; 530;
Microgen Fermentor (New Brunswick Scienctific) -- 220;
Micromonaspora echinospora -- 118;
Micrurus fulvius -- 910;
mineral salts -- 550;
minimally supplemented basal medium (MSBM) -- 651; 659;
Minimum Essential Medium (MEM) -- 532; 533; 656;
MM 294-1/pLW 45, Escherichia coli (E. coli) -- 218;
Modified Vaccinia Ankara (MVA) strain vaccinia virus -- 541;
Mojave rattlesnake venom -- 908;
monkey cells -- 245;
monkey diploid cells, fetal rhesus -- 528; 528; 532; 532;
monkey diploid cells -- 224;
monkey kidney cells -- 440; 440; 516; 517; 519; 520; 521; 530; 532; 540;
monoclonal antibodies -- 309;
monoclonal antibody VEGF Mab A.4.6.1 -- 275;
monoclonal antibody, murine -- 117; 306;
monoclonal antiibody, murine-rat chimeric -- 131;
monocytes -- 742;
Moraxella catarrhalis -- 406;
mouse strain, DI -- 129;
MRC-5 cells -- 445;
MRC-5 human diploid fibroblast cells -- 462; 463; 464; 465; 494; 518; 526; 527; 539; 564; 565;
MSCRAMM , Staphylococcus aureus -- 783;
MTT cell assay -- 652;
mucin-1 (MUC-1) gene -- 111;
Mueller and Miller medium -- 424; 426; 430; 431; 435; 443; 447; 449; 451; 454; 455; 547; 552; 555; 556; 559; 916;
Mueller Hinton agar -- 498; 499; 500; 502;
Mueller medium -- 430;
mumps virus -- 932;
mumps virus Jeryl Lynn strain -- 492; 493; 493.5; 494; 504; 534;
murine (mouse) cell line -- 176;
murine (mouse) hybridoma cells -- 117; 129; 240; 264; 301; 303; 305; 306; 309; 310; 311; 314; 315; 701;
murine (mouse) hybridoma, 225.28S -- 309;
murine ascites -- 302; 303; 304; 307; 309; 314; 701; 804;
murine brains -- 489;
murine embryonic stem (ES) cells -- 129;
murine feeder cells -- 264; 653;
murine hybridoma cells, 225 -- 128;
murine hybridoma cells, B431.13 -- 301;
murine hybridoma E7.6.3 -- 129;
murine hybridoma GI-F8/1.5.6 -- 147; 148; 721; 722;
murine monoclonal antibody, 5G1.1 -- 120;
murine myeloma cells -- 120; 128; 176; 203; 221; 240; 244; 245; 264; 313; 315; 721;
murine parainfluenza virus type 1 (Sendai strain) -- 794;
murine Sp2/0-Ag14 hydridoma -- 214.5;
murine tumor cells C-127 (C127) -- 257;
murine-rat chimeric monoclonal antibody -- 131;
muscle fascia -- 658;
MVA 572 -- 541;
MVA 572 FHE - 22.02.1974 -- 541;
MVA strain vaccinia virus -- 541;
MY-10 (MY10) murine hybridoma cells -- 701;
Mycobacterium bovis -- 407; 409; 410;
Mycobacterium bovis (Bacillus of Calmette and Guerin strain), live -- 408; 411; 412;
myeloma cell line P3-X-63-AG8-653
myeloma cells, murine -- 128; 264;
myeloma cells, P3-NS-1-Ag4 -- 315;
myeloma cells, P3X63Ag8Ul -- 303;
MYPPPY motif -- 123;
Nakayama�NIH strain, Japanese encephalitis virus -- 489;
Namalva cells -- 794;
Neisseria catarrhalis -- 406;
Neisseria meningitidis -- 452; 497; 502.5; 503;
Neisseria meningitidis B11 strain -- 458;
Neisseria meningitidis group A-1 -- 498; 499;
Neisseria meningitidis group C -- 500; 501;
Neisseria meningitidis group C-11 -- 499;
Neisseria meningitidis group W-135-6308 -- 502;
neomycin -- 119; 220; 402; 403; 481.5; 491; 504; 517; 521; 527; 529; 532;
neomycin phosphotransferase marker gene -- 105;
neomycin sulfate -- 441;
New York City Board of Health (NYCBH) vaccinia virus -- 111; 536; 537; 539; 540;
NIBRG-14, influenza A/Viet Nam/1194/2004 (H5N1) virus -- 483.7;
NIBSC 84/703 -- 262;
North American coral snake -- 910;
NR-LU-10 murine hybridoma cells -- 311;
NS-1 murine myeloma cells -- 313;
NS0 mammalian cell line -- 118; 245; 246;
NS0 murine meloma cells -- 120;
Nunc cell factories -- 464; 539;
NZ (or N-Z) Amine A -- 601;
O-phosphorylethanolamine -- 651;
Oka/Merck, varicella-zoster virus strain -- 564; 565;
OmpA signal -- 266;
osteosarcoma cells -- 108;
ovine blood infusion media -- 406;
ovine testes -- 619;
P-3Ag 8653 murine myeloma cells -- 721;
p15A, plasmid -- 266;
P1A, human rotavirus -- 531;
P3-NS-1-Ag4 myeloma cells -- 315;
P3-X-63-AG8-653, myeloma cell line -- 804;
P3x63Ag8.653 myeloma cells -- 312;
P3X63Ag8Ul myeloma cells -- 303;
p40, interleukin-12 (IL-12) and interleukin-23 (IL-23)
p53, adenovirus vector gene therapy -- 232; 233;
p7E3VHhCg4 -- 240;
p7E3VkhCk -- 240;
pAdCMVTK plasmids -- 261.7;
pAdenogal plasmids -- 261.7;
papaya -- 622;
pAPEX-3p, plasmid -- 120;
parainfluenza virus type 1, murine -- 794;
parallel-plate bioreactor (PPB) -- 539;
Park-William no. 8, Corynebacterium diphtheriae -- 419;
pAS1 plasmid -- 230;
pAT153 plasmid -- 112;
pC4 plasmids -- 208.5;
pCAV/NOT-TNFR -- 267;
pCAVDHFR -- 267;
pCAVDHFRhuTNFRFc -- 267;
pcDNAI/Amp (Invitrogen) plasmid -- 120;
pDD6 plasmid -- 214;
pDP34, yeast shuttle vector -- 182;
pDR2 (Clontech) plasmid -- 120;
pDW24 plasmid -- 220;
pDW27 plasmid -- 220;
pEE12.1, plasmids -- 208.5;
penicillin -- 653;
pepticase -- 196;
peptidase -- 182;
peptidyl-glycine alpha-amidating monooxygenase (PAM) -- 110;
peptone (medium) -- 182; 196; 270; 406; 424; 431; 443; 447; 513;
peptone (medium) -- 513.3; 544; 549; 550; 555; 556; 563;
pER10088 plasmid -- 202;
perfusion bioreactors -- 105; 119; 163; 232; 240; 264; 312; 409; 539; 540;
periosteum -- 650;
pET Trc SO5/NI plasmid -- 120;
pFE4S plasmid -- 105;
pGB20, pGB37 and pGB42 plasmids -- 167;
PH05 signal sequence -- 182;
PHA synthetase -- 241;
phage display -- 119; 225; 265;
phage T4 -- 260;
phiX-174 -- 779;
phosphorylethanolamine -- 659;
photoactivation, antibody -- 301;
pHuGTAC1 plasmid -- 222;
phuIL13-Tx plasmid -- 217;
pHuLTAC plasmid -- 222;
Pichia pastoris (yeast) expression -- 153; 225;
pit vipers -- 907;
pIXY15 plasmid -- 169;
pIXY498 plasmid -- 267;
pKV308 plasmid -- 166.5;
placental tissue, human -- 615;
plant cell culture -- 167.3;
pLAPC, plasmid -- 243;
Plasma -- 742;
plasma, equine -- 907; 909; 910; 912; 916; 918;
plasma, human media component -- 149; 151;
plasmid p15A -- 266;
plasmid p7E3VkappahCkappa -- 240;
plasmid pAPEX-3p -- 120;
plasmid pAS1 -- 230;
plasmid pAT153 -- 112;
plasmid pCAV/NOT-TNFR -- 267;
plasmid pCAVDHFR -- 267;
plasmid pCAVDHFRhuTNFRFc -- 267;
plasmid pcDNAI/Amp (Invitrogen) -- 120;
plasmid pDD6 -- 214;
plasmid pDP34/GAPFL-YHIR -- 182;
plasmid pDR2 (Clontech) -- 120;
plasmid pDW24 -- 220;
plasmid pDW27 -- 220;
plasmid pER10088 -- 202;
plasmid pET Trc SO5/NI -- 120;
plasmid pFE4S -- 105;
plasmid pGB20, pGB37 and pGB42 -- 167;
plasmid pHuGTAC1 -- 222;
plasmid phuIL13-Tx -- 217;
plasmid pHuLTAC -- 222;
plasmid pIXY15 -- 169;
plasmid pIXY498 -- 267;
plasmid pKV308 -- 166.5;
plasmid pLAPC -- 243;
plasmid pLPC -- 243;
plasmid pLW45 -- 218;
plasmid pNM21 -- 112;
plasmid pOA15 -- 230;
plasmid pRK -- 269;
plasmid pTACdenV -- 260;
plasmid pTTO -- 266;
plasmid, Bluescript (Stratagene) -- 267;
plasmid, ptPA/DHFR -- 269;
plasmids, pAdCMVTK -- 261.7;
plasmids, pAdenogal -- 261.7;
plasmids, PC4 -- 208.5;
plasmids, pEE12.1 -- 208.5;
plasmids, pPPC0005
plasmids, pSAC35 -- 208.5;
Platelets -- 803;
pLPC, plasmid -- 243;
pM2/alpha vector -- 122;
pMT612 -- 166;
pNM21 plasmid -- 112;
pOA15 plasmid -- 230;
poliomyelitis virus -- 446;
poliovirus type 1 -- 439; 440; 441; 442; 517; 518; 519; 521; 522;
poliovirus type 2 -- 439; 440; 441; 442; 521; 523;
poliovirus type 3 -- 439; 440; 441; 442; 521; 524;
polycarbonate molds -- 651;
polyethyleneimine -- 202;
polyglactin matrix -- 652;
polyglycolic acid matrix -- 652;
polyhedrin promotor -- 271;
polymyxin B -- 441;
porcine dermal collagen -- 657;
porcine endogenous retroviruses (PERV) -- 901;
porcine lung surfactant -- 943;
porcine pancreas -- 632; 633;
porcine parvovirus (PPV) -- 901;
porcine teeth -- 931;
porphobilinogen deaminase -- 716;
potassium phosphate -- 410;
potato medium, glycerinized -- 408;
poxvirus vectors, vaccinia -- 111;
pPPC0005, plasmids -- 208.5;
preproinsulin 5� UTR, rat -- 105;
prethrombin-1 precursor -- 261;
pRIT12363 plasmid -- 175;
pRK plasmid -- 269;
ProCellEx expression system -- 167.5;
protease inhibition -- 105;
Protein A affinity chromatography -- 129;
Protein C zymogen -- 243; 804;
prothrombin, gla-domainless -- 261;
pSAC35
Pseudomonas aeruginosa -- 542;
Pseudomonas aeruginosa exotoxin A�N-succinimidyl 3-(-2-pyridyldithio)propionate -- 542;
Pseudomonas exotoxin (PE38) -- 217;
Pseudomonas sp. strain RS-16 -- 112;
pTACdenV plasmid -- 260;
ptPA/DHFR plasmid -- 269;
pTTO plasmid -- 266;
Puziss-Wright 1095 -- 404;
PYinsl yeast cells -- 193;
pyrimidine dimer DNA glycosylase -- 260;
quadroma -- 131.5;
quadromas -- 131;
R223 human cells -- 141;
RA 27/3 Wistar Inst. strain, rubella virus -- 493; 494; 496; 533; 534;
RA27/3 strain, rubella virus -- 494.5; 495;
rabbits -- 917;
rabbits, transgenic -- 113; 168;
rabies vaccine -- 774; 775;
rabies virus -- 528;
rabies virus strain CL-77 -- 526;
rabies virus strain Flury LEP (Low Egg Passage) C25 -- 529;
rabies virus strain Kissling -- 528;
rabies virus strain Pitman-Moore PM-1503-3M -- 527;
rabies virus strain SAD (Street Alabama Dufferin) -- 526;
Rana pipiens -- 628;
RANKL -- 244;
rat medullary thyroid carcinoma cells -- 110;
rat preproinsulin 5� UTR gene -- 105;
rat-murine chimeric monoclonal antibody -- 131;
rattlesnakes -- 907; 908;
reassortant viruses -- 486;
Receptor Activator of NF-KB -- 244;
Red Blood Cells (erythrocytes) -- 716;
respiratory syncytial virus (RSV) F protein -- 246;
respiratory syncytial virus (RSV) fusion (F) protein -- 245;
retroviruses, porcine endogenous -- 901;
reverse genetics -- 486;
RG-SB strain, hepatitis A virus -- 462;
rhesus lung cells, diploid fetal -- 224; 528; 532; 532;
rhesus rotavirus (serotype 3) -- 532;
rhesus-human rotavirus reassortant virus serotypes 1, 2, and 4 -- 532;
Rho(D) (D-positive) red blood cells -- 776; 777; 778; 779;
RNA intercalation -- 803;
rodent cells -- 109; 115; 116; 116.5; 118; 126; 133; 134; 135; 136; 137; 139; 140; 144; 145; 146; 147; 149; 150; 151; 152; 155; 156; 163; 167; 179; 187; 189; 210; 211; 221; 222; 227; 228; 240; 257; 262; 264; 267; 269; 270; 275; 302; 303; 304; 305; 307; 310; 311; 312; 313; 313; 314; 315;
roller bottles -- 143; 162; 304; 464;
rotavirus -- 532;
rotavirus 89-12C2 -- 530;
rotavirus stain BrB, human -- 531;
RPMI 1640 -- 794;
rubella virus Wistar Inst. RA 27/3 strain -- 493; 493.5; 494; 494.5; 495; 496; 533; 534;
RV308, Escherichia coli (E. coli) strain -- 112;
SA14-14-2, Japanese encephalitis virus -- 224; 490;
Saanen
Saccharomyces cerevisiae (yeast) -- 100; 101; 166; 169; 181; 182; 184; 193; 195; 196; 200; 208.5; 228; 237; 238; 239; 248; 272; 439; 440; 465; 466; 629;
Saccharomyces cerevisiae (yeast) 1454 cells -- 182;
Saccharomyces cerevisiae (yeast) strain 2150-2-3 -- 174; 175; 178;
Saccharomyces cerevisiae (yeast) strain DC5 (RT4376) -- 175; 177; 438; 441; 442; 463;
Saccharomyces cerevisiae (yeast) strain ME1719 -- 166.5;
Saccharomyces cerevisiae (yeast) strain YES2085 -- 166.5;
Saccharomyces cerevisiae MF.alpha.1 signal sequence -- 261;
Saccharomyces cerevisiae spheroplasts -- 129;
Salmonella minnesota -- 938;
Salmonella typhi -- 560; 562; 563;
Salmonella typhi Vi (Ty 2 strain) -- 467; 561;
Sauton medium -- 409;
SB, lymphoblastoid cell line -- 117;
Schertz strain, measles virus -- 493.5;
Schwarz strain, measles virus -- 495;
SelectAME -- 246;
selenious acid -- 651; 659;
semialdehyde dehydrogenase -- 241;
Sendai virus -- 794; 795; 796;
serine -- 105;
Serratia marcescens endonuclease -- 539; 540;
Serum (Human), immunoglobulin-depleted -- 795;
serum, fetal calf -- 105; 140; 402; 403; 652;
SF9 cells -- 191.5;
SGE90, Escherichia coli (E. coli) -- 214;
silica (diatomaceous earth) -- 700;
simian immunodeficiency virus (SIV) -- 516;
simian virus 40 (SV40) -- 516; 519;
skin cells, human -- 656;
snake venoms -- 907; 908; 910;
sodium bicarbonate -- 656; 659;
sodium hexametaphosphate -- 415;
sooty mangabey kidney cells -- 516;
Source Leukocytes -- 795;
Souton medium -- 408;
soy peptone -- 182; 513;
soy peptone -- 513.3;
Sp2/0 murine hybridoma/myeloma cells -- 117; 222; 240; 264;
SP2/Ag14 cells -- 130;
SPGA (sucrose, phosphate, glutamate, albumin) -- 491; 504;
spheroplasts, Saccharomyces cerevisiae (yeast) -- 129;
spider venom, black widow -- 909;
Spodoptera frugiperda Sf21 -- 242;
Spodoptera frugiperda Sf9 caterpillar cells -- 191.5;
SR1268, Escherichia coli (E. coli) strain -- 260;
Stainer-Scholte medium -- 430; 431; 436; 507; 508;
Stainer's Diphtheria Culture Medium -- 420;
Staphylococcus aureus -- 542; 700;
Staphylococcus aureus MSCRAMM proteins -- 783;
Staphyloococcus aureus -- 406;
stem cells, mesenchymal -- 649;
Sterile Water for Injection -- 659;
stirred-tank, fed-batch system -- 245;
stratum corneum, human -- 651;
Streptocccus pneumoniae -- 406;
Streptococcus bacteria -- 929;
Streptococcus pneumoniae -- 512; 513;
Streptococcus pneumoniae -- 513.3; 513.5; 514; 515;
Streptococcus viridans -- 406;
Streptococcus, group C beta-hemolytic -- 606; 624; 625;
Streptomyces lividans -- 171;
streptomycin -- 517; 521; 653;
stroma -- 652; 657;
suspension cell culture -- 115; 179;
SV-40 promoter -- 269;
SV40 origin of replication -- 105;
T-Flask culture -- 245;
T4 bacteriophage -- 260;
TAC promoter -- 260; 266;
tanks, 8,000 Liter -- 794;
Taxus media -- 703.5;
teeth, porcine -- 931;
tetanus toxin -- 784;
tetracycline -- 204;
tetracycline resistance gene -- 266;
tetramethylurea -- 794;
tetrazolium -- 652;
TFF-Cell Separation System -- 416;
thioredoxin/interleukin-11 fusion protein -- 221;
three-demensional cell culture -- 651;
thymine -- 220;
thymocytes, human -- 917; 918;
tissue culture, three-dimensional -- 651; 652; 657;
tissue plasminogen activator leader sequence -- 261;
TNF40 murine (mouse) monoclonal antibody -- 266;
Toggenburg
Tohama strain, Bordetella pertussis -- 508;
toxin production medium (TPM) -- 601;
transferrin, bovine -- 115; 162; 245; 312;
transferrin, human -- 651; 659;
transgenic goats -- 102; 123;
transgenic mice -- 116.5; 222.4; 265.5;
transgenic rabbits -- 113; 168;
transgenic XenoMouse mice -- 129;
trc promoter -- 220;
Trichopulsia ni High Five cells -- 185; 271;
TRICOM -- 111;
triiodothyronine -- 651; 653; 659;
trioma -- 131.5;
tris (tromethamine) -- 197;
trypsin -- 483.8;
trypsin -- 565;
trypticase soy agar medium -- 414;
tumor cells -- 417;
tumor-associated antigen, CA125 -- 301;
tumor-associated glycoprotein-72 (TAG-72) -- 315;
two-chain expression method -- 192;
ubiquitin protein peptidase -- 202;
Ubiquitous Chromatin Opening Element -- 149;
UCOE -- 149;
UltiMAb -- 116.5; 222.4;
UltiMAb HuMAb-Mouse transgenic mice -- 214.5;
vaccinia virus -- 535;
vaccinia virus Conn-Master 17633 strain -- 537;
vaccinia virus strain, CVA -- 541;
vaccinia virus strain, Elstree-BN -- 538;
vaccinia virus strain, Modified Vaccinia Ankara (MVA) -- 541;
vaccinia virus vaccine -- 788; 789; 790;
vaccinia virus, New York City Board of Health (NYCBH) -- 111; 536; 537; 539; 540;
vancomycin -- 653;
Varicella Virus Vaccine -- 791; 792;
varicella-zoster virus strain Oka/Merck -- 564; 565;
Variovorax paradoxus -- 112;
vascular endotelial growth factor (VEGF) -- 949;
vascular endothelial cell growth factor (VEGF) -- 275; 276;
veal infusion agar -- 563;
VEGF Mab A.4.6.1 monoclonal antibody -- 275;
VEGF-165 -- 949;
Vero cells -- 224; 437.5; 440; 445; 445; 446.5;
Vero cells -- 483.8; 490; 517; 520; 530; 531; 540;
vesicular stomatitis virus (VSV) -- 211; 796;
Vibrio cholerae Inaba (NIH 35A3) -- 414;
Vibrio cholerae O1 Inabo, classic -- 415;
Vibrio cholerae O1 Inabo, El Tor -- 415;
Vibrio cholerae O1 Oqawa, classic -- 415;
Vibrio cholerae O1 Oqawa, El Tor -- 415;
Vibrio cholerae Ogawa (NIH 41) -- 414;
Vicryl polymer matrix -- 652;
Viral Antigen Free mice -- 304;
viral inactivation, detergent -- 475;
virus culture -- 176; 183;
virus culture -- 191.1; 229; 462; 463; 464; 465; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 481.5; 482; 483;
virus culture -- 483.1;
virus culture -- 483.11;
virus culture -- 483.2;
virus culture -- 483.3;
virus culture -- 483.7;
virus culture -- 483.8; 484; 485; 486; 487; 488; 489; 491; 492; 493; 494; 494.5; 495; 496; 504; 533; 534; 536; 537; 538; 539; 540; 541; 564; 565; 566; 567;
virus inactivation, beta-propriolactone -- 481;
virus vector, fowlpox -- 111;
virus vector, vaccinia virus -- 111;
VLA-4 -- 203;
W179, human rotavirus stain -- 531;
WAG/Rij rat medullary thyroid carcinoma cells -- 110;
water moccasin venom -- 907; 908;
Watson Scherp media -- 498; 499; 500; 502;
WC-3, bovine rotavirus -- 531;
WC-3, bovine rotavirus G6 strain -- 531;
WI-38 human diploid fibroblasts -- 402; 403; 494; 527; 533; 564;
WISH cells -- 211;
Wistar Calf-3 (WC3), bovine rotavirus stain -- 531;
XenoMouse, transgenic -- 129;
XV2181, Saccharomyces cerevisiae (yeast) strain -- 169;
yeast 2� plasmid -- 196;
yeast acid phosphatase (PH05) -- 182;
yeast artificial chromosome (YAC) vectors -- 129;
yeast extract -- 406; 457; 601;
yeast shuttle vector pDP34 -- 182;
yellow fever virus strain 17D -- 566; 567;
yellow fever virus strain 17D vector -- 224;
Yersinia pestis (plague bacteria) -- 511;
YES2085, Saccharomyces cerevisiae (yeast) strain -- 166.5;
ZS7, Borellia burgdorferi -- 230;
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide -- 205;
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) -- 542;
1,4-butandiol diglycidylether (BDDE) -- 929;
2-deoxyinosine -- 605;
2-ethoxyethanol -- 621.5;
2-phenoxyethanol -- 230; 423; 430; 433; 437; 437.5; 441; 442; 445; 446.5; 463; 465; 466; 467; 517;
2,3-diphosphoglycerate (2,3-DPG) -- 806;
2,3,5,6-tetrafluorophenyl-4,5-bis-S-(1-ethoxyehtyl)-thioacetoamidopentoate) -- 311;
2.2.9 monoclonal antibody -- 147;
2'-deoxyadenosine (DDA) -- 605;
3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-7H-furo(3,2-g)(1)benzopyran-7-one -- 803;
3-A3-2, monoclonal antibody -- 796;
3-beta-D-ribosyl(1-1)ribitol(5-phosphate)-PRP -- 457;
3-deacylated monophosphoryl lipid A -- 177; 185;
3F-concentrate -- 732;
4-acetylphenylacetic acid -- 118;
4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) -- 112;
4-methylumbelliferyl sulphate -- 105;
4-methylumbelliferyl-a-iduronide -- 187;
5 ,20-Epoxy-1,2 ,4,7 ,10 ,13 -hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine -- 703.5;
8A4 Sepharose -- 150;
Absorbable Gelatin Sponge, USP -- 920;
acellular Pertussis Vaccine -- 437.5; 444; 445; 446;
acetic acid -- 110; 181; 205; 212; 212.5; 239; 307; 311; 314; 930.5; 931;
acetone -- 402; 403; 563;
acetonitrile -- 914;
acetylcholine -- 601; 603;
acetylglucosamidase -- 167;
Achromobacter lyticus protease (ALP) -- 196;
acid conditions (low pH) -- 118; 760; 763; 770; 772;
acrinol -- 918;
adenine -- 806;
adenine triphosphate (ATP) -- 806;
adenoside deaminase, bovine -- 605;
adenosine -- 605;
adipic acid dihydrazide (ADH) -- 454;
ADSOL -- 702;
Adsorbable Collagen Sponge (ACS) -- 108;
affinity chromatography -- 112; 142; 220; 710; 736; 914;
affinity chromatography, cellufine sulfate -- 144;
affinity chromatography, concanavalin A -- 168; 168.5;
affinity chromatography, DNA -- 260;
affinity chromatography, heparin-like -- 144;
affinity chromatography, peptide ligands -- 150.5;
affinity chromatography, Q-Sepharose-FF -- 144;
agarose -- 723; 725;
agarose single-stranded DNA -- 260;
alanine -- 272; 493.5; 707; 713.7; 714;
Albumin -- 703.5;
Albumin (Human) -- 117; 133; 136; 143; 147; 149; 150; 151; 152; 170; 186; 187; 204; 206; 210; 211; 212; 212.5; 263; 402; 403; 491; 492; 493; 494; 496; 504; 526; 527; 529; 533; 534; 540; 601; 603; 604; 606; 615; 624; 625; 626; 708; 710; 711; 719; 721; 722; 723; 724; 725; 726; 736; 736.5; 739.5; 747; 748; 749; 761; 767; 771; 780; 781; 790; 794; 795; 796; 798; 800; 804;
albumin, bovine -- 310; 463; 464; 651;
albumin, bovine serum -- 467; 900;
albumin, ovine -- 908;
alginate, propylene glycol -- 931;
alkali lysis -- 609;
alkaline sterilization -- 108;
allantoic fluid, chicken -- 190;
allantoin -- 272;
alpha factor leader peptide -- 169;
alpha granules -- 802;
alpha tocopheryl acid succinate (vitamin E succinate) -- 476;
alpha-amidating enzyme -- 110;
alpha-tocopherol
alpha1-chymotrypsin -- 711;
alpha1-lipoprotein -- 711;
alpha2-plasmin inhibitor -- 711;
aluminium hydroxide -- 446.5;
aluminium hydroxide, hydrated -- 185;
aluminium phosphate -- 437.5;
aluminum -- 437; 724;
aluminum adjuvant -- 432; 485;
aluminum hydroxide -- 175; 176; 230; 404; 422; 427; 433; 434; 435; 436; 440; 441; 442; 458; 460; 462; 463; 464; 465; 466; 467; 490; 490; 501; 551; 553; 554; 724; 726; 937;
aluminum oxide -- 700;
aluminum phosphate -- 423; 425; 426; 430; 435; 437; 441; 442; 445; 449; 451; 466; 510; 513;
aluminum phosphate -- 513.3; 528; 550; 552; 559; 937;
aluminum potassium sulfate (alum) -- 103; 177; 178; 184; 424; 431; 443; 447; 454; 549; 555; 556; 916;
Amberlite -- 402; 403;
amelogenin -- 931;
amidolysis assays -- 268;
amikacin -- 653;
amino acid mixture -- 562;
amino acid oxidases -- 907;
amino acids -- 530;
aminocaproic acid -- 606;
aminohexyl-sepharose gel -- 731;
aminohydrolase -- 608; 609;
ammonia -- 605; 609; 611;
ammonia sulfate -- 804;
ammonium acetate -- 204;
ammonium carbonate acid -- 219;
ammonium chloride -- 795;
ammonium salts -- 550;
ammonium sulfate -- 420; 424; 430; 431; 443; 447; 454; 455; 459; 508; 513;
ammonium sulfate -- 513.3; 544; 547; 549; 555; 556; 601; 609; 912; 916;
amotosalen
amphotericin B -- 653;
amyloid P -- 804;
amylose resins -- 186;
Anti-Inhibitor Coagulant Complex ref. standard -- 704; 705;
antibody photoactivation -- 301;
Anticoagulant Citrate Dextrose Solution (ACD-A; ACD-B) -- 702;
Anticoagulant Citrate Phosphate Dextrose Adenine Solution (CPDA-1) -- 702;
Anticoagulant Heparin Solultion -- 702;
Antigenic Test for Tetanus Toxoid Component -- 543;
antithrombin III (AT-III) -- 181; 711; 798; 805;
ANX resin, Pharmacia Biotech -- 760;
aprotinin -- 736.5;
aprotinin, bovine -- 737;
arcitumomab -- 307;
arginine -- 191;
arginine -- 191.1; 215; 268; 269; 270; 493.5; 725;
arginine hydrochloride -- 267; 736;
argon -- 307;
AS(04) adjuvant -- 177; 185;
AS03 -- 483.7;
AS03 adjuvant -- 485;
ascorbic acid -- 305; 562;
asparaginase, L- -- 611;
asparagine -- 609;
aspartic acid -- 493.5;
aspirin -- 767; 934;
B2036 -- 259;
B3-desamido insulin detemir -- 196;
baby hamster kidney proteins -- 145;
bacillus Calmette-Guerin (BCG) -- 649.5;
bacterial capsular polysaccharides -- 443; 451; 452; 455; 460; 498; 502.5; 503; 513;
bacterial capsular polysaccharides -- 513.3; 513.5; 515; 542;
Bacteriostatic Water for Injection -- 169; 179; 206; 250; 257; 258; 267; 907;
barium citrate -- 731; 733;
bentonite -- 767;
benzene -- 118;
benzethonium chloride -- 404; 920;
Benzonase -- 245; 539; 540;
benzyl alcohol -- 110; 133; 169; 179; 204; 205; 250; 253; 256; 257; 258; 267; 924.5;
Bergman cycloaromatization -- 118;
beta-mercaptoethanol -- 220;
beta-propiolactone (BPL; beta propiolactone) -- 472; 476; 482; 483; 526; 527; 528; 529; 743;
beta-propiolactone (BPL) -- 483.3;
beta-propriolactone (BPL) -- 481;
beta-propriolactone (BPL) -- 483.2;
beta-tricalcium phosphate -- 237;
Biomax-10 membrane (Millipore) -- 113;
biopharmaceutical products -- 621.5;
Biorex-70 resin -- 250;
bis-monomethoxy polyethylene glycol -- 205;
Blue Sepharose -- 138;
Blue Sepharose 6 Fast Flow (FF) -- 105;
borax (disodium tetraborate decahydrate) -- 178;
Bordetella pertussis fimbriae agglutinogen (Agg) -- 430; 437;
Bordetella pertussis toxoid, recombinant -- 432;
botulinum toxin type A protoxin -- 601;
botulinum toxins -- 413; 600; 602;
bovine adenoside deaminase -- 605;
bovine alpha-S1 casein milk-specific promoter -- 113;
bovine aprotinin -- 737; 738;
bovine collagen -- 108; 651; 659; 808; 922; 923;
bovine extracellular collagen matrix -- 651;
bovine IgG -- 145;
bovine lung surfactants -- 941; 942;
bovine milk proteins -- 602;
bovine pituitary extract -- 651;
bovine prothrombin -- 920;
bovine serum -- 494; 526; 565;
bovine serum albumin -- 445;
bovine serum albumin (BSA) -- 310; 463; 464; 467; 651; 900;
bovine serum, fetal -- 491; 492; 493; 496; 504; 531; 534;
bovine thrombin -- 240; 243; 737; 738; 919; 922; 923;
bovine thromboplastin -- 920;
Branched PEG -- 205;
brilliant green (dye) -- 536;
bromide -- 454;
brominated phenols -- 166.5;
butanol, 2- -- 212; 212.5;
butanol, 2-methyl-2- -- 212; 212.5;
Butyl Toyopearl HIC -- 138;
C-peptide -- 192;
C1-esterase inhibitor -- 711;
C7F7 monoclonal antibody -- 149;
cA2, chimeric tumor necrosis factor Mab -- 264;
calcitonin-glycine fusion protein -- 110;
calcium -- 240; 243; 502; 725;
calcium carbonate -- 530;
calcium chloride -- 126; 138; 140; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 268; 474;
calcium chloride -- 483.2; 487; 617; 618; 719; 723; 724; 736; 736.5; 737; 809; 920;
calcium oxide -- 700;
calcium phosphate -- 705; 728;
calcium phosphate hydroxide -- 457;
calcium phosphate, beta-tri- -- 237;
calf thymus DNA -- 260;
calicheamicin -- 118;
calicheamicin N-acetyl gamma dimethyl hydrazide -- 118;
cancer, hairy cell leukemia -- 796;
Capromab -- 312;
caprylic acid (caprylate) -- 760;
carbodiimide (EDAC) -- 454; 455; 459;
carbodiimide condensation -- 456.5;
carbohydrate gels, cross-linked sulfated -- 708;
carbon dioxide (CO2 gas; dry ice) -- 210; 567; 601; 651;
carbon dioxide (CO2) -- 242;
carboxymethylcellulose sodium salt -- 251;
carboxypeptidase-B -- 192;
carcinoembryonic antigen (CEA) -- 304;
carcinoembryonic antigen (CEA) monoclonal antibody -- 307;
casamino-acids -- 185;
casein hydrolysate -- 420;
castor oil -- 402; 403; 736;
CD15 monoclonal antibody -- 305;
CD20 monoclonal antibody -- 117; 306;
CD25 subunit of IL-2 receptor -- 222;
CD3 antibodies -- 131;
CD33 murine IgG1 monoclonal antibody -- 118;
CD34 monoclonal antibody, murine -- 701;
cellufine sulfate affinity chromatography -- 144;
cellulose acetate phthalate (CAP) -- 402; 403;
cementum -- 931;
Cenolate -- 308;
ceramide -- 167;
ceramide trihexoside -- 161;
certolizumab -- 266;
ceruloplasmin -- 713.7; 714;
cesium chloride (CsCl) -- 175; 261.7;
cetic acid -- 234;
cetrimonium bromide -- 498; 500; 502;
cetyltrimethylammonium bromide (CTAB) -- 474; 481; 487;
CH-Sepharose 4B, activated -- 240;
chelate EMD copper chromatography -- 144;
Chelating Sepharose fast flow (Pharmacia)
chelation -- 311; 312; 314;
Chelex-100, Bio-Rad -- 240; 243;
Chemilog process -- 934;
chicken proteins -- 474; 487; 529;
chloroform -- 614; 942;
cholera toxin B, recombinant -- 415;
cholesterol -- 942;
chondroitin sulfate -- 105;
ChromaPlus process -- 776; 780;
chromatography, chelate EMD copper -- 144;
chromatography, tandem anion-exchange -- 760;
Chromogenic Substrate -- 150;
chromosulphonic acid -- 742;
chrondroitin-6-sulfate -- 659;
chymopapain -- 701;
Citrate Phosphate Double Dextrose Solution (CP2D) -- 702;
citric acid -- 110; 133; 136; 167; 170; 220; 227; 231; 257; 265; 310; 415; 474; 487; 532; 702; 771; 795;
CLB-FIX D4, murine monoclonal antibody -- 732;
Cohn Fraction II -- 771; 785;
Cohn Fraction IV -- 705;
collagen -- 658; 659;
collagen, bovine -- 108; 109; 922;
collagen, porcine dermal -- 652; 657;
collagenases -- 907;
Complement-Fixation Test -- 932;
concanavalin A affinity chromatography -- 168; 168.5;
conjugates (see also radioimmune conjugates; immunotoxins; fusion proteins) -- 417; 513.5;
copper -- 110;
copper (CU+2) chelating Sepharose Fast Flow (FF) -- 105;
CorrTest -- 779;
corticosteroids -- 221; 222;
Corynebacterium diphtheriae CRM197 protein -- 444; 451; 457; 501; 513;
Corynebacterium diphtheriae CRM197 protein -- 513.3;
Corynebacterium diphtheriae CRM197 protein (CRM197) -- 502.5;
CpG DNA sequences -- 945;
cresol, meta- -- 195; 196; 197; 198; 234; 239; 248; 248; 252; 254;
CRM197 protein -- 451; 457; 501; 513;
CTAA16.88 monoclonal antibody -- 121;
CTH -- 161;
cyanoborohydride -- 457;
cyanogen bromide -- 456.5;
cyanogen bromide (CNBr) -- 192; 260; 804; 908;
cyclopentaperhydrophenanthrene:lactone -- 914;
cyclopentaperhydrophenanthrene:lactone�keyhole limpet hemocyanin (KLH) conjugate -- 914;
cyclosporine -- 221; 222;
cystamine -- 542;
cysteine -- 307; 493.5; 908; 935; 936;
cystine -- 423; 493.5; 530;
CYT-063 monoclonal antibody -- 314;
cytokeratin tumor antigen -- 121;
Cytomegalovirus Immune Globulin Paste -- 748;
cytomegalovirus major immediate early region 2 mRNA -- 946;
D(RH1) antibodies -- 779;
DAB389 -- 220;
Daronrix -- 485;
DEAE cellulose -- 730;
DEAE Sepharose -- 118; 138; 713.7; 714; 805;
DEAE Sepharose -- 105;
dense bodies -- 802;
deoxyribonuclease (DNase) -- 614; 624; 907;
dermatan sulfate -- 105; 188;
desamido-somatropin -- 248;
detergent -- 481;
dextran matrix -- 118; 518;
dextrose -- 212; 212.5; 218; 402; 403; 423; 702; 733; 806;
dextrose monohydrate
DIAION HP 20 -- 181;
diatomite silica (diatomaceous earth) -- 700;
dibasic sodium phosphate -- 248;
dibutyl phthalate -- 621.5;
diethylenetriaminepentaacetic acid (DTPA) -- 302; 310;
digoxin (or digitoxin) -- 913; 914; 915;
digoxin-albumin conjugate -- 913;
digoxindicarboxymethoxylamine (DDMA) -- 914;
Diluent for Nutropin Depot -- 251;
dimethicone -- 621.5;
dimethylsulfoxide (DMSO) -- 606; 652;
dipalmitoylphosphatidylcholine (DPPC) -- 941; 942; 943;
Diphtheria and Tetanus Toxoids Adsorbed Combined Bulk (For Further Manufacturing Use -- 436;
diphtheria toxin -- 220; 419; 420; 502.5; 503;
diphtheria toxin-neutralizing antibody fragments -- 916;
Diphtheria Toxoid -- 419; 420; 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 454; 502.5; 503; 555; 556; 557; 558; 559;
dipotassium hydrogen phosphate -- 268;
disodium hydrogen phosphate -- 221; 255; 263; 409; 415; 472; 483; 526; 566; 928;
disodium hydrogen phosphate dihydrate -- 195;
disodium hydrogen phosphate dodecahydrate -- 927;
disodium phosphate -- 175; 196; 253; 254; 440; 474; 485; 487; 561; 796;
disodium phosphate dihydrate -- 166.5;
disulfide solution -- 268;
dithiothreitol (DTT) -- 212; 212.5; 219; 743; 765;
divinyl sulfone (DVS) -- 928;
DL-alpha-tocopherol (vitamin E) -- 483.7;
DNA oxidative cleavage -- 118;
DNA repair enzymes -- 260;
DNA, human -- 141;
DNA, mammalian -- 564;
double-stranded DNA -- 948;
doxorubicin -- 628;
Dulbecco's Modified Eagle Medium (DMEM) -- 530;
Duploject syringe -- 737; 738;
Durapore membrane -- 454;
DV50 membrane filter -- 227;
dye affinity chromatography -- 142;
Dynabeads -- 701;
egg proteins -- 483.2;
egg proteins -- 483.3;
egg 487;
elastin -- 658;
ellagic acid -- 705;
enamelin -- 931;
enteric coating (tablets) -- 402; 562; 621.5;
EpCAM 131.5;
Erythrina trypsin inhiibitor (ETI)-Sepharose -- 268;
ethanamine -- 794;
ethanol -- 208; 402; 403; 419; 458; 491; 492; 496; 514; 515; 542; 552; 609; 620; 704; 705; 712; 716; 723; 728; 729; 731; 743; 747; 748; 752; 754; 758; 760; 761; 765; 766; 767; 768; 770; 771; 772; 774; 775; 777; 779; 780; 781; 782; 785; 787; 788; 791; 796; 800; 805; 917; 929;
ethanolamine -- 651;
ethyl ether -- 443; 453; 470; 471; 478; 479; 480;
ethyl mercury -- 908; 939;
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) -- 542;
ethylene glycol -- 795;
ethylene oxide -- 241;
ethylenediaminetetraacetic acid (EDTA) -- 169; 212; 212.5; 214; 218; 220; 305; 494; 564; 617; 931;
F8.1 murine monoclonal antibody -- 147; 148; 721; 722;
Factor II -- 805;
Factor IIa -- 150; 805;
Factor IX -- 704; 798; 805;
Factor IX murine monoclonal antibody -- 731; 732;
Factor IX WHO International Standard -- 730;
Factor IXa -- 805;
Factor V -- 798; 799;
Factor VII -- 704; 728; 730; 731; 733; 734; 798; 799; 805;
Factor VIIa murine monoclonal antibody -- 145;
Factor VIII -- 716; 739; 798;
Factor VIII coagulant antigen (F VIII C:Ag) -- 704;
Factor VIII monoclonal antibodies -- 147; 148; 149; 151; 152; 721; 722; 723;
Factor VIII peptide ligands -- 150.5;
Factor VIII SQ murine monoclonal antibody -- 150;
Factor X -- 728; 729; 730; 731; 733; 734; 799; 805;
Factor Xa -- 150; 805;
Factor XI -- 798; 799;
Factor XII -- 716;
Factor XIII -- 716; 798; 799;
fanolesomab -- 305;
Fast-Flow Q resin, Pharmacia -- 240; 243;
fatty acids -- 941;
fatty-acid esters -- 561;
FD&C blue No.2 -- 621.5;
FD&C Yellow 5 -- 402; 403;
Feiba bulk powder -- 737; 738;
ferric oxide -- 700;
fetal bovine serum (FBS) -- 531;
fetuin -- 434;
fibrin -- 268; 269; 614; 626;
Fibrin Sealant Warming Tray -- 739;
fibrinogen -- 626; 716; 726; 737; 738; 739; 798; 799; 920; 921; 922; 923;
Fibrinogen (Human) -- 736;
fibrinogen
fibrinolysin -- 614;
Fibrinolysis Inhibitor Solution (Synthetic) -- 736.5;
fibroblast uptake assay -- 105;
fibronectin -- 716; 724;
fibronectin, human -- 736;
filamentous hemagglutinin (FHA), Bordetella pertussis -- 430; 431; 432; 436; 437; 437.5; 439; 441; 442; 506; 507;
filgrastim -- 159;
filters, Pall Utrapore VF DV 50 -- 805;
Filtrate (Effluent) III -- 765;
First International Reference Preparation for human menopausal gonadotropins (code 70/45) -- 155;
flavor, raspberry -- 415;
fluorenyl-methoxycarbonyl (Fmoc) peptide synthesis -- 933;
FluroTec-coated stopper -- 136;
follicle-stimulating hormone (FSH) monoclonal antibodies -- 156;
follicle-stimulating hormone (FSH), oxidized -- 156;
formaldehyde -- 174; 178; 404; 413; 415; 419; 420; 421; 422; 423; 424; 425; 426; 427; 429; 430; 431; 432; 433; 434; 435; 436; 439; 440; 441; 442; 443; 444; 445; 446.5; 447; 448; 450; 451; 452; 454; 455; 456.5; 457; 459; 460; 462; 463; 464; 465; 466; 467; 469; 472; 474; 475; 476; 477; 478; 481.5;
formaldehyde -- 483.7;
formaldehyde -- 483.8; 485; 487; 488; 489; 490; 502.5; 503; 505; 507; 508; 509; 511; 517; 518; 519; 520; 544; 545; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 601; 916; 932;
Fourth Intl. Standard (WHO 88/804) for Factor VIII -- 150;
Fraction II -- 767; 770;
Fraction IV -- 705;
Fractogel, E. Merck TMAE resin -- 760;
Fresh Frozen Plasma (FFP) -- 716;
fructose -- 402; 403;
fucose -- 133;
fusion protein, proinsulin-tryptophan synthetase -- 192;
fusion proteins, recombinant -- 110; 242;
G4000PW HPLC column (TosoHass) -- 220;
galactose -- 167; 502;
galactose, O-acylated -- 502;
galactoseamine -- 605;
galactosidase -- 167;
gamma irradiation -- 237;
gamma radiation sterilization -- 109; 649.5; 808; 900; 922;
gamma-globulin I paste -- 767;
Gamunex C-Process -- 760;
ganciclovir triphosphate -- 261.7;
Gb-23-902-531 -- 210; 211;
gelatin -- 494.5; 566;
gelatin (bovine source) -- 167; 431; 471;
gelatin (bovine source) -- 483.4; 489; 491; 492; 493; 496; 504; 529; 533; 534; 562; 564; 567; 624; 626; 808; 920; 922;
gelatin (porcine source) -- 150; 191;
gelatin (porcine source) -- 191.1; 494; 564; 565; 621.5;
gentamicin (gentamycin) -- 115; 126; 179; 189; 191; 270; 275; 402; 403; 480; 653;
gentamicin sulfate -- 191.1;
gentamicin sulfate -- 476;
GL- 3 -- 161;
glass beads -- 742;
glass particles (mannitol ) -- 194;
globulin -- 800;
glucosamine -- 605;
glucose -- 105; 167; 502; 530; 629; 761; 767;
glutamate -- 108; 112; 496; 624;
glutamate buffer -- 160.8;
glutamic acid -- 138; 140;
glutamine -- 530;
glutaraldehyde -- 430; 436; 900; 924;
glutathione -- 148;
gluteraldehyde -- 445;
Gly-Ser linker, fusion protein -- 242;
glycerin -- 166; 536; 540;
glycerol -- 105; 195; 197; 250;
glycerol
glycerol -- 606; 629; 806;
glycine -- 102; 110; 138; 140; 144; 149; 151; 194; 206; 215; 216; 221; 227; 245; 248; 252; 253; 254; 255; 259; 305; 493.5; 721; 722; 725; 726; 736; 752; 754; 756; 758; 760; 761; 765; 767; 772; 774; 775; 777; 778; 779; 780; 788; 794; 918; 920;
glycine-extended precursor -- 110;
glycoaminoglycan -- 659;
glycogen -- 166;
glycoprotein iB receptor -- 802;
glycoproteins -- 163;
glycosidase -- 187;
glycosylation -- 167;
glycosylation enzymes -- 167; 615;
glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl) -- 312; 314;
glycylglycine -- 145;
granulocyte macrophage-colony stimulating factor (GM-CSF) -- 271; 416;
guanidine hydrochloride -- 220;
guinea pig potency test -- 544; 555; 559;
guinea pig test -- 489;
GYK-DTPA-HCl -- 312; 314;
Haemaccel -- 150; 167;
Haemophilus influenzae Protein D -- 513.5;
Haemophilus influenzae type b capsular polysaccharide (PRP) -- 439; 440; 443; 445; 451; 452; 453; 455; 457; 458; 460;
hamster proteins -- 147; 149; 151; 152;
Hank's medium (use Medium 199) -- 467;
haptoglobulin -- 711;
heat treatment (pasteurization) -- 102; 169; 267; 415; 469; 517; 521; 563; 620; 626; 703; 704; 705; 707; 708; 711; 712; 713.7; 714; 722; 723; 724; 725; 726; 728; 729; 730; 731; 733; 734; 736; 736.5; 737; 737; 738; 739.5; 752; 765; 766; 767; 771; 772; 774; 775; 777; 785; 788; 791; 800; 917; 929;
hemagglutinin (HA), influenza A virus -- 462; 476; 477; 483;
hemagglutinin antigen -- 443; 459; 471; 472; 474; 475; 478; 479; 480;
hemagglutinin antigen -- 483.2;
hemagglutinin antigen -- 483.3;
hemagglutinin antigen -- 483.4;
hemagglutinin antigen -- 483.7;
hemagglutinin antigen -- 483.8; 601; 604;
hemoglobin -- 702; 741; 806;
hemoglobin, bovine -- 902;
hemostatic agents -- 809;
HEp-2 human epidermoid cells -- 795;
heparan sulfate -- 188;
heparin -- 181; 188; 702; 705; 707; 724; 725; 728; 733; 734; 804; 805;
heparin affinity chromatography -- 102;
heparin-like affinity chromatography -- 144;
heparin, porcine -- 102; 162;
heparinase -- 924.5;
hepatitis B immunoglobulin -- 713.7; 714;
Hepatitis B Vaccine (Recombinant) -- 460; 753; 754;
hepatitis B virus pre-S1 antigen -- 176;
hepatitis B virus surface antigen (HBsAg) -- 452;
hepatitis B virus surface antigen, recombinant -- 441;
heptane -- 730;
HER-2/neu (c-erbB2) proto-oncogene -- 179;
hexadecyltrimethylammonium bromide -- 561;
hexoses -- 133;
histidine -- 114; 144; 146; 147; 148; 150;
histidine
histidine -- 152; 179; 184; 189; 214.5; 215; 226; 245; 261.5; 265.5; 276; 493.5; 719; 721; 722; 723; 724; 725; 731; 732; 736.5;
histidine hydrochloride monohydrate -- 114;
histidine tags -- 173;
HLA-DR bioassay -- 213;
HPC4, murine monoclonal antibody -- 804;
human chorionic gonadotropin (hCG) -- 615;
human papillomavirus (HPV) type 16 L1 virus-like particles (VLPs) -- 184; 185;
human proinsulin (S-sulfonate) -- 192;
Human Recombinant Alpha 2 (Alpha A), WHO -- 204;
Hy-Case SF -- 562;
hyaluronic acid -- 186; 616; 617; 618; 619;
hyaluronidase -- 624; 907;
hydrobic interaction chromatography (HIC) -- 265;
hydrochloric acid -- 166.5; 248;
hydrochloric acid (HCl) -- 110; 117; 155; 165; 166; 195; 196; 197; 198; 222; 234; 261.5; 307; 311; 314; 465; 626; 712; 723; 731; 774; 794; 933; 949;
hydrocortisone -- 476;
hydrophobic interactioN chromatography (HIC) -- 138;
hydrophobic-interaction column chromatography -- 102;
hydroxproline -- 493.5;
hydroxyapatite -- 457; 796; 931;
hydroxyapatite chromatography -- 142; 144;
Hydroxyapatite Ultrogel -- 138;
hydroxyethyl starch (HES) -- 150; 802;
hydroxylamine -- 900;
Hypan SS 201 hydrogel -- 260;
iduronic acid -- 187;
ifosfamide -- 934.5;
imidazole -- 149; 151; 614; 725;
imidazole exchange column -- 173;
immobilized enzymes -- 908;
Immune Globulin (Human) -- 750;
Immune Globulin (Human) Fraction II Bulk Powder -- 754;
immune globulin (IgM) -- 748;
immune globulin A (IgA) -- 711; 748; 778;
immune globulin G type 2a (IgG2a) -- 303;
immune globulin G1 (IgG1) -- 267;
immune globulin G4 (IgG4) -- 770;
immunoaffinity chromatography -- 145; 147; 148; 149; 150; 151; 152; 156; 204; 719; 721; 722; 723; 731; 732; 794; 804; 908; 914;
immunoglobulin G -- 714;
immunoglobulin G (IgG) -- 713.7;
Inactivated Polio Vaccine (IPV) -- 437.5; 445; 446;
indium-111 radioisotope -- 117; 302; 310; 312; 314; 315;
Infanrix -- 441;
influenza prophylaxis -- 481;
influenza virus hemagglutinin (HA) -- 462; 476; 482; 483;
influenza virus neuraminidase (NA) -- 462; 482; 483;
inosine -- 605;
insulin B1-B29-Ala-Ala-Lys-insulin A1-A21 -- 196;
insulin dimers -- 630;
insulin monomers -- 193.5;
Interferon alfa-2a, recombinant -- 205;
Interferon alfa-2b, recombinant -- 208;
interferon alpha murine monoclonal antibody -- 795;
interferon alpha-1 -- 796;
interferon alpha-10 -- 796;
interferon alpha-14 -- 796;
interferon alpha-2 -- 796;
interferon alpha-21 -- 796;
interferon alpha-5 -- 796;
interferon alpha-8 -- 796;
interferon gamma -- 405;
interferon omega -- 796;
Interferon, Human Fibroblast (Gb-23-902-531), Second International Standard -- 210; 211;
interleukin-11/thioredoxin fusion protein -- 216;
interleukin-2 (IL-2) -- 405;
interleukin-2 receptors (IL-2r) -- 220; 221; 222;
International Reference Preparation for Human Menopausal Gonadotropins -- 156;
International Standard of Factor VIIa 89/688 -- 145;
Iodine-131 -- 306;
iodoacetamide -- 743; 765; 908;
iodosobenzoic acid -- 212; 212.5; 218;
iron oxide -- 621.5;
isoleucine -- 138; 140; 493.5;
isopropanol -- 181; 311;
isopropyl alcohol -- 659;
isopropyl-beta-D- thiogalactopyranoside (IPTG) -- 220;
Japanese encephalitis virus (JE) E -- 224;
kanamycin -- 474; 487;
keyhole limpet hemaggluttin 417;
keyhole limpet hemocyanin (KLH)�cyclopentaperhydrophenanthrene:lactone conjugate -- 914;
kifunensine -- 167.5;
Kistler-Nitschmann fractionation -- 743; 770;
lactalbumin -- 494.5;
lactate dehydrogenases -- 907;
Lactated Ringer�s Solution -- 242; 902;
lactic acid -- 266;
lactoferrin -- 102;
lactose -- 165; 166; 402; 403; 408; 410; 441; 456.5; 458; 493.5; 494.5; 498; 499; 502; 562; 602; 619;
lecithin -- 260; 462; 482; 483;
LEDERJECT disposable syringes -- 514; 552; 559;
leucine -- 138; 140; 493.5;
lidocaine -- 924;
light, ultraviolet (UV) -- 301;
light, ultraviolet (UV) -- 477;
light, ultraviolet (UV) -- 803;
liposomes -- 260; 462; 482; 483;
lmciromab Pentetate -- 310;
LT-CAGE Lumbar Tapered Fusion Device -- 108;
luteinizing hormone -- 155;
lyophilized (freeze-dried) -- 108; 109; 114; 118; 119; 123; 123.5; 138; 145; 147; 148; 149; 150; 150.5; 151; 152; 155; 156; 157; 165; 166; 167; 169; 172; 179; 181; 182; 189; 194; 204; 206; 208; 210; 214.5; 216; 218; 219; 221; 224; 226; 227; 228; 231; 235; 243; 245; 246; 248; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259;
lyophilized (freeze-dried)
lyophilized (freeze-dried) -- 262; 263; 264; 266; 267; 268; 272; 274; 305; 307; 309; 311; 408; 455; 456.5; 458; 459; 489; 491; 494; 501; 502; 504; 514; 526; 527; 528; 529; 530; 532; 533; 534; 536; 538; 539; 540; 562; 563; 564; 565; 566; 567; 602;
lyophilized (freeze-dried)
lyophilized (freeze-dried) -- 610; 614; 616; 619; 620; 624; 625; 626; 627; 658; 703.5; 704; 710; 712; 713.7; 714; 719; 721; 722; 723; 729; 730; 731; 732; 733; 734; 737; 738; 739.5; 747; 761; 764; 767; 770; 771; 778; 804; 805; 808; 901; 908; 913; 914; 917; 920; 922; 931; 935; 936;
Lys-Plasminogen -- 606;
lysine -- 493.5;
lysine hydrochloride -- 239;
lysine-affinity chromatography -- 269;
Lysine-Biogel chromatography matrix -- 620;
lysozomal enzymes -- 187;
lysyl endopeptidase -- 196;
magnesium chloride -- 182; 474; 476;
magnesium chloride -- 483.7; 485; 487; 521;
magnesium oxide -- 700;
magnesium stearate -- 402; 403; 562;
magnesium sulfate -- 250; 530;
magnetic microspheres -- 701;
maltose -- 123; 306; 310; 423; 755; 765; 770;
maltose monohydrate -- 305;
mannitol -- 142; 145; 148; 158; 169; 170; 181; 182; 194; 195; 196; 211; 212; 212.5; 213; 218; 219; 221; 226; 231; 235; 248; 250; 252; 253; 254; 256; 258; 261.5; 262; 265; 267; 501; 540; 609; 626; 702; 723; 731; 736; 767; 806; 914; 920; 933; 935; 936;
mannose -- 402; 403;
mannose-terminated oligosaccharides -- 167;
MDX-1379 -- 124;
Medium 199 -- 446.5;
Medium 199 (M-199; Hank's medium) -- 220; 440; 442; 465; 467;
melphalan -- 263;
mercury -- 914; 939;
methanol -- 942;
methionine -- 142; 145; 155; 228; 493.5;
Method M -- 719; 721;
methotrexate -- 264;
methoxy-polyethylene glycol-priopionaldehyde -- 159;
methoxypropyl(ethyleneglycol) polymers -- 266;
methylparaben -- 239;
MF59C.1 adjuvant -- 474; 487;
Micro-Injection System -- 481.5;
Millex GV filter -- 314;
mineral oil -- 621.5;
monobasic sodium phosphate
monoclonal antibody 3-A3-2 -- 796;
monoclonal antibody 4D5 -- 179;
monoclonal antibody 7E11-C5.3 -- 312;
monoclonal antibody A2 (cA2) -- 264;
monoclonal antibody C7F7 -- 149;
monoclonal antibody CYT-351 -- 312;
monoclonal antibody hP67.6 -- 118;
monoclonal antibody, 2.2.9 (Factor VII) -- 147;
monoclonal antibody, carcinoembryonic antigen (CEA) -- 307;
monoclonal antibody, Factor VIII -- 147; 722;
monoclonal antibody, Factor VIII x domain -- 151;
monoclonal antibody, follicle-stimulating hormone -- 156;
monoclonal antibody, human Eu -- 222;
monoclonal antibody, interferon alpha -- 204;
monoclonal antibody, Mab 1129 -- 245;
monoclonal antibody, murine Factor VIII -- 719; 721;
monoclonal antibody, Prostate Specific Membrane Antigen -- 312;
monoclonal antibody, Protein C -- 804;
monomethoxy polyethylene glycol (PEG) -- 142; 208; 273; 273; 605; 611;
monophosphoryl lipid A (MPL) -- 177; 185;
monopotassium phosphate -- 440;
monosodium glutamate -- 191.1;
monosodium glutamate -- 191.1;
monosodium glutamate -- 402; 403; 409; 494; 532; 564; 565;
monosodium phosphate -- 561;
mouse immunoglobulin -- 148;
mPEG2-NHS 40 kDa reagent -- 205;
MRC5 cellular proteins -- 463;
MSBA30K -- 142;
murine immune globulin -- 145; 795;
murine monoclonal antibody CLB-FIX D4 -- 732;
murine monoclonal antibody HPC4 -- 804;
murine monoclonal antibody, carcinoembryonic antigen -- 307;
murine monoclonal antibody, CC49 -- 315;
murine monoclonal antibody, CD3 -- 303; 303;
murine monoclonal antibody, F8.1 -- 147; 148; 719; 721; 722;
murine monoclonal antibody, Fab myosin chimeric -- 310;
murine monoclonal antibody, Factor IX -- 731;
murine monoclonal antibody, Factor VII -- 145;
murine monoclonal antibody, Factor VIII -- 147; 148; 149; 151; 152; 721; 722;
murine monoclonal antibody, follicle-stimulating hormone -- 156;
murine monoclonal antibody, MY-10 ( MY10) -- 701;
murine monoclonal antibody, NR-LU-10 -- 311;
murine monoclonal antibody, Protein C -- 804;
murine monoclonal antibody, RFT5 -- 221;
murine monoclonal antibody, von Willebrand's factor -- 723;
murine proteins -- 147; 149; 151; 152; 721; 722; 731; 804;
murine serum proteins -- 489;
MY-10 ( MY10) CD34 murine monoclonal antibody -- 701;
myelin basic protein (MBP) -- 489;
myosin -- 310;
myosin chimeric murine Mab Fab fragment -- 310;
N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine -- 117;
N-acetyl galactosamine -- 133;
N-acetyl glucosamine -- 133; 167; 928;
N-acetyl neuraminic acid -- 133; 498; 499; 500; 502;
N-acetyl-gamma calicheamicin -- 118;
N-acetyl-L-cysteine (NAC) -- 902;
N-acetyl-O-acetyl mannosamine phosphate -- 498; 502;
N-acetylgalactosamine-4-sulphate -- 187;
N-benzoyl-L-arginine ethyl ester (BAEE) -- 622;
N-methyl-2-pyrrolidinone -- 796;
N-succinimidyl 3-(-2-pyridyldithio)propionate (SPDP) -- 542;
N-succinyl-L-alanyl-L-alanyl-L-alanyl-p-nitroanilide -- 711;
N-succinyl-L-alanyl-L-alanyl-L-alanyl-p-nitroanilide (SA3 pNA) -- 709;
nanofiltration -- 712; 714;
nanofiltration (virus removal) -- 102; 105; 113; 118; 129; 141; 261; 710; 713.7; 731; 732; 736; 747; 755; 756; 761; 763; 770; 778; 779; 780; 789; 790; 796; 805; 911;
Neisseria meningitidis capsular polysaccharides -- 498; 503;
Neisseria meningitidis vaccine -- 452; 497;
Neisseria mennigitidis outer membrane protein (OMP) -- 458;
neomycin -- 445; 472; 475;
neomycin -- 483.3; 491; 492; 493; 494; 496; 504; 521; 526; 533; 534; 540; 564; 565; 795;
neomycin -- 437.5; 446;
neomycin sulfate -- 441; 474;
neomycin sulfate -- 483.2; 487; 493.5;
neuraminidase -- 167;
neuraminidase (NA), influenza virus -- 462; 482; 483;
NF-kappaB -- 243;
niacinamide -- 736.5;
NIAID interferon reference standard, leukocyte Sendai -- 209;
NIH mouse potency test -- 526; 529;
nitrogen -- 172;
nitrogen (gas and liquid) -- 489; 527; 601; 620; 651; 798;
NK2 monoclonal antibody affinity column -- 795;
nonoxynol 101 (Triton N101) -- 472;
nonrecombinant -- 739.5;
nonylphenol ethoxylate -- 472;
nonylphenol ethoxylate -- 483.3;
Not1 digestion -- 267;
nuclease enzyme -- 464;
nuclease, Benzonase -- 245;
nucleic acid -- 601;
nucleic acid testing (NAT) -- 702;
nucleotidases -- 907;
nylon mesh -- 652; 657;
octanoic acid -- 493; 763;
octanol -- 212; 212.5;
octoxynol -- 148; 430; 471; 476; 481.5; 488; 719; 721; 722; 724; 747; 748; 755; 756; 761; 768; 778; 780; 789; 790; 911;
octoxynol 10 -- 485;
odium phosphate -- 483.7;
oleic acid -- 260;
ovalbumin -- 476; 477;
ovalbumin -- 483.3;
ovalbumin-Sepharose 4B chromatography media -- 220;
ovine (sheep) plasma -- 908; 913; 914; 915;
oxidized follitropin alfa -- 156;
oxygen -- 110; 902;
p-amindinophenyl-p-anisate -- 606;
p-nitrophenyl-beta-D-glucopyranoside -- 615;
p55, IL-2 receptor alpha subunit -- 222;
p75, tumor necrosis factor-2 (TNFR2) receptor -- 267;
PA2024 -- 242;
paclitaxel -- 703.5;
Pall Utrapore VF DV 50 filter -- 805;
palmitic acid -- 941; 942;
papain digestion -- 240; 311; 908; 913; 914;
para-nitrophenyl-beta-D-glucopyranoside (pNP-Glc) -- 167;
paramagnetic beads -- 701;
PedvaxHIB -- 460;
PEG-3350 -- 215;
PEG-Intron Diluent -- 208;
PEG-SBA -- 142;
PEG2-NHS -- 205;
pegylation -- 159; 205; 208; 273; 605; 611; 949;
pentetic acid -- 117;
pepsin digestion -- 302; 307; 656; 743; 770; 911; 912; 916;
peptide ligand, Factor VIII heavy chain -- 150.5;
peptide synthesis, solid phase -- 935;
peptide synthesis, solid phase Fmoc -- 933;
peptidyl-glycine alpha-amidating monooxygenase (PAM) -- 110;
periplastic E. coli proteins (PECP) -- 254;
pertactin (69 kDa protein) -- 430; 432; 433; 436; 439; 440; 441; 442; 445; 506;
pertussis fimbrial agglutinogens -- 437.5;
pertussis toxin (PT) -- 436; 507;
pertussis toxin, S1 subunit -- 236;
pertussis toxoid (PT) -- 430; 437; 437.5; 446;
pertussis toxoid, recombinant -- 432;
Pertussis Vaccine Adsorbed -- 429; 448; 449; 450; 451; 452;
Pertussis Vaccine Adsorbed, Acellular -- 429; 430; 431; 432; 433; 434; 435; 436; 437; 439; 440; 441; 442; 443; 444; 445; 446; 506;
Pertussis Vaccine Concentrate (For Further Manufacturing Use), Acellular -- 435;
petrolatum -- 612; 614;
petrolatum gauze -- 653;
phenol -- 166.5; 195; 196; 204; 249; 250; 406; 414; 458; 515; 536; 540; 542; 561; 563; 795; 907; 912; 912;
phenol red -- 527; 528; 530;
phenols, brominated -- 166.5;
Phenomenex Jupiter C4 column -- 105;
phenthioate ligand -- 311;
phenyethyleneimine -- 263;
Phenyl Sepharose HP -- 105;
phenylalanine -- 138; 140; 493.5;
phenylethyl alcohol -- 110;
phosphatases -- 907;
phosphate buffer -- 218; 303; 431; 455; 508; 552; 601;
phosphate buffered saline -- 191.5; 650.5;
phosphate buffered saline (PBS) -- 212; 230; 260; 264; 311; 312; 409; 435; 447; 463; 478; 481.5; 487; 488; 489; 517; 542; 712; 795; 927;
phosphatidylcholine -- 260; 941;
phosphatidylethanolamine -- 260;
phospholipases -- 907;
phospholipids -- 462; 482; 483; 941; 942; 943;
phosphoric acid -- 156; 172; 228; 252; 257; 258; 268; 269; 270;
phosphoric acid, meta- -- 419;
photoactivation, antibody -- 301;
photoinactivation -- 803;
Pillmer alcohol fractionation -- 552;
pithelial cell adhesion molecule
pituitary extract, bovine -- 651;
Planova 15 nm Virus Filter -- 113; 713.7; 780;
Planova 35 nm Virus Filter -- 755; 756; 778; 789;
plasdone -- 402; 403;
Plasma -- 805;
plasma (bovine) -- 920; 921;
plasma (equine) -- 904; 905; 918;
Plasma (Human) -- 110; 144; 146; 469; 606; 620; 703; 703.5; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 736; 736.5; 737; 739; 739.5; 743; 747; 748; 750; 752; 753; 754; 755; 756; 757; 758; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 785; 786; 787; 788; 789; 790; 791; 792; 798; 800; 801; 802; 803; 806; 807; 917; 918; 921; 923;
plasma proteins, immunoglobulin-depleted -- 918;
plasmin -- 268; 269; 606; 620; 626; 737;
plasminogen -- 268; 269; 274; 606; 620; 626; 779;
Platelets -- 216; 702;
Pluronic F-68 -- 249;
Poliomyelitis Vaccine -- 439; 440; 441; 442;
Poliovirus Vaccine (IPV) -- 441;
poloxamer 188 -- 142; 257; 272;
polycarbonate -- 700;
polydimethylsiloxane -- 561;
polyelectrolyte resin -- 901;
polyethylene glycol -- 621.5;
polyethylene glycol (PEG 4000) -- 713.7; 714;
polyethylene glycol (PEG) -- 142; 147; 150; 150.5; 152; 159; 170; 205; 208; 259; 264; 266; 273; 430; 605; 611; 614; 705; 710; 711; 719; 722; 724; 725; 743; 761; 766; 767;
polyethylene glycol (PEG) nonylpheyl ether -- 472;
polyethylene glycol 3350 (PEG-3350) -- 215;
polyethylene glycol p-isooctylphenyl ether (Triton X-100) -- 483.4;
polyethylene glycol p-isooctylphenyl ether (Triton X-100) -- 488;
polyethylene glycol-priopionaldehyde, methoxy- -- 159;
polyethylene glycol, bis-monomethoxy branched N-hydroxysuccinimide ester -- 205;
polyethylene glycol
polyethyleneimine -- 250;
Polygard-CR filters -- 795;
polygeline -- 529;
polyglactin -- 652; 657;
polyglycolic acid -- 652; 657;
polyhistidine-tag
polylactide-coglycolide (PLG) -- 251;
polymer membrane matrix -- 652; 657;
polymerase chain reaction (PCR) -- 702;
polymerization, cross-linking -- 900;
polymyxin -- 446; 472; 475;
polymyxin -- 483.3; 517; 526;
polymyxin B -- 437.5; 441;
polymyxin B -- 483.2; 540;
polymyxin B sulfate -- 445;
polyribosylribitol -- 437.5;
polyribosylribitol phosphate -- 445;
polyribosylribitol phosphate (PRP) -- 439; 440; 443; 451; 454; 455; 457;
polysaccharides, bacterial capsular -- 443; 451; 452; 455; 460; 498; 502.5; 503; 513;
polysaccharides, bacterial capsular -- 513.3; 513.5; 515; 542;
Polysep-TP filters -- 795;
polysiloxane -- 659;
polysorbate -- 266;
polysorbate 100 (Tween 100) -- 719; 799;
polysorbate 20 (Tween 20) -- 114; 138; 140; 141; 155; 159; 162; 179; 188; 189; 197; 198; 213; 220; 226; 228; 250; 251; 261.5; 270; 275; 276; 463; 466;
polysorbate 60 (Tween 60) -- 269;
polysorbate 80 (Tween 80 -- 485;
polysorbate 80 (Tween 80) -- 101; 105; 108; 110; 115; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 150.5; 151; 152; 158; 160.1; 160.2; 160.3; 160.9; 167; 184; 203; 204; 205; 208; 214; 214.5; 222; 240; 264; 265; 265.5; 268; 303; 409; 437.5; 441; 445; 446.5; 465; 474; 476; 478; 480;
polysorbate 80 (Tween 80) -- 483.7;
polysorbate 80 (Tween 80) -- 483.8; 487; 489; 724; 725; 730; 732; 733; 736.5; 747; 748; 755; 756; 761; 767; 778; 779; 789; 805; 911;
polysorbate 80 (Tween-80) -- 804;
polysorbate 80 710;
polysorbate 90 (Tween 90) -- 474; 487;
polystyrene beads, paramagnetic -- 701;
polystyrene
porcine (pig) heparin -- 924.5;
porcine dermal collagen -- 652; 657;
porcine gelatin -- 191;
porcine gelatin stabilizer (PGS) -- 494; 564; 565;
porcine heparin -- 162;
porcine pancreatic elastase -- 709; 711;
porcine pepsin -- 770;
porcine plasma -- 901;
POROS HS resin (PerSeptive Biosystems) -- 120;
potassium chloride -- 474; 476;
potassium chloride -- 483.2;
potassium chloride -- 483.7; 485;
potassium chloride
potassium chloride -- 530; 564; 565; 566; 795; 902;
potassium dihydrogen phosphate -- 472; 474; 483;
potassium dihydrogen phosphate -- 483.7; 485; 487; 566;
potassium glutamate -- 529;
potassium monophosphate -- 532;
potassium phosphate -- 117;
potassium phosphate -- 191.1; 220; 221; 402; 403; 430;
potassium phosphate -- 483.2; 564; 619; 795;
potassium phosphate monobasic -- 476; 565;
potassium sodium tartrate tetrahydrate -- 305; 307;
potassium tartrate -- 796;
potassium thiocyanate -- 796;
povidone -- 306;
pPSC12 plasmid, baculovirus -- 191.5;
pre-proinsulin -- 193;
PrefGel -- 931;
pristane -- 304; 307;
Procion Red H-8BN
profibrinolysin -- 614;
proinsulin (S-SO3-)6, human -- 192;
proinsulin-tryptophan synthetase fusion protein -- 192;
proinsulin, human -- 630;
ProLease microencapsulation -- 251;
proline -- 493.5;
proline, L- -- 763;
propylene glycol -- 166.5;
propylene glycol alginate -- 931;
propylparaben -- 239;
Prostate Specific Membrane Antigen (PSMA) monoclonal antibody -- 312;
prostatic acid phosphatase--granulocyte-macrophage colony-stimulating factor fusion protein -- 242;
Protac -- 804;
protamine -- 192; 193; 630; 632; 633;
protamine sulfate -- 195; 490;
protease, Achromobacter lyticus -- 196;
protease, yeast KexII -- 169;
protective antigen (PA) -- 404;
Protein A -- 147; 148;
Protein A affinity chromatography -- 115; 116; 119; 123; 264; 271; 307; 312; 700;
Protein A-silica matrix -- 700;
Protein C -- 150; 798; 805;
Protein C murine monoclonal antibody -- 804;
Protein D, Haemophilus influenzae -- 513.5;
Protein S -- 798; 805;
Protein Z -- 805;
proteoglycans -- 658;
proteolytic enzymes -- 907;
prothrombin complex concentrate -- 804;
prothrombin, bovine -- 920;
prothrombin, human -- 704; 705; 728; 729; 730; 731; 734; 737; 738; 798; 799;
Pseudomonas aeruginosa exotoxin A -- 542;
purogenated -- 435;
Q resin, Pharmacia Biotech -- 760;
Q membrane chromatography media -- 129;
Q Sepharose -- 150;
Q Sepharose FF (Pharmacia)
Q-Sepharose -- 189; 721; 804;
Q-Sepharose-FF affinity chromatography, -- 144;
QAE-Sephadex (Pharmacia) -- 804;
quartz (silicon dioxide) -- 700;
rabbit plasma -- 917;
rabies Challenge Virus Standard (CVS) -- 528;
raspberry flavor -- 415;
rattlesnake venom -- 907; 908;
receptors, epidermal growth factor -- 179;
receptors, interleukin-2 -- 221;
receptors, leukocyte function-associated antigen-3 (LFA-3) -- 227;
receptors, tumor necrosis factor-2 (TNFR2) -- 267;
Recombumin -- 493;
Red Blood Cells (Human) -- 702; 802; 917; 918;
reduction -- 220;
Respiratory Syncytial Virus Immune Globulin Reference Standard -- 781;
Retavase reference standard -- 268;
RFT5, murine monoclonal antibody -- 221;
ribitol -- 454; 455; 457;
ribonucleases -- 907;
ribose -- 454; 455; 457;
Rituxan -- 271;
rituximab -- 117;
RO0503819 -- 142;
Rosen-modified Sampath-Reddi assay -- 108;
rotavirus capsid protein 7 (VP7) -- 532;
RSV High Titer Fraction II+III Paste (For Further Manufacturing Use) -- 781;
S-(carboxymethyl)-homocysteine -- 458;
S-59 -- 803;
SA3 pNA -- 709; 711;
saccharin sodium -- 415;
saccharose -- 713.7; 714;
saline-adenine-glucose -- 806;
Salmonella typhi Vi polysaccharide (Ty 2 strain) -- 467;
SDS-polyacrylamide gels -- 220;
Sealer Protein (Human) -- 736.5;
SELEX process -- 949;
Sephacryl -- 212; 212.5; 250; 457;
Sephadex -- 212; 212.5; 250; 312; 314; 630; 728; 737; 738; 761; 767; 804;
Sepharose -- 119; 138; 150; 214; 260; 264; 307; 312; 314; 457; 721; 722; 723; 731; 761; 795; 804; 908;
Sepharose 4B-ovalbumin chromatography media -- 220;
Sepharose 4B, (CNBr)-activated -- 804;
Sepharose 4B, Activated CH-, Pharmacia -- 243;
Sepharose FF, copper (CU+2) chelating -- 105;
Sepharose SP big bead column
Sepharose-Protein A -- 264;
Sepharose, Erythrina trypsin inhibitor (ETI)- -- 268;
Sepharose
serine -- 493.5;
serine protease enzyme -- 243;
serum, fetal calf -- 651;
sheep anti-mouse (SAM) antibody -- 701;
shellac -- 621.5;
sialic acid derivatives -- 167; 500; 502;
silica, PEI -- 430;
silicon dioxide -- 700;
silicone polymer membranes -- 652; 654; 657; 659;
simian virus 40 (SV40) -- 516;
SingleJect prefilled syringe -- 209;
SmartJect autoinjector -- 265.5;
snake venoms -- 906; 907; 908; 910;
SNAP-2 -- 601;
sodiium phosphate -- 249;
sodium acetate -- 117; 129; 158; 159; 160.1; 160.2; 160.3; 160.9; 211; 239; 307; 312; 314; 736; 914;
sodium acetate trihydrate -- 110; 205;
sodium azide -- 795;
sodium bicarbonate -- 311; 440; 532; 651; 775;
sodium borate -- 184; 460; 464;
sodium bromide -- 469;
sodium caprylate -- 760;
sodium carbonate -- 415; 440; 716; 752; 771; 933;
sodium carboxymethylcellulose -- 239;
sodium chloride -- 101;
sodium chloride
sodium chloride -- 105; 108; 109; 110; 113; 115; 117; 118; 123; 126; 128; 129; 133; 136; 138; 140; 141; 143; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 162; 174; 181; 184; 185; 188; 195; 196; 198; 203; 204; 205; 209; 212; 212.5; 214; 220; 221; 222; 239; 240; 243; 250; 251; 256; 261; 262; 263; 265; 267; 303; 306; 307; 310; 312; 314; 404; 406; 408; 409; 414; 415; 423; 424; 430; 433; 436; 447; 454; 455; 456.5; 458; 459; 460; 462; 464; 471; 472; 474; 476; 483;
sodium chloride -- 483.2;
sodium chloride -- 483.4;
sodium chloride -- 483.7;
sodium chloride -- 483.8; 485; 487; 491; 492; 493; 494; 496; 504; 508; 509; 510; 514; 515; 530; 533; 534; 540; 544; 549; 550; 552; 555; 561; 563; 564; 565; 566; 567; 601; 604; 610; 611; 614; 617; 618; 619; 626; 702; 703.5; 704; 707; 711; 712; 713.7; 714; 716; 719; 723; 725; 726; 731; 732; 736; 736.5; 754; 756; 760; 761; 763; 767; 770; 771; 772; 778; 779; 780; 788; 794; 795; 796; 804; 806; 908; 912; 920; 922; 924; 926; 927; 928; 930; 932; 935; 936; 941; 949;
sodium cholate -- 752; 758; 765; 775; 777; 785;
sodium citrate -- 102; 113; 115; 133; 136; 155; 167; 194; 214; 227; 231; 235; 243; 250; 265; 415; 474; 487; 531; 532; 705; 713.7; 726; 736;
sodium citrate
sodium deoxycholate -- 476; 477;
sodium deoxycholate -- 483.7; 485;
sodium dihydrogen phosphate -- 138;
sodium dihydrogen phosphate
sodium dihydrogen phosphate -- 175; 254; 255; 263; 310; 409; 415; 526; 796; 928;
sodium dihydrogen phosphate dihydrate -- 185; 927;
sodium disphosphate -- 532;
sodium dodecyl sulfate (SDS) -- 212; 212.5; 218; 219;
sodium glucuronate -- 928;
sodium glutamate -- 624; 625;
sodium hyaluronate -- 927;
sodium hydrogen carbonate -- 415;
sodium hydrogencarbonate -- 530;
sodium hydroxide -- 110; 117; 155; 156; 166.5; 167; 172; 181; 182; 194; 195; 196; 197; 198; 212; 212.5; 222; 228; 234; 248; 252; 257; 265; 269; 465; 606; 608; 618; 624; 626; 712; 723; 774; 794; 924.5; 929; 930.5; 933; 949;
sodium lactate -- 902;
sodium lauryl sulfate -- 621.5;
sodium metabisulfite
sodium metabisulphite -- 490;
sodium metaperoxidate -- 312;
sodium monohydrogen phosphate -- 138;
sodium monohydrogen phosphate
sodium octanoate
sodium periodate -- 457;
sodium pertechnetate Tc 99m Injection -- 305;
sodium phosphate -- 113; 117; 118; 142; 162; 209; 216; 240; 262; 303; 312; 314; 423; 454; 471;
sodium phosphate -- 483.2;
sodium phosphate -- 483.4; 488; 491; 492; 493; 494; 496; 501; 504; 533; 534; 549; 555; 601; 625; 711; 712; 748; 930;
sodium phosphate dibasic -- 188;
sodium phosphate monobasic
sodium phosphate, dibasic -- 105; 128; 141; 143; 156; 170; 203; 206; 208; 218; 222; 228; 250; 252; 258; 259; 264; 265; 267; 272; 275; 303; 467; 476; 494; 501; 552; 564; 565; 611; 795; 908; 930; 949;
sodium phosphate, monobasic -- 105; 118; 128; 141; 143; 156; 203; 206; 208; 210; 216; 218; 222; 228; 250; 258; 259; 264; 265; 267; 275; 467; 494; 501; 531; 552; 564; 611; 617; 618; 626; 806; 949;
sodium pyrophosphate -- 212; 212.5;
sodium pyruvate -- 530;
sodium succinate -- 213; 604;
sodium sulfate -- 142;
sodium taurodeoxycholate -- 475;
sodium taurodeoxycholate -- 483.2;
sodium taurodeoxycholate -- 483.3;
sodium thiocyanate -- 731;
solvent detergent viral inactivation -- 761;
somatropin, deaminated -- 251;
somatropin, desamido- -- 248;
somatropin, recombinant -- 251;
sorbitan trioleate -- 474; 487;
sorbitol -- 159; 160.1; 160.2; 160.3; 160.8; 160.9; 265.5; 491; 521; 530; 533; 534; 566; 567; 716; 766; 767; 913;
sorbitol (E420) -- 493.5;
Source Plasma -- 737; 738; 798;
soya lecithin -- 621.5;
squalene -- 483.7;
squalene -- 485;
squalene-based 487;
stannic tin -- 305;
stannous chloride -- 307; 311;
stannous gluconate -- 311;
stannous tartrate -- 305;
Staphylococcus aureus type 5 capsular polysaccharide -- 542;
Staphylococcus aureus type 8 capsular polysaccharide -- 542;
starch -- 802;
Sterile Diluent for Antivenin -- 909;
Sterile Water for Injection -- 108; 110; 114; 115; 117; 123; 128; 133; 140; 141; 143; 145; 147; 148; 149; 151; 152; 155; 156; 158; 159; 166; 167; 169; 172; 174; 179; 182; 184; 185; 197; 198; 208; 210; 211; 213; 214; 214.5; 216; 218; 227; 234; 245; 251; 252; 253; 257; 257; 259; 262; 263; 264; 265; 268; 269; 270; 303; 312; 314; 433; 434; 440; 441; 467; 472; 482; 483; 489; 526; 527; 529; 536; 561; 566; 606; 608; 611; 704; 705; 707; 711; 712; 723; 725; 726; 728; 729; 730; 731; 733; 736; 761; 772; 804; 901; 908; 913; 914; 926; 927; 928; 930; 933;
sterilization, gamma irradiation -- 237;
sterilization, photoinactivation -- 803;
stratum corneum -- 651;
Streptococcus pneumoniae capsular polysaccharides -- 513;
Streptococcus pneumoniae capsular polysaccharides -- 513.3; 515;
streptokinase -- 606; 614;
streptolysin O -- 624;
streptomycin -- 437.5; 445; 478; 521;
succinic acid -- 305;
succinimdyl butanoic acid linker -- 142;
sucrose -- 108; 113; 114; 118; 144; 145; 146; 149; 150; 150.5; 151; 155; 156; 169; 172; 189;
sucrose -- 191.1; 208; 212; 212.5; 214.5; 215; 226; 227; 228; 243; 257; 261.5; 264; 266; 267; 268; 307; 402; 403; 431; 440; 455; 459; 471; 472; 476;
sucrose -- 483.4;
sucrose -- 483.8; 487; 488; 489; 490; 491; 492; 493; 494; 496; 504; 526; 529; 530; 532; 533; 534; 562; 564; 565; 603; 614; 629; 711; 732; 747; 748; 770; 771; 781; 790;
sucrose-phosphate-glutamate (SPG) -- 190;
Superdex chromatography medium -- 168; 168.5;
Superose 12 -- 312; 795;
surfactant protein B (SP-B) -- 941; 942;
surfactant protein C (SP-C) -- 941; 942;
Systematic Evolution of Ligands of Exponential enrichment -- 949;
T-Flask culture -- 304;
Tac subunit of IL-2 receptor -- 222;
tangential flow filtration (TFF) -- 105; 129;
tartrazine -- 402; 403;
Technetium Tc 99m sodium pertechnetate -- 121; 305; 307; 311;
Technetium Tc 99m-phenthioate ligand -- 311;
tetanus prophylaxis -- 446.5;
Tetanus Toxoid -- 421; 423; 424; 425; 426; 427; 428; 429; 431; 432; 433; 434; 435; 436; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 455; 456.5; 459; 544; 545; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559;
Tetanus Toxoid Adsorbed -- 422; 430; 432; 786;
Tetanus Toxoid Concentrate (For Further Manufacturing Use) -- 436;
tetracycline -- 206; 218; 276;
tetradecanoyl-N-hydroxysuccinimide ester -- 196;
tetramethylurea -- 794;
theophylline -- 796;
thimerosal (mercury derivative) -- 174; 175; 421; 424; 425; 427; 431; 434; 435; 441; 447; 447; 449; 450; 451; 454; 457; 458; 466; 471; 472; 474; 475; 476; 477; 478; 480;
thimerosal (mercury derivative) -- 483.2;
thimerosal (mercury derivative) -- 483.3;
thimerosal (mercury derivative) -- 483.4;
thimerosal (mercury derivative) -- 483.7; 487; 488; 489; 502; 508; 509; 510; 514; 515; 544; 549; 552; 555; 557; 558; 559; 614; 617; 754; 774; 775; 779; 788; 907; 908; 909; 914; 918; 932;
thiocyanate -- 174; 175;
thioether spacer -- 458;
thiomersal (mercury derivative) -- 485;
thioredoxin/interleukin-11 fusion protein -- 216;
threonine -- 138; 140; 493.5; 713.7; 714;
Thrombin Activation Device (TAD) -- 739;
Thrombin-JMI -- 923;
thrombin, bovine -- 240; 243; 737; 738; 919; 921; 922; 923;
thrombin, human -- 150; 181; 707; 739; 807; 808;
Thrombin, Topical (Bovine Origin) -- 922;
thrombin
thrombomodulin -- 243;
thromboplastin -- 799; 920;
titanium cages -- 108;
titanium dioxide -- 621.5;
TMAE Fractogel, E. Merck -- 760;
Tn5 (Pharmacia) -- 220;
TN8.2
tocopheryl acid succinate (vitamin E succinate) -- 476;
tositumomab -- 306;
tranexamic acid -- 268; 736;
trehalose -- 148;
trehalose dihydrate -- 179; 275; 276;
tri-n-butyl phosphate (TNBP) -- 113; 148; 150; 150.5; 264; 480; 710; 719; 721; 722; 724; 725; 730; 732; 733; 747; 748; 752; 756; 758; 761; 765; 767; 768; 769; 775; 777; 778; 780; 785; 789; 790; 799; 804; 805; 911;
tricresol -- 916;
triethylamine phosphate -- 235;
triglycerides -- 941;
tripalmitin -- 941;
tris (tromethamine) -- 146; 147; 148; 152; 169; 198; 264; 267; 794; 795;
trisodium citrate -- 702; 713.7; 714; 736.5;
trisodium citrate
trometamol (see also tris) -- 440;
trometamol (see also tris) -- 483.8;
trypsin -- 483.8;
trypsin digestion -- 162; 192; 196; 504; 630;
tryptophan -- 493.5;
tryptophan synthetase-proinsulin fusion protein -- 192;
tuberculin -- 409;
tumor necrosis factor alpha (TNF-alpha) -- 264;
tumor necrosis factor-2 receptor (TNFR2) -- 267;
TypLE' Met Proinsulin -- 192;
tyrosine -- 530;
U.S. Control Tetanus Toxin -- 785;
U.S. Reference Mumps Virus -- 534;
U.S. Reference Standard Vaccinia Immune Globulin -- 788;
U.S. Standard Antitoxin (tetanus) -- 785;
U.S. Standard Rabies Immune Globulin -- 775;
U.S. Standard Rabies Vaccine -- 526;
Ultrapor VF grade DV50 membrane filter -- 227;
ultraviolet (UV)
ultraviolet (UV)
ultraviolet
uracil -- 423;
urea -- 138; 430; 564; 622;
uric acid -- 272;
uridine diphosphogalactose-4-epimerase -- 562;
valine -- 493.5; 713.7; 714;
vegetable oil extraction -- 799;
vesicular stomatitis virus (VSV) -- 795;
Vicryl polymer sheet -- 657;
Vira/Gard 500 membrane (AG/T) -- 113;
viral (nano)filtration -- 105; 118; 129; 141; 188; 710; 731; 732; 736; 747; 755; 756; 761; 763; 763; 770; 778; 779; 780; 790; 796; 805;
viral inactivation, acid (low pH) -- 105; 118; 129; 179; 760; 761; 763; 765; 768; 769; 770; 772;
viral inactivation, beta-propiolactone (BPL) -- 472; 476; 482; 483; 526; 527; 528; 529;
viral inactivation, caprylate -- 760;
viral inactivation, detergent -- 113;
viral inactivation, fatty alcohol/pH precipitation -- 772;
viral inactivation, gamma irradiation -- 900;
viral inactivation, photoinactivation -- 477; 803;
viral inactivation, sodium thiocyanate -- 731;
viral inactivation, solvent detergent -- 148; 149; 150; 150.5; 151; 261; 264; 480; 710; 712; 719; 721; 722; 724; 725; 730; 732; 733; 736; 736.5; 747; 748; 752; 755; 756; 758; 761; 764; 765; 767; 768; 769; 775; 777; 778; 780; 781; 785; 789; 790; 799; 804; 805; 911;
viral inactivation, solvent-detergent -- 737;
viral inactivation, ultraviolet (UV) light -- 477;
viral inactivation, ultraviolet (UV) light -- 483.8; 803;
viral inactivation, unspecified -- 115; 156; 210; 240; 245; 265; 311; 918;
virosomes (liposomes) -- 462; 482; 483;
virus culture -- 483.4;
virus-like particles (VLPs), human papillomavirus (HPV) -- 184; 185;
vitamin E -- 485;
vitamin E succinate -- 476;
vitamin K -- 144;
vitamin solution -- 530;
VitriLife -- 530;
von Willebrand's factor (vWF) -- 146; 147; 148; 150; 152; 716;
von Willebrand�s factor (vWF) multimers -- 726;
von Willebrand's factor (vWF):Ristocetin Cofactor (vWF:Rcof) -- 726;
von Willebrand's factor murine monoclonal antibody -- 723;
VP7, rotavirus capsid protein -- 532;
Vydac-C4 -- 138;
Water for Injection -- 136; 166.5; 181; 195; 196; 203; 209; 220; 240; 265.5; 437.5; 445; 446.5; 465; 474;
Water for Injection -- 483.8; 540; 732; 736.5; 794; 796; 930.5; 949;
Water for injections -- 483.7;
Western Diamondback rattlesnake venom -- 908;
wet cryo -- 716; 739;
WHO 1st Intl. Stand. 83/514 (recombinant interferon alpha) -- 209;
WHO 2nd Intl. Reference Preparation for Human Menopausal Gonadotropins -- 156;
WHO 69/19 1st Intl. Stand., interferon (leukocyte, Sendai) -- 209;
WHO human pituitary derived TSH reference standard -- 262;
WHO Intl. Standard Factor VIII -- 722;
WHO Intl. Standard Factor VIII:C Concentrate -- 147; 152;
WHO Intl. Standard, Factor IX -- 730;
WHO thrombin preparation 89/588 -- 181;
Whole Blood -- 741; 798; 799; 802; 803; 806;
xanthan -- 530;
xylenes -- 166.5;
ydroxypropylmethyl cellulose phthalate -- 621.5;
yeast KexII protease -- 169;
yeast source materials -- 153;
yeast spheroplasts -- 129;
yttrium-90 -- 117;
Yttrium-90 chloride -- 117;
zinc -- 153; 192; 193; 197; 199; 630; 632; 633;
zinc acetate -- 251;
zinc acetate dihydrate -- 196;
zinc binding motif -- 601;
zinc carbonate -- 251;
zinc chloride -- 195; 710;
zinc ligands, affinity chromatography -- 112;
zinc-insulin lispro -- 199;
adjuvants -- 937; 938;
albumin conjugate proteins -- 208.5;
amphibian source -- 628;
animal materials used -- 494.5;
animal/human products-free -- 144;
antibodies (see also immune globulins; monoclonal antibodies) -- 114; 115; 116; 116.5; 117; 118; 119; 120; 121; 123; 123.5; 124; 125; 125; 128; 129; 130; 131; 131.5; 173; 179; 189; 203; 221; 222; 223; 227; 240; 244; 245; 246; 264; 265; 265.5; 267; 275; 276; 300; 303; 304; 305; 306; 307; 308; 310; 311; 312; 313; 314; 701; 702; 722; 723; 743; 744; 745; 746; 747; 748; 749; 749; 750; 752; 753; 754; 755; 756; 757; 758; 760; 761; 762; 763; 764; 765; 766; 767; 769; 770; 771; 772; 773; 774; 775; 777; 778; 779; 781; 782; 783; 784; 785; 786; 787; 788; 791; 792; 800; 903; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918;
antibodies, peptibodies -- 261.5;
antibody-toxin conjugates -- 118;
antihemophilic factors -- 144; 145; 146; 147; 148; 149; 150; 151; 152; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 739; 805; 901;
antisense oligonucleotides -- 944; 945; 946;
antitoxins -- 911; 912; 916;
antivenins -- 906; 907; 908; 909; 914; 915;
apoptosis inducers -- 115; 116.5; 117; 129; 130; 227; 628;
aptamers -- 949;
bacterial polysaccharides -- 929;
biophamaceutical products -- 713.5;
biopharmaceutical products -- 100; 101; 102; 102.5; 103; 104; 105; 106; 107; 108; 109; 110; 111; 112; 113; 114; 115; 116; 116.5; 117; 118; 119; 120; 121; 122; 123; 123.5; 124; 125; 126; 127; 128; 129; 130; 131; 131.5; 132; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 153; 155; 156; 157; 158; 159; 160; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 161; 162; 163; 164; 165; 166; 166.5; 167; 167.3; 167.5; 168; 168.5; 169; 170; 171; 172; 173; 174; 175; 176; 177; 178; 179; 180; 181; 182; 183; 184; 185; 186; 187; 188; 189; 190; 191; 192; 192.3; 192.5; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 208.5; 209; 210; 211; 212; 212.5; 213; 214; 214.5; 215; 216; 217; 218; 219; 220; 221; 222; 222.2; 222.4; 222.6; 223; 224; 225; 226; 227; 228; 229; 230; 231; 232; 233; 234; 235; 236; 237; 238; 239; 240; 242; 243; 244; 245; 246; 247; 248; 249; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259; 260; 261; 261.5; 261.7; 262; 263; 264; 265; 265.5; 266; 267; 268; 269; 270; 271; 272; 273; 274; 275; 276; 300; 301; 302; 303; 304; 305; 306; 307; 308; 309; 310; 311; 312; 313; 314; 315; 400; 401; 402; 403; 404; 405; 406; 407; 408; 409; 410; 411; 412; 413; 414; 415; 416; 417; 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 428; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 438; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 453; 454; 455; 456; 456.5; 457; 458; 459; 460; 461; 462; 463; 464; 465; 466; 467; 468; 469; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 481.5; 482; 483;
biopharmaceutical products -- 483.2;
biopharmaceutical products -- 483.3;
biopharmaceutical products -- 483.8; 484; 485; 486; 487; 488; 489; 490; 491; 492; 493; 493.5; 494; 494.5; 495; 496; 497; 498; 499; 500; 501; 502; 502.5; 503; 504; 505; 506; 507; 508; 509; 510; 511; 512; 513;
biopharmaceutical products -- 513.3; 513.5; 514; 515; 516; 517; 518; 519; 520; 521; 522; 523; 524; 525; 526; 527; 528; 529; 530; 531; 532; 533; 534; 535; 536; 537; 538; 539; 540; 541; 542; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 560; 561; 562; 563; 564; 565; 566; 567; 600; 601; 602; 602.5; 603; 604; 605; 606; 607; 608; 609; 610; 611; 612; 613; 614; 615; 616; 617; 618; 619; 620; 623; 624; 625; 626; 627; 628; 629; 630; 631; 632; 633; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 659; 700; 701; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 736.5; 737; 738; 739; 739.5; 740; 740; 741; 742; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 807; 808; 809; 900; 901; 902; 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918; 919; 920; 921; 922; 923; 924; 925; 927; 929; 931; 932; 949;
blockbuster sales (over $1 billion/year) -- 115; 128; 132; 136; 138; 143; 149; 158; 159; 167; 179; 195; 197; 199; 205; 210; 211; 212; 245; 247; 264; 265; 267; 275; 400; 468; 470; 513; 600; 702; 703; 715; 743; 798; 802; 806;
blood products -- 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 469; 606; 614; 620; 700; 701; 702; 703; 703.5; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 736.5; 737; 738; 739; 739.5; 740; 741; 742; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 807; 808; 809; 900; 901; 902; 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918; 919; 920; 921; 922; 923;
bone growth factors -- 107; 108; 109; 234; 237;
bovine materials used -- 108; 109; 110; 115; 128; 145; 147; 151; 152; 162; 163; 167; 167; 182; 196; 240; 243; 245; 264; 270; 304; 310; 312; 404; 406; 420; 422; 423; 431; 433; 434; 436; 443; 445; 455; 457; 463; 464; 466; 467; 471; 476; 485; 489; 491; 492; 493; 494; 495; 496; 504; 514; 517; 520; 521; 526; 528; 529; 531; 532; 533; 534; 536; 537; 540; 547; 549; 555; 562; 563; 564; 565; 566; 567; 601; 602; 605; 612; 614; 616; 617; 618; 624; 626; 631; 651; 652; 653; 656; 659; 737; 738; 794; 808; 900; 902; 920; 921; 922; 923; 941; 942;
bovine materials used -- 513;
bovine materials used -- 513.3;
cancer vaccines -- 111; 183; 184; 185; 242; 271; 412; 416; 417;
chicken source materials -- 191.1;
chicken source materials -- 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 482;
chicken source materials -- 483.11;
chicken source materials -- 483.2;
chicken source materials -- 483.3;
chicken source materials -- 483.4;
chicken source materials -- 483.7; 484; 485; 486; 487; 488; 491; 492; 493; 493.5; 494; 495; 496; 504; 529; 534; 541; 566; 567; 926; 928; 930;
conjugates (see also radioimmune conjugates; immunotoxins; fusion proteins) -- 117; 118; 121; 122; 123; 123.5; 131.5; 202; 205; 215; 217; 220; 266; 271; 273; 305; 306; 307; 308; 310; 311; 312; 314; 315; 439; 440; 444; 445; 453; 454; 455; 456.5; 457; 458; 459; 501; 502.5; 503; 513;
conjugates (see also radioimmune conjugates; immunotoxins; fusion proteins) -- 513.3; 515; 542; 611;
conjugates, albumin -- 208.5;
cytokine antagonists -- 125; 214; 221; 221; 244; 264; 265; 742;
cytokine antogonists -- 215;
cytokine trap -- 215;
cytokine-cytotoxin conjugate -- 217;
cytokines -- 218; 219; 263;
enzyme inhibitors -- 709; 710; 711; 712; 712.5;
enzymes -- 105; 112; 126; 153; 161; 162; 163; 167; 167.3; 167.5; 168; 168.5; 186; 187; 236; 243; 260; 268; 269; 270; 272; 605; 606; 607; 608; 609; 610; 611; 612; 613; 614; 615; 616; 617; 618; 619; 620; 621; 621.5; 622; 623; 624; 625; 626; 627; 628; 629; 804;
enzymes, fibrinolytic/thrombolytic -- 153; 268; 269; 270; 272; 606; 613; 614; 620; 623; 624; 625; 626; 627;
equine immune globulins -- 903; 907; 909; 910; 911; 912; 916; 918;
equine materials used -- 270; 903; 907; 909; 910; 911; 912; 916; 918;
expression, bacterial -- 110; 128; 158; 159; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 165; 171; 173; 192; 192.3; 192.5; 197; 199; 201; 202; 204; 205; 206; 208; 209; 212; 212.5; 213; 214; 216; 218; 219; 220; 229; 230; 231; 234; 235; 236; 248; 249; 250; 251; 252; 253; 254; 256; 258; 259; 261.5; 268; 274; 542;
expression, baculovirus -- 185; 242; 271;
expression, insect cells -- 185; 191.5; 242; 271;
expression, mammalian -- 102; 105; 108; 109; 113; 114; 115; 116; 116.5; 117; 117; 118; 119; 121; 123; 123.5; 124; 125; 126; 129; 130; 131.5; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 155; 156; 160; 162; 163; 167; 168; 168.5; 172; 176; 179; 186; 187; 189; 202; 203; 210; 211; 222; 222.4; 222.6; 223; 227; 228; 240; 243; 244; 245; 246; 257; 262; 264; 265; 265.5; 267; 269; 270; 275;
expression, transgenic animals -- 102; 113; 123; 129; 168;
expression, yeast -- 153; 166; 169; 174; 175; 177; 178; 181; 182; 184; 193; 195; 196; 200; 208.5; 225; 237; 238; 239; 272; 466;
expresssion, bacterial -- 217;
fibrin sealants -- 735; 736; 736.5; 737; 738; 739; 739.5;
fungal (non-yeast) source -- 610;
fusion proteins, recombinant -- 122; 123; 123.5; 215; 217; 220; 227; 267;
gene therapy, viral vectors -- 232; 233; 261.7;
glycoconjugates -- 513;
glycoconjugates -- 513.3; 513.5;
glycosaminoglycans -- 925; 926; 928; 928; 929;
goat source materials -- 102;
growth factors -- 107; 108; 109; 127; 200; 226; 234; 275; 931;
growth factors, hematopoietic -- 132; 133; 136; 141; 143; 158; 159; 160; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 169; 170; 171; 216; 237; 238;
growth hormones -- 200; 201; 202; 247; 248; 249; 250; 251; 252; 253; 254; 255; 256; 257;
hamster source materials -- 105; 108; 109; 110; 114; 115; 116; 116.5; 117; 119; 122; 123; 123.5; 126; 129; 131.5; 133; 134; 135; 136; 137; 138; 139; 140; 142; 143; 144; 145; 146; 147; 148; 150; 150.5; 152; 155; 156; 157; 160; 163; 167; 168; 172; 179; 186; 187; 188; 189; 202; 202; 210; 211; 222.4; 222.4; 227; 262; 267; 269; 270; 275; 438;
hemostatic agents -- 225;
hormone antagonists -- 259;
hormones -- 110; 122; 132; 133; 136; 141; 143; 155; 164; 165; 166; 172; 192; 192.3; 192.5; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 228; 231; 234; 235; 247; 247; 248; 250; 251; 252; 253; 254; 255; 256; 257; 258; 262; 630; 631; 632; 633; 935; 936;
hormones, leutenizing -- 228;
Human Cellular and Tissue Based Products -- 649;
human materials used -- 110; 117; 133; 136; 141; 143; 144; 146; 147; 148; 149; 150; 150.5; 151; 152; 155; 167.5; 170; 186; 187; 192; 206; 210; 212; 212.5; 221; 222; 242; 243; 245; 262; 263; 265; 267; 303; 312; 402; 403; 462; 463; 464; 465; 469; 489; 491; 492; 493; 493.5; 494; 494.5; 495; 496; 504; 518; 526; 527; 529; 533; 534; 564; 565; 601; 604; 606; 615; 620; 624; 625; 626; 627; 649; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 658; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 736; 737; 738; 739; 739.5; 740; 741; 743; 744; 745; 746; 747; 748; 749; 750; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 806; 807; 917; 918; 928;
immune globulin fusion proteins -- 123; 124; 125; 215;
immune globulins, equine -- 903; 906; 907; 909; 910; 916; 918;
immune globulins, Fab fragments -- 302; 309; 908; 911; 913; 914; 915;
immune globulins, human -- 744; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 784; 785; 786; 787; 788; 789; 790; 791; 792;
immune globulins, ovine -- 906; 908; 913; 914;
immune globulins, rabbit -- 917;
immune modulator -- 405; 934.5; 947;
immunoadhesins -- 123; 123.5; 124; 125; 215; 227; 261.5; 267;
immunotoxins -- 118; 131.5;
implants -- 108; 109; 241; 924; 929;
influenza vaccines, pandemic -- 484; 486; 487; 488;
inorganic substances -- 937;
insulins -- 192; 192.3; 193; 194; 195; 196; 197; 198; 199; 630; 631; 632; 633;
interferons -- 204; 205; 206; 207; 207; 208; 208.5; 209; 210; 211; 212; 212.5; 213; 793; 794; 795; 796;
intermediate/precursor products -- 101; 116; 146; 238; 304; 313; 420; 422; 498; 500; 507; 508; 547; 620; 750; 807;
lipoproteins -- 230;
liposomal formulations -- 462; 482; 483;
live microorganisms (as active agent) -- 190; 191; 402; 403; 408; 409; 410; 411; 412; 481.5; 486; 491; 492; 493; 494; 494.5; 495; 496; 504; 521; 522; 523; 524; 532; 533; 534; 535; 536; 537; 539; 540; 562; 564; 565; 567;
lung surfactants -- 940; 941; 942; 943;
mammalian cells/tissue/organism source -- 120; 486; 490; 739.5; 772; 807;
monkey source materials -- 224; 490; 516; 517; 519; 520; 521; 528; 530; 531; 532; 540;
monoclonal antibodies -- 114; 116; 117; 118; 119; 128; 129; 130; 179; 189; 221; 222; 223; 227; 240; 264; 265; 265.5; 267; 300; 302; 303; 304; 305; 306; 307; 308; 310; 311; 312; 313; 314; 315; 701; 723;
monoclonal antibodies, human -- 214.5;
monoclonal antibodies, recombinant -- 114; 116; 116.5; 118; 119; 120; 121; 123; 124; 125; 128; 129; 130; 131; 173; 179; 189; 203; 214.5; 221; 227; 240; 245; 264; 265; 265.5; 266; 267; 275; 276;
monoclonal antibodies, recombinant, bispecific -- 131.5;
monoclonal antibodies, recombinant, chimeric -- 115; 131.5;
monoclonal antibodies, recombinant, fully human -- 116.5; 129; 244; 265; 265.5;
monoclonal antibodies, recombnant, human -- 222.4;
monoclonal antibodies, recombnant, humanized -- 114; 120; 189; 203; 222; 222.2; 223; 246; 275; 276;
monoclonal antiibody, murine-rat chimeric -- 131.5;
murine (mouse) materials used -- 105; 117; 118; 120; 128; 145; 147; 148; 149; 151; 152; 156; 157; 179; 221; 222; 240; 245; 246; 257; 264; 301; 302; 303; 304; 305; 306; 307; 309; 310; 311; 312; 313; 314; 315; 489; 510; 653; 701; 721; 722; 723; 731; 732; 794; 795; 804;
murine (mouse) monoclonal antibodies -- 302; 303; 304; 305; 306; 307; 309; 310; 311; 312; 313; 314; 315;
murine source materials -- 150;
nonbiopharmaceutical products -- 622; 658; 926; 928; 930; 933; 934; 935; 936; 937; 939; 941; 942; 943; 945; 947; 948; 949;
nonrecombinant -- 475;
nonrecombinant -- 483.1;
nonrecombinant -- 483.11;
nonrecombinant -- 483.2;
nonrecombinant -- 483.3;
nonrecombinant -- 483.4;
nonrecombinant -- 483.7;
nonrecombinant -- 483.8; 490;
nonrecombinant -- 513.3; 538; 546; 608; 618; 703.5; 713.7; 714; 719; 736.5; 739.5; 749; 807;
oligonucleotides -- 944; 945; 946; 947; 948; 949;
ovine (sheep) immune globulins -- 908; 913; 914; 915;
ovine (sheep) source materials -- 406; 619; 701; 908; 913; 914; 915;
ovine source materials -- 619;
peptides, recombinant -- 110; 231;
peptides, synthetic -- 930.5; 933; 934; 935; 936;
phosphatidylethanolamine -- 934.5;
phosphorothioates -- 944; 945; 946; 949;
polysaccharides -- 925; 926; 927; 928; 929;
porcine source materials -- 102; 128; 150; 162; 191;
porcine source materials -- 191.1; 196; 270; 494; 564; 565; 621.5; 657; 770; 924.5; 931; 943;
poxvirus vectors, vaccinia -- 111;
preservatives, vaccines -- 939;
rabbit materials used -- 113; 168; 917;
radioimmune conjugates -- 117; 121; 302; 305; 306; 307; 308; 309; 310; 311; 312; 314; 315;
reassortant viruses -- 190; 191; 531; 532;
receptor antagonists (see also receptor antibodies) -- 742;
receptor antibodies -- 114; 115; 116.5; 128; 129; 130; 131; 131.5; 203; 222; 223; 227; 240;
recombinant -- 191.1;
recombinant DNA -- 100; 101; 102; 102.5; 103; 104; 105; 106; 107; 108; 109; 110; 111; 112; 113; 114; 115; 116; 116.5; 117; 118; 119; 120; 121; 122; 123; 123.5; 124; 125; 126; 127; 128; 129; 130; 131; 131.5; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 144; 145; 146; 147; 148; 149; 150; 151; 152; 153; 155; 156; 157; 158; 159; 160; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 161; 162; 163; 164; 165; 166; 166.5; 167; 167.3; 167.5; 168; 168.5; 169; 170; 171; 172; 174; 175; 176; 177; 178; 179; 180; 181; 182; 184; 185; 186; 187; 188; 189; 190; 191; 191.5; 192; 192.3; 192.5; 193; 193.5; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 209; 210; 211; 212; 212.5; 213; 214; 216; 217; 218; 219; 220; 221; 222; 222.2; 222.4; 222.6; 223; 224; 225; 226; 227; 228; 229; 230; 231; 232; 233; 234; 235; 236; 237; 238; 239; 240; 243; 244; 245; 246; 248; 249; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259; 260; 261; 261.5; 261.5; 261.7; 262; 263; 264; 265; 265.5; 266; 267; 268; 269; 270; 271; 272; 273; 274; 275; 276; 415; 428; 438; 439; 440; 441; 442; 466; 486; 542;
Rho(D) red blood cell antibodies -- 776; 777; 778; 779; 780;
rodent, non-murine (e.g., rat, hamster) source materials -- 105; 108; 109; 110; 114; 115; 116; 117; 119; 122; 123; 123.5; 126; 129; 130; 131.5; 133; 136; 138; 142; 142; 143; 144; 145; 146; 147; 148; 149; 151; 152; 155; 156; 157; 160; 163; 167; 168; 168.5; 172; 179; 187; 188; 189; 202; 210; 211; 227; 228; 262; 267; 269; 270; 275; 438; 489; 494; 564; 565;
skin replacements -- 651; 652; 653; 656; 657; 658; 659;
Streptococcus pnuemoniae capsular antigens -- 513.5;
synthetic manufacture -- 930.5; 933; 934; 934.5; 935; 936; 937; 944; 945; 946; 947; 948; 949;
toxins (see also toxoids) -- 118; 220; 600; 601; 602; 602.5; 603; 604;
tumor differentiation inhibitors -- 129;
tumor necrosis factor antagonists -- 264; 265; 265.5; 266; 267;
vaccines, anti-idiotypic -- 271; 416; 417;
vaccines, bacterial -- 103; 104; 229; 230; 236; 404; 405; 406; 407; 408; 409; 410; 411; 412; 413; 414; 415; 418; 419; 420; 421; 422; 423; 424; 425; 426; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 453; 454; 455; 456; 456.5; 457; 458; 459; 460; 497; 498; 499; 500; 501; 502; 502.5; 503; 505; 506; 507; 508; 509; 510; 511; 512; 513; 513.5; 514; 515; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 560; 561; 562; 563;
vaccines, cancer -- 183; 184; 185; 242; 412;
vaccines, cellular -- 242; 271; 416; 417;
vaccines, combination -- 415; 420; 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 438; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 460; 466; 467; 492; 493; 493.5; 494; 494.5; 495; 496; 499; 502; 502.5; 503; 534; 555; 556; 557; 558; 559;
vaccines, inactivated -- 191.1;
vaccines, inactivated -- 404; 413; 414; 420; 447; 461; 462; 463; 464; 465; 466; 467; 469; 470; 471; 472; 473; 474; 475; 477; 478; 480; 481; 481.5; 482; 483;
vaccines, inactivated -- 483.11;
vaccines, inactivated -- 483.2;
vaccines, inactivated -- 483.3;
vaccines, inactivated -- 483.4;
vaccines, inactivated -- 483.7;
vaccines, inactivated -- 483.8; 484; 485; 487; 488; 489; 490; 508; 509; 510; 511; 514; 515; 517; 518; 519; 520; 525; 526; 527; 528; 529; 561;
vaccines, intranasal -- 190; 191; 486;
vaccines, liposomal -- 462; 482; 483;
vaccines, live -- 111; 190; 191; 191.5; 224; 401; 402; 403; 407; 408; 409; 410; 411; 412; 486; 491; 492; 493; 493.5; 494; 494.5; 495; 496; 504; 521; 522; 523; 524; 530; 531; 532; 533; 534; 535; 536; 537; 538; 539; 540; 541; 560; 562; 564; 565; 566; 567;
vaccines, oral -- 521; 530; 531; 532;
vaccines, personalized -- 271; 416; 417;
vaccines, subunit -- 103; 104; 174; 175; 176; 177; 178; 183; 184; 185;
vaccines, subunit -- 191.1; 224; 229; 230; 236; 404; 405; 406; 415; 418; 419; 420; 429; 438; 452; 454; 455; 456; 456.5; 457; 458; 459; 460; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 482; 483;
vaccines, subunit -- 483.11;
vaccines, subunit -- 483.2;
vaccines, subunit -- 483.3;
vaccines, subunit -- 483.4;
vaccines, subunit -- 483.7;
vaccines, subunit -- 483.8; 484; 485; 489; 497; 498; 499; 500; 501; 502; 502.5; 503; 506; 508; 513; 513.5; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554;
vaccines, toxoids (inactivated toxins) -- 236; 413; 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 429; 430; 431; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 454; 455; 507; 513; 513.5; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559;
vaccines, viral -- 174; 175; 176; 177; 178; 183; 184; 185; 190; 191;
vaccines, viral -- 191.1; 191.5; 224; 401; 402; 403; 428; 437.5; 441; 442; 446; 446.5; 460; 461; 462; 464; 465; 466; 468; 469; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481.5; 482; 483;
vaccines, viral -- 483.1;
vaccines, viral -- 483.11;
vaccines, viral -- 483.2;
vaccines, viral -- 483.3;
vaccines, viral -- 483.4;
vaccines, viral -- 483.7;
vaccines, viral -- 483.8; 484; 485; 486; 487; 488; 489; 490; 492; 493; 493.5; 494; 494.5; 495; 496; 504; 517; 518; 519; 520; 521; 522; 523; 524; 525; 526; 527; 528; 529; 530; 531; 532; 533; 534; 535; 536; 537; 538; 539; 540; 541; 564; 565; 566; 567; 932;
viral (nano)filtration -- 140;
yeast source materials -- 166; 169; 174; 175; 177; 178; 181; 182; 184; 193; 195; 196; 200; 208.5; 225; 228; 228; 237; 238; 239; 245; 245; 272; 438; 438; 441; 441; 442; 442; 465; 465; 466; 466; 493; 493; 629;
19970411 xxxxxx -- 905;
EC 3.2.1.22 -- 161; 162; 163;
adenovirus vector viradeno genether -- 261.7;
autologous cells, human -- 649.5;
bacteria, E. coli -- 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 192.3; 192.5; 212.5;
Bacterial cell culture micbac -- 456.5; 502.5; 513.5; 602.5;
chicken eggs mampoulchickeggs -- 483.2;
chicken eggs mampoulchickeggs -- 483.3;
chicken eggs mampoulchickeggs -- 483.4;
hamster, Chinese ovary (CHO) -- 116.5; 123.5; 131.5; 150.5; 168; 168.5;
human autologous cell culture mamprimhumcell -- 650.3; 650.5;
human autologous cell culture mamprimhumcell -- 649;
human blood/plasma -- 703.5; 712.5; 713.7; 736.5; 739.5;
human, autologous cells source -- 649.5;
Insect insectcell -- 191.5;
Mammalian mam -- 222.2; 222.4; 222.6;
porcine tissues -- 621.5;
hamster, Chinese ovary (CHO) -- 115;
Amphibian source -- 628;
bacteria, E. coli -- 608; 609; 611;
Bacterial cell culture micbac -- 404; 405; 406; 408; 409; 410; 411; 412; 413; 414; 419; 420; 429; 430; 432; 433; 435; 436; 437; 443; 454; 455; 456; 457; 458; 459; 497; 498; 500; 501; 503; 507; 508; 509; 510; 511; 513; 514; 515; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 556; 561; 562; 563; 601; 602; 603; 604; 606; 612; 624; 625; 700; 927; 929; 938;
bovine skin in vivo mambovskin -- 536;
bovine tissues -- 537; 605; 614; 616; 617; 618; 631; 659; 900; 902; 919; 920; 921; 922; 923; 941; 942;
chicken eggs mampoulchickeggs -- 485;
chicken eggs mampoulchickeggs -- 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 482; 487; 488; 566; 567; 932;
chicken embryo cells -- 486; 491; 504; 529; 541;
chicken tissues mampoulchick -- 930;
chicken tissues mampoulchick -- 926; 928;
duck kidney mampoulduck -- 483;
equine tissues mamequine -- 911;
equine tissues mamequine -- 903; 904; 905; 906; 907; 908; 909; 910; 912; 916; 918;
Fungal culture micfung -- 610;
human autologous cell culture mamprimhumcell -- 650;
human autologous cell culture mamprimhumcell -- 653; 654;
Human blood-derived mamprimhumblood -- 469;
human blood/plasma -- 620; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 713; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 737; 738; 739; 740; 741; 742; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 807; 808; 809;
human cells -- 416; 417; 658;
human diploid -- 402; 403; 462; 463; 464; 465; 518; 522; 523; 524; 526; 527; 533; 539; 564; 565;
human embryronic kidney (HEK) -- 540; 626; 627;
human fibroblast -- 924;
human neonatal foreskin mamprimhumforeskin -- 651; 652; 656; 657;
human placentae -- 615;
Mammalian mam -- 538;
monkey kidney mamprimemonkkidney -- 490; 521;
monkey kidney mamprimemonk -- 517; 519; 520;
monkey lung mamprimemonklung -- 528;
mouse brains mamrodmurbrains -- 489;
murine ascites mammurhybascites -- 302; 304; 307; 309; 314; 701;
murine ascites mammurhybascites -- 303;
Murine hybridomas mamrodmurhybcellcult -- 305; 306; 308; 310; 311; 312;
murine myeloma -- 301; 313;
ovine tissues -- 619; 913; 914; 915;
Plant source -- 622;
porcine tissues -- 621; 632; 633; 901; 931; 943;
rabbit tissues * mamrabbit -- 917;
rotavirus -- 530; 531; 532;
Saccharomyces micyeastsacch -- 629;
Synthetic -- 933; 935; 936; 939; 945; 947; 948; 949;
-- 273;
adenovirus vector viradeno genether -- 233;
adenovirus vector genetheradeno -- 232;
bacteria, E. coli -- 103; 106; 110; 112; 120; 158; 159; 165; 170; 173; 186; 192; 194; 197; 198; 199; 201; 204; 205; 206; 207; 208; 209; 212; 213; 214; 216; 217; 218; 219; 220; 226; 229; 230; 231; 234; 235; 236; 241; 250; 251; 252; 253; 254; 255; 256; 258; 259; 260; 263; 266; 268; 274; 276; 415; 542;
BHK mamrodhambhk -- 145; 149; 151;
chicken eggs mampoulchickeggs -- 190; 191;
chicken embryo cell culture mampoulchiccells -- 111;
hamster, Chinese ovary (CHO) -- 105; 108; 109; 114; 116; 117; 119; 122; 123; 126; 129; 133; 134; 135; 136; 137; 138; 139; 140; 142; 143; 144; 146; 147; 148; 150; 152; 155; 156; 160; 163; 167; 172; 179; 187; 189; 202; 210; 211; 227; 228; 244; 261; 262; 267; 269; 270; 275;
human autologous cell culture mamprimhumcell Insect insectcell -- 242;
human cells -- 121; 141; 188; 265;
human embryronic kidney mamhukidmfibr -- 243;
human fibroblasts -- 162;
Insect insectcell -- 185; 271;
Mammalian mam -- 124; 125; 131; 215; 223;
monkey kidney mamprimemonkkidney -- 224;
Murine mamrodmur -- 130;
murine myeloma -- 118; 128; 176; 203; 221; 222; 240; 245; 246; 257; 264;
Pichia micyeastpich -- 153; 225;
Saccharomyces micyeastsacch -- 101; 166; 169; 174; 175; 177; 178; 181; 182; 184; 193; 196; 200; 237; 238; 239; 272;
Saccharomyces micyeastsacch -- 195; 248;
Streptomyces micbacstrep -- 171;
transgenic goats mamtransgoat -- 102;
transgenic rabbits mamtransrabbit -- 113;
unknown -- 104;
becaplermin -- 237;
abdominal
ablation, thyroid cancer radiotreatment -- 262;
abscesses -- 219;
acid maltase deficiency -- 168;
acromegaly treatment -- 259;
actinic keratosis -- 260;
acute ischemic stroke -- 269;
acute myocardial infarction (AMI) -- 268; 269; 270; 274; 606; 624; 625; 626; 627;
acute respiratory distress syndrome (ARDS) -- 940;
adenoside deaminase (ADA) deficiency -- 605;
adenovirus infection prophylaxis -- 401; 402; 403;
adhesive, surgical -- 900;
agammaglobulinemia -- 758; 760; 761; 765; 767; 768; 771;
age-related macular degeneration (AMD) -- 275; 276; 949;
AIDS wasting -- 257;
alpha1-antitrypsin deficiency (A1AD) -- 709; 710; 711; 712; 712.5;
amyotrophic lateral sclerosis (ALS) -- 200;
anastomoses, sealing -- 900;
anemia -- 132; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 702; 741; 902; 918;
angina -- 240;
angiogenesis inhibitors -- 129; 130; 275; 275; 276; 949;
angioplasty -- 240; 934;
ankylosing spondylitis -- 264;
ankylosing spondylitis
anovulation -- 155; 156; 157;
anthrax (inhalational) treatment -- 102.5;
anthrax prophylaxis -- 103; 104; 404;
anthrax treatment -- 744; 745; 746;
anticoagulation -- 180; 181; 182; 934;
antiinflammation -- 227;
antithrombin III deficiency -- 102; 706; 707; 708;
aplastic anemia -- 918;
apoptosis inhibition -- 945;
appendicitis, radiodiagnosis -- 305;
arthritis, juvenile idiopathic -- 223;
arthritis, psoriatic -- 264; 265; 265.5; 267;
arthritis, rheumatoid -- 265.5;
arylsulfatase B deficiency -- 105;
ascites, malignant -- 131.5;
asparaginase deficiency -- 607; 608; 609; 611;
Assisted Reproductive Technology (ART) -- 155; 156; 157; 172; 228;
asthma, allergic -- 189;
autism -- 935; 936; 939;
autoimmune disorders -- 120; 227; 948;
Bacillus anthracis prophylaxis -- 103; 104; 404;
bacteremia, Staphylococcus aureus -- 542;
bacterial infections, Gram negative -- 243;
Bcl-2 messenger RNA (mRNA) inhibition -- 945;
Behcet's disease -- 264;
biopharmaceutical products -- 483.4;
biopharmaceutical products -- 649;
black widow spider bites -- 909;
blepharospasm -- 601; 603;
blood chromatography -- 700;
blood progenitor cell transplants -- 169; 170; 171;
blood transfusion -- 702;
blood-brain barrier blockage -- 203;
bone calcium metabolism -- 110;
bone fracture repair -- 107; 108; 109;
bone marrow transplantation (BMT) -- 169; 170; 171; 226; 761; 765;
bone repair, periodontal -- 237; 931;
botulism -- 413; 911; 912;
brain cancer -- 217; 416;
breast cancer -- 179;
breast cancer treatment -- 703.5;
bronchopulmonary dysplasia (BPD) -- 245; 781;
burns -- 612; 653; 657; 659; 703;
cachexia (wasting) -- 257;
cancer prophylaxis, skin cancer -- 260;
cancer radiodiagnosis -- 121; 262; 302; 311; 314; 315;
cancer treatment adverse effects -- 112; 133; 134; 135; 136; 137; 139; 140; 143; 158; 159; 160; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 169; 170; 171; 216; 226; 272; 701; 802;
cancer treatment, abdominal
cancer treatment, breast -- 703.5;
cancer treatment, epithelial -- 131.5;
cancer treatment, gastric cancer -- 131;
cancer treatment, malignant ascites -- 131.5;
cancer treatment, ovarian -- 131;
cancer treatment, thyroid cancer -- 262;
cancer vaccines -- 183; 184; 185; 242; 412; 649.5;
cancer, acute myelogenous leukemia (AML) -- 118; 169;
cancer, bladder -- 219; 407; 408; 409; 410;
cancer, brain -- 217; 416;
cancer, breast -- 179;
cancer, chronic lymphocytic leukaemia (CLL) -- 116.5;
cancer, chronic lymphocytic leukemia (CLL) -- 119; 761; 764; 769; 769; 945;
cancer, colorectal -- 121; 128; 129; 130; 219; 244; 275; 307; 314; 315; 649.5;
cancer, cutaneous T-cell lymphoma -- 220;
cancer, gastrinoma diagnosis -- 935; 936;
cancer, glioma -- 261.7;
cancer, hairy cell leukemia -- 204; 206;
cancer, head and neck -- 128;
cancer, Hodgkin's lymphoma -- 169; 171;
cancer, hypereosinophilic syndrome -- 222.4;
cancer, Kaposi's sarcoma -- 204; 206;
cancer, kidney -- 275;
cancer, Li-Fraumeni Syndrome
cancer, melanoma -- 206; 218; 219; 219; 796; 945;
cancer, melanoma radiodiagnostic imaging -- 309;
cancer, mesothelioma -- 628;
cancer, non-Hodgkin's lymphoma -- 115; 117; 169; 171; 206; 220; 306; 611;
cancer, non-Hodgkin's Lymphoma (NHL) -- 417;
cancer, non-small cell lung cancer (NSCLC) -- 275;
cancer, osteosarcoma -- 934.5;
cancer, ovarian -- 314;
cancer, ovarian radiodiagnostic imaging -- 302;
cancer, prostate -- 242; 312;
cancer, rectum carcinoma -- 275;
cancer, renal cell carcinoma -- 218; 219; 219;
cancer, small cell lung cancer -- 311;
cancer, squamous cell carcinoma -- 232; 233;
cancer, thyroid -- 262;
candidiais -- 173;
cardiopulmonary bypass surgery -- 102; 225; 703; 713; 737; 738;
cardiovascular -- 181; 240; 268; 269; 270; 310; 606; 624; 625; 626; 627; 703; 934;
Castleman's disease -- 223;
catheter clearance -- 153; 269; 626; 627;
CD34+ stem cell enrichment -- 701;
cervical cancer prophylactic vaccines -- 183; 184; 185;
cervical dystonia -- 601; 602; 603; 604;
cervical, cervical -- 184; 185;
cervicitis -- 614;
chicken pox prophylaxis -- 494; 564;
cholangiopancreatography -- 935; 936;
cholera prophylaxis -- 414; 415;
chronic fatigue syndrome -- 795;
chronic granulomatous disease (CGD) -- 213;
chronic heart failure (CHF) -- 231;
chronic lymphocytic leukaemia (CLL) -- 116.5;
chronic lymphocytic leukemia (CLL) -- 115; 119; 761; 764; 769; 945;
chronic myelogenous leukemia (CML) -- 796;
chronic renal failure -- 132; 133; 134; 135; 136; 137; 139; 140; 141; 142; 143;
colitis, ulcerative -- 264;
colon cancer -- 275; 649.5;
colorectal cancer -- 128; 244;
colorectal cancer radiodiagnosis -- 121; 314;
complement C1 esterase inhibitor deficiency -- 113; 713.7; 714;
complement system -- 120;
condyloma acuminata -- 184; 206; 795;
congenital heart disease -- 245;
congenital sucrase-isomaltase deficiency (CSID) -- 629;
controlled ovarian stimulation (COS) -- 122;
coral snake bites -- 910;
coronary angioplasty, percutaneous tranluminal (PTCA) -- 240;
Crohn's disease -- 169; 264; 203; 266;
Cryopyrin-Associated Periodic Syndromes (CAPS) -- 214.5;
cryopyrin-associated periodic syndromes (CAPS)
cystic fibrosis -- 621; 621.5;
cystic fibrosis (CF) -- 126;
cytomegalovirus (CMV) prophylaxis/retinitis -- 219; 748; 749; 946;
deep vein thrombosis (DVT) -- 102; 924.5;
degenerative disc disease (DDD) -- 108;
delayed-hypersensitivity (DH) -- 932;
dermal filler -- 928; 929;
diabetes -- 192; 192.3; 192.5; 193; 193.5; 194; 195; 196; 197; 198; 199; 630; 632; 633;
diabetes type 2 -- 166.5;
diabetic foot ulcers -- 127; 239; 651; 652;
diabetic retinopathy (DME) -- 949;
dialysis patients, hepatitis B vaccination -- 177;
dialysis patients, Staphylococcus aureus vaccination -- 542;
diarrhea, traveler�s -- 415;
digitalis poisoning -- 913; 914; 915;
diphtheria prophylaxis -- 418; 419; 421; 423; 424; 425; 426; 427; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 438; 439; 440; 442; 443; 444; 445; 446; 446.5; 447; 448; 449; 450; 451; 452; 555; 557; 558; 559; 916;
diphtheria treatment -- 916;
disc prolapse -- 742;
disseminated intravascular coagulation (DIC) -- 243;
DNA repair -- 260;
dsDNA antibody inhibition -- 948;
Dupuytren�s disease -- 612;
elastase inhibition -- 709; 710; 711; 712; 712.5;
emphysema -- 709; 710; 711; 712; 712.5;
endoscopic retrograde cholangiopancreatography (ERCP) -- 935;
enterotoxigenic E. coli (ETEC) prophylaxis -- 415;
enzyme replacement therapy (ERT) -- 105; 126; 161; 167; 167.3; 167.5; 168; 168.5; 187; 605; 607; 608; 609; 610; 611; 615; 629;
eosinophilic esophagitis (EE) -- 222.2;
eosinophilic syndrome -- 222.4;
epidermolysis bullosa (EB) -- 656;
epidermolysis bullosa (RDEB), recessive dystrophic -- 656;
epithelial cancer -- 131.5;
erythema multiforme (EM) -- 656;
extracorporeal plasma filtration -- 700;
extravasation, intradermal fluids -- 186; 616; 617; 618; 619;
Fabry disease -- 161; 162; 163;
facial wrinkles and folds -- 601; 602; 604; 924; 929;
Factor IX inhibitors -- 145;
Factor VII deficiency -- 728;
Factor VIII inhibitors -- 145; 728; 901;
Familial Cold Autoinflammatory Syndrome (FCAS) -- 214.5; 215;
fistulas -- 264;
folate antagonist toxicity -- 112;
follicular maturation -- 172;
follicular non-Hodgkin's Lymphoma (NHL) -- 417;
frozen shoulder -- 612;
Fuchs heterochromic iridocyclitis prophylaxis -- 533;
gastric cancer treatment -- 131;
gastrinoma diagnosis -- 935; 936;
Gaucher disease -- 167; 167.3; 167.5; 615;
gene therapy -- 232;
genetic diseases -- 102; 105; 113; 120; 126; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 168; 168.5; 187; 213; 215; 225; 233; 247; 250; 251; 252; 253; 254; 256; 257; 260; 605; 607; 608; 609; 611; 629; 656; 704; 705; 706; 707; 708; 709; 710; 711; 712; 713.7; 714; 715; 716; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 730; 731; 733; 734; 739; 743; 761; 767; 798; 804; 901;
genital warts -- 206; 795;
genital warts prophylactic vaccines -- 183; 184;
glabellar lines/folds -- 601; 602; 602.5; 604; 924;
glioblastoma multiformes (GBM) -- 416;
glioblastoma multiformes (GBMs) -- 217;
glioma -- 261.7;
glucocorticoid-induced osteoporosis -- 110;
glycogenosis type II (GSD II) -- 168; 168.5;
glycoprotein (GP)IIb/IIIa receptor inhibition -- 240;
gout -- 273;
growth hormone deficiencies -- 201; 202; 248; 249; 250; 251; 252; 253; 254; 255; 256; 257; 258;
growth hormone insensitivity syndrome (GHIS) -- 201; 202;
Guillain Barre Syndrome -- 761;
Haemophilus influenzae b prophylaxis -- 439; 440; 443; 445; 451; 452; 453; 454; 455; 456; 456.5; 457; 458; 459; 460;
hairy cell leukemia -- 204; 206; 796;
hantavirus infection -- 219;
head and neck cancer -- 232; 233;
head cancer -- 128;
heart failure (CHF), congestive, acutely decompensated -- 231;
heart failure, acute (CHF) -- 231;
heart failure, chronic -- 713.5;
hemoglobinopathies -- 806;
hemoglobinuria, paroxysmal nocturnal -- 120;
hemolytic disease of the newborn (HDN) -- 703; 776; 777; 778; 779; 780;
hemophilia A -- 145; 147; 148; 149; 150; 150.5; 151; 152; 700; 704; 705; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 739; 805; 901;
hemophilia B -- 144; 700; 704; 728; 730; 731; 732; 733; 734; 798; 805;
hemophilia, acquired -- 145;
hemorrhage, acute intracerebral -- 145;
hemorrhage, intraocular -- 186; 619;
hemostatic agents -- 261; 619; 713; 713.7; 714; 735; 736; 736.5; 737; 738; 739; 739.5; 798; 799; 802; 803; 807; 808; 900; 919; 920; 921; 921; 922; 923; 928;
heparin-induced thrombocytopenia (HIT) -- 181; 934;
hepatitis A prophylaxis -- 461; 462; 463; 464; 465; 466; 467; 758;
hepatitis B prophylaxis -- 174; 175; 176; 177; 178; 428; 438; 439; 440; 441; 442; 452; 460; 466; 468; 469; 754; 755; 756;
hepatitis B, chronic -- 205;
hepatitis C, chronic -- 204; 205; 206; 207; 207; 208; 208.5; 209; 219; 794; 796;
hereditary angioedema (HAE) -- 113; 225; 713.7; 714; 930.5;
herpes simplex virus (HSV) infections -- 219;
herpes zoster prophylaxis -- 565;
hip replacement surgery -- 182;
HIV-infection -- 133; 136; 765; 933;
HLA alloimmunization -- 802;
human papillomavirus (HPV) vaccines -- 183; 184; 185;
Hunter syndrome -- 188;
Hurler-Scheie syndrome -- 187;
hydration, under the skin -- 186; 617; 618; 619;
hypercalcemia -- 110;
hypereosinophilic syndrome (HES) -- 222.4;
hyperglycemia -- 192; 192.3; 192.5; 193; 194; 195; 196; 197; 198; 199; 630; 631; 632; 633;
hyperhydrosis, axillary -- 601;
hyperuricemia -- 273;
hyperuricemia, cancer-associated -- 272;
hypoalbuminemia -- 703;
hypodermoclysis -- 186; 617; 618; 619;
hypogammaglobulinemia -- 761; 768; 771;
hypoglycemia -- 164; 165; 166; 192; 193; 195; 196; 198; 199; 630; 632; 633;
hypopituitarism -- 250; 252;
hypovolemia -- 703;
idiopathic pulmonary fibrosis (IPF) -- 213;
idiopathic thrombocytopenic purpura (ITP) -- 261.5; 700; 760; 761; 761; 762; 763; 764; 765; 767; 769; 769; 770; 778; 801;
immune deficiencies, primary -- 743; 758; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772;
immunodeficiency, secondary -- 219;
in vitro fertilization (IVF) -- 122; 186; 616; 617; 619;
infections, radiodiagnosis -- 305;
infertility treatment -- 122; 155; 156; 157; 172; 228;
inflammation treatment -- 225; 713; 713.5; 742;
inflammation, erysipelatous -- 219;
influenza prophylaxis -- 190; 191;
influenza prophylaxis -- 191.1; 191.5; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 482; 483;
influenza prophylaxis -- 483.1;
influenza prophylaxis -- 483.11;
influenza prophylaxis -- 483.2;
influenza prophylaxis -- 483.3;
influenza prophylaxis -- 483.4;
influenza prophylaxis -- 483.7;
influenza prophylaxis -- 483.7;
influenza prophylaxis -- 483.8;
influenza, avian/pandemic prophylaxis -- 484; 485; 486; 487; 488;
influezna prophylaxis -- 481.5;
inhalation delivery -- 194;
insulin-like growth factor (IGF-1) deficiency -- 201; 202;
interferon resistance treatment -- 796;
interferons -- 208.5;
intestinal motility -- 165;
intracytoplasmic sperm injection (ICSI) -- 122; 186; 616; 617; 619;
isolated limb perfusion (ILP) -- 263;
Japanese encephalitis prophylaxis -- 224; 489;
juvenile idiopathic arthritis
juvenile rheumatoid arthritis (JRA) -- 123;
Kaposi's sarcoma -- 204; 206;
Kawasaki Syndrome -- 761; 761; 764; 767;
kidney cancer -- 275;
kidney disease -- 801;
knee cartilage repair -- 650; 650.3;
knee lubrication -- 926; 927; 928; 930;
Laron Syndrome -- 201; 202;
leukemia, acute lymphoblastic (ALL) -- 169; 170; 171; 608; 609; 611;
leukemia, acute myelogenous (AML) -- 118; 169; 170; 171;
leukemia, chronic lymphocytic -- 115;
leukemia, chronic myelogenous (CML) -- 796;
leukemia, hairy cell -- 204; 206; 796;
leukopenia -- 169; 170; 171;
Li-Fraumeni Syndrome cancers -- 233;
liver transplantation, hepatitis B prophylaxis -- 755;
Lou Gehrig�s disease -- 200;
lung cancer, non-small cell lung cancer (NSCLC) -- 275;
Lyme disease prophylaxis -- 229; 230;
lymphoma, cutaneous T-cell -- 220;
lymphoma, Hodgkin's -- 169; 171;
lymphoma, indolent -- 115;
lymphoma, non-Hodgkin's (NHL) -- 115; 117; 169; 171; 206; 220; 271; 306; 611;
lysosomal storage diseases -- 105; 161; 167; 168; 168.5; 187; 188; 615;
macular degeneration (AMD), age-related -- 275; 276; 949;
malignant ascites -- 131.5;
Maroteaux-Lamy syndrome -- 105;
measles prophylaxis -- 491; 492; 493; 493.5; 494; 494.5; 495; 496; 534; 758;
melanoma -- 124; 125; 206; 208; 218; 219; 219; 796; 945;
melanoma prophylaxis -- 260;
melanoma radiodiagnostic imaging -- 309; 309;
meningitis prophylaxis -- 452; 497; 498; 499; 500; 501; 502; 502.5; 503;
meningococcemia
mesothelioma -- 628;
methotrexate toxicity -- 112; 747;
Muckle-Wells Syndrome (MWS) -- 214.5; 215;
mucopolysaccharidosis II (MPS II) -- 188;
mucopolysaccharidosis I (MPS I) -- 187;
mucopolysaccharidosis VI (MPS VI) -- 105;
mucositis, oral -- 226;
multiple sclerosis (MS) -- 203; 210; 211; 212; 212.5; 222;
mumps prophylaxis -- 492; 493; 493.5; 494; 504; 534;
mumps skin testing -- 932;
mycosis -- 219;
myeloma -- 761;
myocardial infarction radiodiagnosis -- 310;
myotrophic lateral sclerosis (ALS) -- 202;
nasal administration -- 110; 190; 191; 486;
nasal surgery -- 928;
nasolabial folds (see also facial wrinkles and folds) -- 929;
neck cancer -- 128; 232; 233;
neonatal onset multisystem inflammatory disease
nephritis, membranous -- 120;
nephrosis -- 703;
nephrotoxicity -- 112;
nerve root inflammation -- 742;
neuromuscular blocking -- 600; 601; 602; 602.5; 603; 604;
neutropenia -- 158; 159; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9;
neutropenia -- 160;
non-Hodgkin's lymphoma (NHL) -- 115; 117; 169; 171; 206; 220; 271; 306; 417; 611; 114;
non-small cell lung cancer (NSCLC) -- 275;
oleander poisoning -- 914;
ophthalmic disease -- 949;
ophthalmic surgery -- 186; 616; 617; 618; 619;
oral mucositis -- 226;
osteoarthritis -- 650; 650.3; 742; 926; 927; 928; 930;
osteomyelitis -- 219;
osteoporosis -- 110; 234; 235;
osteoporosis, glucocorticoid-induced -- 110;
osteosarcoma -- 934.5;
ovarian cancer -- 301;
ovarian cancer radiodiagnostic imaging -- 302; 302;
ovarian cancer treatment -- 131;
ovary follicle stimulation -- 155; 156; 157; 228;
Paget�s disease -- 110;
pancreatic cancer -- 111;
pancreatic function diagnosis -- 935; 936;
pancreatic insufficiency -- 621; 621.5;
pancreatitis -- 219;
paraproteinemic conditions -- 801;
paroxysmal nocturnal hemoglobinuria (PNH) -- 120;
percutaneous coronary intervention -- 934;
percutaneous transluminal coronary angioplasty (PTCA) -- 934;
periodontal bone repair -- 237; 931;
peripheral arterial occlusion (PAO) -- 153;
peritonitis -- 219;
pertussis prophylaxis -- 236; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 439; 440; 441; 442; 443; 444; 445; 446; 447; 448; 449; 450; 451; 452; 505; 506; 507; 508; 509; 510;
plague prophylaxis -- 511;
plaque psoriasis -- 222.6;
plasmapheresis -- 700;
plasmapheresis, therapeutic -- 801;
plastic surgery -- 924; 929;
platelet aggregation inhibition -- 240;
pneumococcal infection prophylaxis -- 513;
pneumococcal infection prophylaxis -- 513.3; 514; 515;
polio prophylaxis -- 437.5; 439; 440; 441; 442; 446; 446.5; 516; 517; 518; 519; 520; 521;
polydystrophic dwarfism -- 105;
Pompe disease -- 168; 168.5;
porphyria, acute intermittent -- 716;
positive-pressure convection-enhanced delivery (CED) -- 217;
post-herpetic neuralgia treatment -- 565;
Prader-Willi syndrome (PWS) -- 254;
prostate cancer treatment -- 242;
prostate carcinoma radiodiagnosis -- 312;
Protein C deficiency
prothrombin complex deficiency -- 805;
psoriasis -- 114; 227;
psoriasis, plaque -- 222.6;
psoriatic arthritis -- 264; 265; 265.5; 267;
pulmonary embolism -- 626; 627; 924.5;
purpura fulminans -- 804;
pyelonephritis -- 219;
pyoderma -- 219;
rabies prophylaxis/treatment -- 525; 526; 527; 528; 529; 773; 774; 775;
radicular lumbar syndrome -- 742;
radiodiagnostic aid (digestive) -- 164; 165; 166;
radioimmune therapy -- 117; 306;
rattlesnake bites -- 908;
recessive dystrophic epidermolysis bullosa (RDEB)
recombinant DNA -- 215;
recombinant proteins -- 214.5;
rectal cancer -- 275;
rejection, heart transplants -- 303;
rejection, kidney transplants -- 221; 222; 303; 917; 918;
rejection, liver transplants -- 303;
rejection, transplants -- 221; 222;
renal cell carcinoma -- 219;
renal cell carcinoma (RCC) -- 218; 219;
renal insufficiency, chronic -- 250;
renal transplantation -- 221; 222; 303; 917; 918;
respiratory distress syndrome (RDS) -- 941; 942; 943;
respiratory infections, bacterial -- 406;
respiratory syncytial virus (RSV) prophylaxis -- 245; 246; 781; 782;
respiratory syncytial virus (RSV) treatment -- 782;
rheumatoid arthritis -- 223; 265.5;
rheumatoid arthritis (RA) -- 114; 115; 123; 123.5; 214; 264; 265; 266; 267; 700;
Rho(D) isoimmunization -- 777; 778; 779; 780;
rotavirus prophylaxis -- 530; 531; 532;
rubella prophylaxis -- 493; 493.5; 494; 494.5; 495; 496; 533; 534; 758;
scars -- 924;
Scheie syndrome -- 187;
sealant, hemostatic -- 261; 736; 737; 738; 739; 739.5; 739.5; 808; 809; 920; 922;
sepsis -- 106; 219; 243;
severe combined immunodeficiency (SCID) -- 760; 761; 765; 766; 767; 768;
shingles prophylaxis -- 565;
shock, hypovolumic -- 806;
short bowel syndrome -- 257;
silica matrix-Protein A -- 700;
single photon emission computed tomography (SPECT) -- 312;
sinus filling -- 928;
sinusitis -- 219;
skin damage ultraviolet light -- 260;
skin damage, ultraviolet light -- 260;
skin grafts, autologous -- 653; 654; 656;
skin grafts, gluing -- 736.5;
skin grafts, heterologous -- 651;
skin lines/folds (see also facial wrinkles and folds) -- 924;
skin necrosis, coumarin induced -- 804;
skin ulcers -- 239; 612; 614; 651; 654;
small cell lung cancer radiodiagnosis -- 311;
smallpox prophylaxis -- 535; 536; 537; 538; 539; 540; 541;
smallpox vaccine adverse effects -- 788; 789; 790;
snake venom poisoning -- 907; 908; 909; 910;
somatotropin antagonists -- 259;
spasmodic torticollis -- 603;
spinal fusion -- 108; 109; 649;
spreading agent -- 186; 616; 617; 618; 619;
squamous cell carcinoma of the head and neck (SCCHN) -- 128;
squamous cell carcinoma, head and neck -- 232; 233;
Staphylococcus aureus infections -- 783;
Staphylococcus aureus prophylaxis -- 542;
stem cell enrichment, autologous -- 701;
stem cell transplants -- 171;
Stevens-Johnson syndrome (SJS) -- 656;
strabismus -- 601; 602;
Streptococcus pneumoniae prophylaxis -- 513;
Streptococcus pneumoniae prophylaxis -- 513.3; 514; 515;
stroke, acute ischemic -- 269;
surgery, intraocular -- 186; 616; 617; 926;
surgery, limb tumors -- 263;
sutures -- 241;
sutures, sealing -- 900;
sweating, underarm -- 601;
systemic inflammatory response syndrome (SIRS) -- 713;
systemic lupus erythematosus (SLE) -- 948;
T-cell co-stimulation modulators -- 123; 123.5; 124; 124; 125;
teeth reattachment -- 237; 931;
tetanus prophylaxis -- 421; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 437.5; 438; 439; 441; 442; 443; 444; 445; 446; 447; 448; 449; 450; 451; 452; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 784; 785; 786; 787;
thoracic aortic dissection repair -- 900;
thrombin inhibition -- 180; 181; 182; 934;
thrombocytopenia (see also ITP entries) -- 216; 802; 803;
thromboembolism -- 102; 706; 707; 708;
thrombosis, deep-vein -- 182;
thrombotic thrombocytopenic purpura (TTP) -- 798;
thyroglobulin (Tg), serum testing -- 262;
thyroid cancer, radiodiagnosis -- 262;
thyroid cancer, treatment -- 262;
tibia fracture repair -- 108; 109;
tissue hypoxia -- 949;
toleragens -- 948;
toxic epidermal necrolysis (TEN) -- 656;
transfusion reactions, recurrent febrile -- 802;
transplants (see also rejection) -- 222; 748; 749;
tuberculosis -- 219;
tuberculosis prophylaxis -- 407; 411; 412;
tumor lysis syndrome (TLS) -- 272;
Turner syndrome -- 249; 250; 252;
typhoid fever prophylaxis -- 467; 561; 562; 563;
ulcerative colitis -- 264;
urography, subcutaneous -- 186; 616; 617; 618; 619;
vaccination, prime-boost -- 541;
vaccines, intradermal -- 481.5;
vaccinia virus infection prophylaxis -- 788; 789; 790;
vaginitis -- 614;
varicella-zoster virus infection prophylaxis -- 494; 564; 565; 758; 791; 792;
variola virus prophylaxis -- 535; 536; 537; 538; 539; 540; 541;
vermilion borders -- 924; 924;
Vibrio cholerae prophylaxis -- 414; 415;
vitreous hemorrhage (eye) -- 186; 619;
vitronectin receptor inhibition -- 240;
von Willebrand's disease (vWD) -- 716; 726;
West Nile virus (WNV) -- 769;
Wiskott-Aldrich syndrome -- 760; 761; 765; 766; 767; 768;
wound coverings, skin -- 651; 653; 656; 657; 658; 659;
wound debridement -- 612; 614; 622;
wound healing (see also skin entries) -- 931;
x-linked immunodeficiency -- 760; 765; 766; 767;
xeroderma pigmentosum -- 260;
yellow fever prophylaxis -- 566; 567;
Yersinia pestis prophylaxis -- 511;
Yersinia pestis treatment -- 219;
Zollinger-Ellison Syndrome (ZES) diagnosis -- 935; 936;
505(b)(2) generic drug approvals -- 165; 166; 186; 195; 255; 617; 618; 703.5;
accelerated approval (based on surrogate endpoints) (FDAapproved) -- 117; 118; 118; 119; 126; 128; 129; 163; 163; 168.5; 203; 203; 211; 212; 212; 220; 228; 235; 257; 264; 264; 306; 456.5; 477; 488; 650; 768; 790; 933; 945;
application expected (2007-8) in U.S. 106; 112; 113; 122; 124; 125; 173; 224; 242; 246; 271; 273; 301; 417; 481; 541; 566; 602; 610; 627; 628; 769; 911; 938; 947;
application expected (2007/8) in Europe (EU or European countries) -- 112; 122; 131; 185; 215; 223; 627; 914;
application pending, EU or European countries -- 106; 113; 129; 134; 135; 139; 237; 266; 603; 619; 763; 945;
application rejected, EU -- 173; 207; 274;
application withdrawn in EU -- 112; 137; 236; 251; 258; 523; 633;
approval dates uncertain (FDA reports erroneous, conflicting, or simply has lost the original approval dates) (FDAapproved) -- 136; 406; 410; 411; 412; 419; 421; 425; 426; 448; 449; 450; 471; 509; 514; 517; 518; 525; 526; 533; 536; 544; 548; 549; 550; 551; 552; 553; 554; 557; 558; 559; 563; 567; 609; 702; 731; 733; 752; 753; 767; 797; 806; 916; 917;
approval pending, U.S. -- 142; 153; 185; 191.5; 215; 225; 244; 249; 260; 315; 445; 530; 540; 656; 741; 742; 902; 903; 945; 948;
approval rejected in U.S. -- 141; 162; 235;
approvals , FDA, as biologic -- 115;
approvals 116; 117; 119; 126; 128; 129; 133; 136; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 158; 159; 163; 165; 166; 169; 174; 175; 179; 184; 186; 187; 188; 189; 190; 191; 203; 204; 205; 206; 208; 209; 210; 211; 212; 213; 214; 216; 218; 220; 221; 222; 226; 227; 230; 238; 239; 240; 243; 245; 255; 264; 265; 267; 268; 269; 270; 275; 276; 303; 304; 305; 306; 307; 310; 311; 312; 313; 314; 402; 403; 404; 405; 406; 408; 409; 410; 411; 412; 414; 419; 420; 421; 422; 423; 424; 425; 426; 427; 430; 431; 433; 434; 435; 436; 437; 441; 443; 447; 448; 449; 450; 451; 454; 455; 456; 456.5; 457; 458; 459; 460; 463; 464; 466; 469; 471; 472; 477; 478; 479; 480; 488; 489; 491; 492; 493; 496; 498; 499; 500; 502; 503; 504; 507; 508; 509; 510; 511; 513;
approvals 514; 515; 517; 518; 519; 521; 522; 523; 524; 526; 527; 528; 529; 531; 532; 533; 534; 536; 537; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 561; 562; 563; 564; 565; 567; 601; 604; 606; 609; 611; 614; 617; 618; 620; 624; 625; 650; 653; 659; 702; 703; 704; 705; 707; 708; 710; 711; 712; 716; 717; 718; 720; 721; 722; 723; 724; 725; 726; 728; 729; 730; 731; 733; 734; 736; 737; 738; 740; 747; 748; 750; 752; 753; 754; 755; 756; 757; 758; 760; 761; 762; 763; 764; 765; 766; 767; 768; 770; 771; 772; 774; 775; 777; 778; 779; 780; 781; 782; 785; 786; 787; 788; 789; 790; 791; 794; 795; 797; 798; 799; 800; 801; 802; 804; 806; 807; 901; 904; 905; 907; 908; 909; 910; 912; 913; 914; 916; 917; 918; 920; 921;
approvals, Mexico -- 530;
approvals
approvals, U.S., as drugs -- 105; 110; 118; 155; 156; 165; 166; 167; 168; 172; 181; 182; 186; 192; 193; 194; 195; 196; 197; 198; 199; 228; 231; 234; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259; 262; 272; 605; 612; 615; 617; 618; 619; 626; 629; 631; 632; 633; 713; 933; 934; 935; 936; 941; 942; 943; 946; 949;
approvals, U.S., as medical devices -- 108; 109; 237; 241; 651; 652; 654; 656; 657; 658; 700; 701; 739; 808; 900; 922; 923; 924; 926; 927; 928; 929; 930; 931;
approved in U.S. -- 446;
approved, EU or European countries, but not actively marketed -- 101; 116; 146; 176; 238; 304; 498; 500; 507; 508; 546; 565; 566; 807; 915; 922; 938; 939;
approved, formerly in U.S. (approval withdrawn) -- 190; 229; 230; 258; 307; 310; 311; 313; 314; 402; 403; 405; 406; 414; 419; 421; 425; 426; 427; 432; 434; 435; 444; 447; 448; 449; 450; 451; 454; 456; 469; 478; 479; 480; 508; 509; 510; 514; 519; 521; 522; 523; 524; 526; 528; 532; 534; 537; 545; 548; 550; 551; 552; 553; 554; 557; 559; 563; 606; 616; 620; 625; 631; 632; 633; 708; 717; 718; 720; 738; 753; 754; 780; 781; 786; 787; 788; 791; 794; 901; 904; 905; 916; 921; 932;
approved, formerly, in EU or European countries -- 302; 309; 310; 313; 314; 414; 428; 432; 434; 440; 447; 448; 449; 454; 469; 509; 514; 519; 521; 522; 524; 526; 534; 537; 545; 548; 552; 554; 559; 563; 606; 616; 620; 631; 632; 657; 718; 720; 754; 765; 780; 781; 786; 794; 901; 904; 905; 916; 921; 932;
approved, U.S. -- 809;
biodefense stockpile (U.S.) -- 102.5; 103; 104; 413; 484; 485; 486; 487; 488; 535; 536; 537; 539; 540; 541; 744; 745; 746; 789; 790; 911;
biodefense stockpile, European countries -- 404; 484; 485; 538; 541;
biogenerics, biosimilars, biocomparables, follow-on proteins, etc. (approval based on abbbreviated/comparative filing) -- 110; 132; 133; 134; 135; 137; 139; 140; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 165; 166; 168.5; 171; 178; 186; 192.3; 192.5; 207; 210; 219; 247; 248; 253; 255; 423; 468; 477; 617; 618; 619; 623; 626; 627; 630; 793; 796; 914;
bovine source warning, BSE country -- 422; 431; 433; 434; 443; 455; 463; 466; 514; 547;
bovine source warning, unknown/undocumented country -- 404; 517; 528;
CBER to CDER transfers -- 114; 115; 116; 117; 119; 126; 133; 136; 143; 158; 159; 163; 169; 179; 187; 189; 204; 206; 208; 209; 210; 211; 212; 213; 214; 216; 218; 220; 221; 222; 227; 239; 240; 243; 245; 264; 265; 267; 268; 269; 270; 272; 303; 306; 307; 311; 312; 601; 604; 609; 611; 612; 624; 795;
Collaborative R&D Agreements (CRADA) -- 233; 417; 486; 945;
Continuous Marketing Application (CMA) Pilot 2 Program -- 217;
controlled/gov�t distribution in European counties -- 404; 484; 485; 487; 536; 538; 541; 912;
controlled/gov�t distribution in U.S. -- 103; 104; 404; 427; 484; 485; 486; 487; 488; 499; 511; 536; 537; 539; 540; 541; 558; 744; 745; 746; 747; 789; 790; 911; 912; 916;
Drug Efficacy Study Implementation (DESI) -- 616;
exempt from CBER lot release requirements -- 115; 116; 117; 118; 119; 143; 145; 146; 147; 148; 150.5; 159; 175; 179; 187; 189; 205; 208; 209; 210; 211; 213; 214; 220; 227; 243; 264; 268; 270; 272; 305; 306; 307; 311; 312; 313; 314; 649; 650; 782;
expanded access/compassionate use -- 167.3; 167.5; 233; 792;
FDA application denied -- 141; 162;
FDA application withdrawn -- 176; 229; 236; 307; 311; 314; 402; 403; 432; 444; 447; 509; 521; 548; 554; 557; 559; 563; 566; 606; 616; 620; 717; 734; 738; 905; 916; 945;
Good Manufacturing Practices (GMP) violations -- 478; 511;
IND, available through -- 744; 745; 746; 788; 789; 790; 792; 916;
murine source materials -- 140;
not available in U.S., currently (not marketed; includes intermediates, components, etc.) -- 101; 102; 106; 111; 112; 113; 121; 122; 124; 125; 127; 130; 131; 134; 135; 136; 137; 138; 139; 140; 142; 146; 157; 160; 162; 170; 171; 173; 176; 177; 178; 185; 190; 200; 202; 207; 215; 217; 219; 223; 224; 225; 229; 230; 232; 233; 235; 236; 238; 242; 244; 246; 248; 249; 251; 258; 260; 261; 263; 266; 271; 273; 274; 302; 304; 305; 307; 308; 309; 310; 311; 313; 314; 315; 402; 403; 405; 406; 412; 414; 415; 416; 417; 419; 421; 422; 423; 425; 426; 428; 432; 434; 435; 437.5; 438; 439; 440; 442; 444; 445; 447; 448; 450; 451; 452; 454; 462; 465; 467; 469; 473; 474; 478; 479; 480; 481; 482; 483; 490; 494.5; 495; 498; 500; 501; 507; 508; 509; 510; 514; 518; 519; 520; 521; 522; 523; 524; 526; 528; 530; 532; 534; 538; 542; 545; 546; 547; 548; 550; 551; 552; 553; 554; 556; 557; 559; 563; 602; 603; 606; 610; 614; 616; 620; 625; 627; 628; 631; 632; 633; 656; 708; 714; 717; 718; 719; 720; 732; 738; 741; 742; 749; 750; 753; 754; 757; 765; 769; 781; 782; 783; 786; 787; 788; 791; 794; 795; 796; 801; 803; 805; 807; 902; 903; 904; 905; 915; 921; 922; 932; 938; 939; 945; 947; 948;
not available, currently, in EU or European countries (not marketed) -- 101; 103; 104; 106; 111; 112; 113; 116; 122; 124; 125; 127; 129; 130; 131; 134; 135; 137; 139; 146; 153; 171; 173; 176; 185; 190; 191; 200; 202; 207; 215; 217; 219; 224; 225; 229; 230; 231; 232; 233; 236; 237; 238; 241; 242; 244; 246; 249; 251; 258; 260; 261; 266; 271; 273; 274; 301; 302; 304; 305; 306; 307; 309; 310; 311; 313; 314; 315; 402; 403; 405; 406; 413; 414; 416; 417; 419; 421; 422; 423; 424; 425; 426; 427; 428; 430; 431; 432; 434; 435; 436; 440; 443; 444; 445; 447; 448; 449; 450; 451; 452; 453; 454; 456; 457; 469; 471; 477; 478; 479; 480; 486; 488; 498; 499; 500; 507; 508; 509; 510; 511; 514; 519; 520; 521; 522; 523; 524; 526; 528; 532; 534; 537; 539; 540; 542; 544; 545; 546; 547; 548; 549; 551; 552; 553; 554; 556; 557; 558; 559; 563; 565; 566; 603; 606; 614; 616; 617; 618; 619; 620; 627; 628; 629; 631; 632; 633; 656; 657; 717; 718; 720; 738; 741; 744; 745; 746; 747; 753; 754; 755; 757; 763; 765; 769; 781; 783; 786; 787; 788; 789; 790; 791; 792; 794; 801; 807; 809; 901; 902; 903; 904; 905; 911; 914; 915; 916; 921; 922; 932; 935; 936; 938; 939; 945; 947; 948;
orphan status -- 102; 105; 106; 111; 112; 113; 115;
orphan status -- 116.5; 117; 118; 119; 120; 124; 126; 130; 131; 131.5; 133; 136; 144; 145; 149; 150; 151; 153; 156; 157; 158; 162; 163; 167; 167.3; 167.5; 168; 168.5; 169; 173; 179; 181; 187; 188; 201; 202; 202; 204; 206; 210; 212; 213; 214.5; 215; 216; 217; 218; 220; 221; 222; 222.2; 222.4; 225; 228; 233; 250; 251; 252; 253; 254; 257; 258; 259; 260; 261.5; 262; 264; 267; 272; 273; 301; 306; 310; 314; 490; 601; 604; 605; 611; 615; 629; 707; 708; 711; 713; 713.7; 714; 716; 723; 726; 731; 733; 734; 747; 748; 749; 755; 756; 765; 778; 781; 789; 790; 804; 908; 913; 935; 936; 941; 942; 943; 945; 948;
orphan status (EU) -- 261.7;
patent extended (under 35 USC �156) -- 166; 182; 206; 209; 212; 216; 218; 238; 239; 303; 311; 312; 434; 435; 562; 606; 651; 659; 708; 941; 946;
priority review -- 214.5;
priority review status -- 105; 112; 115; 116.5; 117; 118; 119; 120; 144; 145; 162; 163; 166; 167; 179; 181; 187; 188; 203; 210; 211; 212; 220; 221; 222; 227; 235; 240; 242; 245; 262; 264; 267; 273; 276; 306; 477; 513; 541; 617; 619; 629; 651; 659; 714; 756; 804; 933; 945; 946;
risk evaluation and mitigation strategy (REMS) -- 114; 160.9; 168.5; 222.6; 223; 225; 261.5; 264; 265; 266; 267; 602;
Special Protocol Assessment (SPA) -- 111; 120; 124; 128; 153; 162; 242; 273; 649.5; 650.5; 741;
Treatment IND -- 162;
bacterial cells -- 103; 104; 110; 158; 159; 160.1; 160.2; 160.3; 160.7; 160.8; 160.9; 165; 170; 171; 192; 192.3; 192.5; 194; 197; 198; 199; 201; 202; 204; 205; 206; 207; 208; 209; 212; 212.5; 213; 214; 216; 217; 218; 219; 220; 226; 229; 230; 231; 234; 235; 236; 248; 250; 251; 252; 253; 254; 255; 256; 258; 259; 263; 266; 268; 274; 404; 405; 406; 408; 409; 410; 411; 412; 413; 414; 415; 419; 420; 421; 424; 425; 426; 427; 428; 429; 430; 432; 433; 435; 436; 437; 437.5; 438; 439; 440; 441; 442; 443; 444; 445; 446; 446.5; 447; 448; 450; 451; 452; 454; 455; 456; 456.5; 457; 458; 459; 460; 466; 498; 500; 501; 507; 508; 509; 510; 511; 513;
bacterial cells -- 513.3; 513.5; 514; 515; 542; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 561; 562; 563; 601; 602; 602.5; 603; 604; 606; 608; 609; 611; 612; 624; 625; 700; 926; 927; 929;
bacterial source -- 103; 104; 404; 405; 405; 406; 406; 408; 408; 409; 409; 410; 410; 411; 411; 412; 412; 413; 413; 414; 414; 415; 415; 415; 419; 419; 420; 420; 421; 421; 424; 424; 425; 425; 426; 427; 428; 428; 429; 429; 430; 430; 432; 433; 433; 435; 435; 436; 436; 437; 437; 437.5; 438; 439; 439; 440; 440; 441; 441; 442; 442; 443; 443; 444; 445; 446; 446.5; 447; 447; 448; 448; 450; 450; 451; 452; 454; 455; 455; 456; 456; 456.5; 457; 458; 459; 460; 460; 466; 498; 498; 500; 500; 501; 507; 507; 508; 509; 509; 510; 511; 511; 513; 513.5; 514; 515; 542; 542; 544; 545; 545; 546; 547; 547; 548; 548; 549; 549; 550; 550; 551; 551; 552; 552; 553; 553; 554; 554; 561; 561; 562; 562; 563; 563; 601; 602; 602; 602.5; 604; 604; 606; 606; 608; 609; 611; 611; 612; 612; 624; 624; 625; 625; 700; 929; 929; 938;
bacterial, E. coli source -- 103; 104; 110; 112; 159; 160.1; 160.2; 165; 192; 192.3; 197; 198; 199; 201; 202; 204; 205; 206; 207; 208; 209; 212; 213; 214; 216; 218; 219; 220; 226; 229; 230; 231; 234; 235; 236; 250; 251; 252; 253; 254; 255; 256; 258; 259; 261.5; 263; 266; 268; 274; 415; 542; 542;
bacterial, Streptomyces -- 171;
bovine cells/tissues -- 445; 536; 605; 614; 616; 617; 618; 631; 632; 633; 659; 900; 902; 919; 920; 921; 922; 923; 941; 942;
bovine materials -- 467; 471; 476; 566; 617; 618;
canine source materials -- 481;
chicken cells (cell culture) -- 926; 928; 930;
chicken embryos (eggs) -- 190; 191; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481.5; 482; 485; 487; 488; 566; 567; 932;
duck cells/tissues -- 483;
equine blood -- 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 916; 918;
expression, mammalian -- 276;
fungal cells -- 610;
hamster source materials -- 130; 168.5;
hamster, Chinese ovary (CHO) cells -- 105; 108; 109; 114; 115; 116; 116.5; 117; 119; 122; 123; 123.5; 126; 129; 130; 131.5; 133; 134; 136; 137; 138; 139; 142; 143; 144; 146; 147; 148; 150; 150.5; 152; 155; 156; 160; 163; 167; 168; 168.5; 172; 179; 186; 187; 188; 189; 210; 211; 222.4; 222.6; 227; 228; 262; 267; 269; 270; 275;
human blood source -- 469; 620; 702; 703; 703.5; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 736.5; 737; 738; 739; 739.5; 740; 741; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806;
human cells/tissues -- 531; 808; 809;
human cells/tissues sources -- 121; 141; 162; 242; 243; 265; 402; 403; 462; 463; 464; 465; 469; 518; 522; 523; 524; 526; 527; 533; 539; 540; 564; 565; 615; 620; 626; 627; 649; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 658; 702; 703; 703.5; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 713.7; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 736.5; 737; 738; 739; 740; 741; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 923; 924;
human, autologous cells source -- 242; 649.5; 650; 650.5; 653; 654; 742;
immune globulins, human -- 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 784; 785; 786; 787; 788; 789; 790; 791; 792;
mammalian cells/tissue/organism source -- 102; 105; 108; 109; 113; 114; 115; 116; 116.5; 117; 118; 119; 121; 123; 123.5; 124; 125; 126; 128; 129; 130; 131.5; 133; 136; 137; 138; 141; 142; 143; 144; 145; 146; 147; 148; 149; 150; 150.5; 151; 152; 155; 156; 160; 162; 163; 167; 167.5; 168; 168.5; 172; 176; 179; 186; 187; 188; 189; 190; 191;
mammalian cells/tissue/organism source -- 191.1; 202; 203; 210; 211; 221; 222; 222.4; 222.6; 223; 227; 228; 240; 242; 243; 245; 246; 257; 262; 264; 265; 265.5; 267; 269; 270; 275; 302; 303; 304; 305; 306; 307; 308; 310; 311; 312; 313; 314; 402; 403; 422; 449; 462; 463; 464; 465; 469; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 482; 483;
mammalian cells/tissue/organism source -- 483.1;
mammalian cells/tissue/organism source -- 483.11;
mammalian cells/tissue/organism source -- 483.2;
mammalian cells/tissue/organism source -- 483.3;
mammalian cells/tissue/organism source -- 483.4;
mammalian cells/tissue/organism source -- 483.7;
mammalian cells/tissue/organism source -- 483.8; 489; 491; 504; 517; 518; 519; 520; 522; 523; 524; 526; 527; 528; 529; 530; 531; 532; 533; 536; 538; 539; 540; 541; 556; 564; 565; 566; 567; 605; 614; 615; 616; 617; 618; 619; 620; 621; 621.5; 626; 627; 631; 632; 633; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 658; 659; 701; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 713.7; 714; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 736.5; 737; 738; 739; 740; 741; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 804; 804; 805; 806; 808; 809; 900; 901; 902; 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918; 919; 920; 921; 922; 923; 924; 926; 928; 931; 932; 941; 942; 943;
monkey cells/tissues -- 490; 517; 519; 520; 528; 530; 531; 532; 540;
monkey source materials -- 437.5;
murine ascites -- 302; 304;
murine myeloma (mammalian.rodent.murine) -- 301;
murine, baby hamster kidney (BHK) -- 145; 149; 151;
murine, myeloma cells -- 118; 221; 240; 245; 246; 257; 264; 313;
nonrecombinant -- 242; 302; 304; 305; 306; 307; 308; 309; 310; 311; 312; 313; 314; 315; 400; 401; 402; 403; 404; 405; 406; 407; 408; 409; 410; 411; 412; 413; 414; 415; 416; 417; 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 429; 430; 431; 432; 433; 434; 435; 436; 437; 443; 444; 447; 448; 449; 450; 451; 453; 454; 455; 456; 456.5; 457; 458; 459; 461; 462; 463; 464; 465; 467; 469; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 481.5; 482; 483; 489; 491; 492; 493; 493.5; 494; 494.5; 495; 496; 497; 498; 499; 500; 501; 502; 502.5; 503; 504; 505; 506; 507; 508; 509; 510; 511; 512; 513; 513.5; 514; 515; 516; 517; 518; 519; 520; 521; 522; 523; 524; 525; 526; 527; 528; 529; 533; 534; 535; 536; 537; 539; 540; 541; 542; 543; 544; 545; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 560; 561; 562; 563; 564; 566; 567; 600; 601; 602; 604; 605; 606; 607; 609; 610; 611; 612; 613; 614; 615; 616; 617; 619; 620; 621; 621.5; 622; 623; 624; 625; 626; 627; 629; 630; 631; 632; 633; 650; 650.3; 650.5; 651; 652; 653; 654; 656; 657; 658; 659; 700; 701; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 712.5; 713; 715; 716; 717; 718; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 737; 738; 739; 740; 741; 743; 744; 745; 746; 747; 748; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 807; 808; 809; 900; 901; 902; 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918; 919; 920; 921; 922; 923; 924; 924.5; 925; 926; 927; 928; 929; 930; 931; 932; 933; 934; 935; 936; 937; 939; 940; 941; 942; 943; 945; 946; 948; 949;
ovine (sheep) source -- 619; 913; 914; 915;
plant source -- 622;
porcine materials -- 924.5;
yeast source -- 101; 153; 166; 166.5; 169; 174; 175; 177; 178; 181; 182; 184; 193; 195; 196; 200; 208.5; 225; 237; 238; 239; 248; 272; 466; 629;
zzz -- ;

Further Information:

Biopharmaceutical Products in the U.S. and European Markets - Home Page

Flyer (Description);

Book Reviews

Products database; Companies database - partial entries online